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Metastasis is the leading cause of cancer related deaths, yet it remains the most 
poorly understood aspect of tumor biology. This can be attributed to the lack of relevant 
experimental models that can recapitulate the complex and lengthy progression of 
metastatic relapse observed in patients. Mouse models have been widely used to study 
cancer, however they are critically limited to study metastasis. Most models generate 
aggressive metastases in the lung without the use of unique cell lines or specialized 
injection techniques. This limits the ability to study disseminated tumor cells (DTCs) in 
other relevant metastasis prone tissues. Prolonged observation of the post-dissemination 
phase of cancer cell biology and the dormant-to-active transition are additional challenges 
to study in mouse models due to the rapid onset of actively growing primary and secondary 
tumors that shorten the experimental timeframe. These limitations have left a critical gap 
in the understanding of metastasis, specifically the long-term bi-directional crosstalk 
between DTCs and their local microenvironment. Previous findings have demonstrated 
that subcutaneously implanted inverted colloidal crystal (ICC) hydrogel scaffolds recruit 
circulating tumor cells and capture metastatic progression. Here, I introduce new 
 
 viii 
implantable tissue engineered metastasis models that overcome the fundamental 
restrictions of existing mouse models and substantiate the role of the tumor niche in the 
reactivation of dormant DTCs with molecular and cellular detail.  
Throughout my dissertation work I engineered DTC niches leveraging ICC 
scaffolds to identify critical niche components that enable metastatic progression. 
Changing the anatomical location of the implant yielded unique microenvironments with 
varying levels of metastatic potential. In a secondary approach, I utilized the 
immunomodulatory properties of ICC scaffolds to assist the transplantation of adult lung 
and liver tissues into the subcutaneous space for prolonged study of metastasis-relevant 
tissues. Next, I leveraged the transplantable nature of scaffold niches to investigate DTC 
dormancy and potential triggers of metastatic relapse. I developed a fully humanized mouse 
model to explore local niche evolution as human DTCs progress from single cells to small 
colonies and overt metastases. The local vasculature and Ly6G+ cells were observed to 
play important roles during each step of the transition to aggressive proliferation. The effect 
of adjuvant chemotherapy and surgical disruption on DTCs and their niche was also 
explored by using a fully immunocompetent mouse model. Lastly, I improved the 
fabrication of ICC hydrogel scaffolds to make the process more scalable for widespread 
use. The use of expanded polystyrene beads enabled cheaper, faster, and safer production 
of ICC hydrogel scaffolds. 
Tissue engineering approaches to recreate in vivo DTC microenvironments 
represent an exciting opportunity to better understand metastasis. The presented models 
and techniques may be enabling tools to aid in the development of anti-metastasis therapies 
that significantly benefit patient health. 
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CANCER METASTASIS AND EXPERIMENTAL MODELS 
1.1 Introduction 
Cancer is a disease whereby cells in the body divide uncontrollably. Cancer is 
caused by genetic changes that alter genes that are involved in cell growth, division, and 
DNA repair1. During cancer progression, cells can gain a malignant phenotype 
characterized by the ability to invade local tissues and spread to distant tissues. Metastatic 
disease occurs once the cancer spreads to a distant site and proliferates. Patient survival 
rates dramatically decline as cancers spread from the local organ of origin to distant organs 
(Figure 1.1). For example, the five-year relative survival rate for breast cancer is 99% 
when diagnosed locally, and only 27% when diagnosed in distant organs. This 
phenomenon is further amplified during aging with five-year survival rates in breast cancer 
diagnosed in distant organs dropping to 22% and 15% for patients 65-84 and 85+, 
respectively2.  
 
Figure 1.1. 5-year patient survival rate based on stage at time of diagnosis.  




 Metastatic disease presents several clinical challenges3. First, detection of 
disseminated tumor cells (DTCs) is not practical and even secondary tumor colonies can 
be challenging to find. Some patients may remain asymptomatic until metastatic disease 
reaches an advanced stage. Second, treatment options for patients diagnosed with 
metastatic disease are severely limited. In most cases there is no cure for metastatic disease. 
Instead treatment is used to slow tumor growth and reduce symptoms. Most metastatic 
cancer treatment strategies are similar to the primary tumor of origin, however cancer cells 
can gain new genetic alterations that make them resistant to therapy. 
Although several aspects of metastasis have been uncovered, treatment for patients 
has only marginally improved4-7. Current experimental models of metastasis are limited in 
their ability to fully recapitulate the metastatic cascade and it remains unclear if these 
models provide accurately represent human metastasis. The work of this dissertation aimed 
to provide new experimental models to study DTC biology and the evolution of the local 
microenvironment during metastatic progression. In this chapter, the current understanding 
of metastatic disease progression are highlighted as well as the experimental models to 
study circulating, disseminated, and metastatic cancer cells.  
1.2 The Metastatic Cascade 
The initial step of the metastatic cascade is invasion into nearby normal tissue or 
blood and lymphatic vessels. As cancer cells proliferate and form a primary tumor they 
may gain additional phenotypic traits that enable eventual metastatic disease. This 
hypothesized event is commonly referred to as an epithelial-mesenchymal transition 
(EMT). In the early-stage carcinomas cancer cells are generally in an epithelial-like state 
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characterized by maintenance of cell-cell junctions, apical-basal polarity, and interaction 
with the underlying basement membrane. The transition to the mesenchymal state is 
characterized by loss of cell-cell junctions, loss of cellular polarity, degradation of the 
basement membrane and reorganization of the surrounding extracellular matrix. Activation 
of EMT programs via EMT related transcription factors like ZEB1 and SNAIL in non-
metastatic cells has been shown to increase their metastatic potential8. The phenomenon of 
EMT is still not fully understood and evidence of metastases that appear to not undergo 
such a transition have been presented. 
Invasion into draining lymph nodes is generally the first clinical identification of 
potential metastatic disease, however the spread to distant anatomical locations is widely 
believed to occur through the blood circulation. Entrance into the blood system presents 
cancer cells new challenges including hemodynamic forces9. Circulating tumor cells 
(CTCs) are one of the most challenging aspects of the metastatic cascade to study due to 
their relative rarity in the blood, inability to detect via platelet shielding, and limited 
success in expansion once purified. While in circulation, cancer cells home to new 
locations via passive mechanical trapping and active processes such as cell-mediated 
adhesion. While this phenomenon is traditionally viewed as the circulation of singular 
CTCs, recent findings suggest that CTCs with the highest metastatic potential exist as 
clusters10. Once extravasated from systemic circulation, CTCs are considered 
disseminated. Like CTCs, DTCs are exposed to a new set of microenvironment pressures 
present in the secondary tissue. The microenvironment plays an important role in 
determining the proliferative state of the DTCs and are explained in further detail below.  
 
 4 
In the nineteenth century organ specific patterns of metastatic growth were 
identified11. A study of 735 breast cancer patients and their resulting metastatic disease 
revealed a preference to form in the liver and lungs. These observations initiated research 
into the apparent pre-disposition of certain organs to undergo metastasis. Metastatic 
organotropism is largely observed in the liver, bone, lung, and brain (Figure 1.2). The liver 
is the most common distant site of metastasis from solid tumors. The liver is anatomically 
situated to capture many CTCs that enter portal circulation. Additionally, hepatic blood 
vessels are fenestrated, providing a low barrier of entry into the parenchymal tissue. The 
bone marrow vasculature also consists of fenestrated sinusoidal capillaries that normally 
facilitate trafficking of hematopoietic cells12. Besides anatomical and physical features, 
several cellular and molecular mechanisms have been uncovered in each tissue 
microenvironment that are important for CTC homing and metastasis formation. In the 
liver, claudin-2, MIF, CCL2, and IL-6 have been shown to promote metastasis13-15. 
CXCL12, RANKL, OPN, and BMPs are important in CTC recruitment to the bone 
marrow16. Osteolytic metastasis is characterized by a “vicious cycle” whereby growth 
factors, such as TGF-β, embedded in the bone matrix are released and further metastatic 
growth occurs. Cancer cells that extravasate into lung tissue can stimulate local fibroblasts 
which ultimately increases WNT signaling and promotion of colonization17. DTCs in the 
brain can induce astrocytes to establish Notch signaling and endothelin production for 
favorable metastasis conditions18-19. In addition to microenvironment features, cancer cells 
themselves can develop intrinsic mechanisms that can be identified to predict relapse in 
specific tissues. One example of this is breast cancer cells with high expression of CXCR4, 
IL-11, osteopontin, and CTGF have been shown to have prometastatic effects in the 
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formation of bone metastases20. Although organ specific mechanisms have been identified, 
targeting these individual pathways may prove to be impractical. Rather, understanding 
potential shared mechanisms of metastatic outgrowth could yield targetable pathways for 
more effective treatment. 
 
Figure 1.2. Organotropic behavior of tumor cell dissemination to distant tissues.  
Metastatic tumor development primarily occurs in a subset of organs. Here a primary breast 
tumor is shown to generated disseminated tumor cells in the brain, bone, lung, and liver.  
 
In the early 2000s, the pre-metastatic niche hypothesis was developed based on the 
finding that the presence of non-cancer cells can predict a future metastatic site21. Findings 
by Kaplan et al. revealed that soluble factors derived from the primary tumor can activate 
VLA-4+ (integrin α4β1) VEGFR1+ hematopoietic bone marrow progenitors, changing their 
phenotype to be more mobile and supportive of metastatic growth in visceral organs. 
Additionally, tumor derived factors upregulated fibronectin expression in lung fibroblasts 
to improve homing of these bone marrow derived cells. Removal of these bone marrow 
derived cells prevented metastasis, however their function and the precise mechanism of 
soluble factor activation were unknown21. Since these findings, work has been expanded 
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to identify the role of the primary tumor has on changing normal host tissue and 
hematopoietic response (Figure 1.3). In addition to cytokines, exosomes, small membrane 
vesicles that contain functional biomolecules including proteins, lipids, RNA, and DNA, 
have been identified as key drivers of pre-metastatic niche development22. Exosomes have 
been shown to interact with bone marrow cells and organ-specific niche cells to prepare 
pre-metastatic niches. One of the first exosome-mediated steps in the pre-metastatic niche 
formation is believed to be the induction of vascular leakiness. Delivery of microRNAs 
through exosomes can disrupt the blood-brain barrier and enable the formation of brain 
metastases23. Additionally, vascular integrity is decreased in the lung following 
upregulation of Angpt2, MMP3, and MMP10 early in pre-metastatic niche development 
and prior to tumor dissemination24. The next step in pre-metastatic niche evolution is 
activation of resident stroma. Aside from interfering with vascular cells, exosomes have 
been shown to increase S100 protein upregulation in lung fibroblasts and liver-specific 
Kupffer cells through integrin-mediated binding25. Interestingly, the site of pre-metastatic 
niche formation was defined by the integrin expression pattern on the exosome. S100 
proteins have been shown to be strong chemoattractants of myeloid and endothelial cells 
and appear at several stages of cancer26-27. As explained above, activation of local 
fibroblasts has been shown to increase fibronectin deposition in the lung and liver. Tumor 
derived exosomes were recently shown to alter perivascular cells to a less differentiated 
state, with enhanced extracellular matrix production28. The LOX family of proteins, 
involved in collagen crosslinking have also been shown to prime the pre-metastatic niche, 
however the source is believed to be from the primary tumor rather than activated 
fibroblasts. LOX accumulates with fibronectin, crosslinks collagen IV and enables 
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adhesion of myeloid cells. The recruited myeloid cells break down the matrix and create a 
feed-forward loop of increased bone marrow derived cell recruitment 29. The final step and 
hallmark of pre-metastatic niche formation is the systemic recruitment of immune cells. 
Bone marrow derived cells and myeloid derived suppressor cells play an important role in 
repressing IFN-γ-mediated immune responses and increasing proinflammatory signaling 
to make the microenvironment more permissive for immune evasion, extravasation, 
survival, and proliferation of DTCs30. The secretion of MMP9 from recruited 
hematopoietic cells aids in additional matrix remodeling. Neutrophils respond strongly to 
chemokines, CXCL1, CXCL2, CXCL5, CXCL12 (SDF-1), secreted by stromal cells 
activated by exosomes31. A recent study found that recruited neutrophils secrete 
leukotrienes, that can convert cancer cell populations into metastasis-initiating cells32.  
 
Figure 1.3. Schematic of pre-metastatic niche formation. 
Soluble molecules released from the primary tumor act on CTC-recipient tissue fibroblasts 
and the bone marrow to generate a metastasis-prone microenvironment.  
 
Although the pre-metastatic niche hypothesis is an exciting direction to uncover 
potential therapeutic targets it does not explain all potential avenues for metastatic relapse. 
Once a cancer cell has disseminated it generally does not immediately proliferate. A period 
of cellular dormancy can exist for periods ranging from months to years before relapse into 
a proliferative metastatic tumor. Clinically, DTCs can be found in the bone marrow years 
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after primary tumor removal33-35. CTCs and cell-free DNA can also be found in circulation 
in patients in remission36-38. There are three hypothesized mechanisms of dormancy: 
cellular, angiogenic, and immunologic39. Cellular dormancy refers to cells that remain in a 
singular state due to intrinsic signaling. This is the least understood mechanism of DTC 
dormancy due to challenges in identifying single cells and their proliferative state through 
histological characterization. Traditionally cellular dormancy was evaluated by negative 
Ki67, a marker for proliferation, signal. The ratio of ERK and p38 activity has been found 
to also signal dormancy. High ERK:p38 ratio is required for proliferation, whereas low 
ERK:p38 ratio is seen in a dormant state40. Dormancy can also be induced by 
downregulation of the PI3K-AKT pathway41. NR2F1 upregulation plays a critical role in 
driving growth arrest via SOX9, RARβ, and NANOG42. The microenvironment can play a 
key role in regulating the dormant phenotype in DTCs. In the bone marrow, GAS6 
produced by osteoblasts induces dormancy through Axl, Tyro3, and Mer43. BMP7 secreted 
from bone stromal cells causes cancer cells to activate p38 MAPK, p21, and NDRG1 44. 
The p38 pathway and associated dormancy was also found to be activated by TGFβ2 
signaling in the bone marrow45. Angiogenic dormancy arises from a lack of vasculature to 
continually sustain the initial growth of a micrometastasis. Without adequate nutrients, the 
tumors fail to become metastases and can undergo apoptosis46. This mechanism of 
dormancy is challenged by findings of non-proliferative tumors in direct contact with 
endothelial cells47-48. Finally, immunological dormancy describes a hypothesis whereby 
immune cells control the growth of proliferating tumors but do not eliminate them. Clinical 
observations of patients with transplanted organs containing donor tumor cells have 
developed metastasis after immunosuppression suggesting the host immune system was 
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keeping the tumor in check49. A preclinical model found that maintenance of metastatic 
dormancy was halted once CD8+ T cells were selectively removed50. Adaptive immune 
cells may also inhibit pro-angiogenic pathways to prevent growth51. The dual nature of the 
immune system in tumor progression have made the mechanisms for potential 
immunological dormancy unclear. 
1.3 Experimental Models of Metastasis 
Despite success in treating primary tumors, metastatic relapse remains a 
challenging disease to treat. A great emphasis has been placed in better understanding the 
fate of tumor cells that escape the primary lesion. Considerable efforts have been made in 
understanding the biology of CTCs and early stage DTCs to identify targets that may 
prevent metastatic outbreak. Although limited in study for ethical reasons, human samples 
remain the best samples for understanding metastasis and the development of effective 
therapies. Alternatively, mouse models provide an invaluable intermediate between 
reductionist in vitro approaches and human patients. However, mouse models are often 
imperfect and do not always produce translational findings to human patients. There is a 
critical need to generate new methods and models to better simulate and investigate disease 
progression for translatable outcomes. In this section various techniques are highlighted 




1.3.1 Isolation and Culture of Circulating Tumor Cells 
CTCs are rare cells within the diverse population of cells in the blood. Red blood 
cells, leukocytes, myeloid cells, endothelial cells, and various epithelial cells can be found 
in the blood. Early research in the field of CTCs utilized existing cell sorting techniques 
via antibody targeting 52. EpCAM and cytokeratin are prevalent markers to isolate CTCs 
from whole blood samples. CellSearch, the only FDA approved diagnostic tool for clinical 
use, detects EpCAM+/Cytokeratin+ CTCs 53. However, these methods require a cell-
fixation step preventing subsequent functional assays. Additionally, selection of 
EpCAM+/Cytokeratin+ cell populations has been shown to be limited in its ability to 
Figure 1.4. Schematic of the metastatic cascade and advanced techniques developed 
to elucidate the biology of circulating and disseminated tumor cells 
Circulating tumor cells can be isolated via microfluidic devices and traditional cell 
separation techniques. Captured circulating tumor cells are kept viable in optimized ex vivo 
culture conditions and transplantation into mice. Disseminated tumor cells can be captured 
in tissue engineered microenvironments for long-term monitoring of progression to 
metastases. Intravital imaging windows have been used to visualize extravasation into 
scaffold niches.  
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capture all tumor-derived cells as CTCs may have undergone an epithelial-to-mesenchymal 
transition during intravasation into the blood stream and no longer display epithelial 
markers. 
Due to the rarity of CTCs there have been efforts to culture captured cells ex vivo 
to increase the yield and accuracy of analytical characterization. Additionally, new 
techniques have been developed to isolate CTCs. Several microfluidic devices have been 
developed to streamline the isolation process and minimally damage cell populations. In 
general, these devices are constructed with PDMS with the flow chambers coated with 
EpCAM antibodies 54. Utilizing the unique flow properties of different blood components, 
devices have been made to separate CTCs with minimal exogenous processing such as red 
blood cell lysis buffers 55. An additional solution to separate CTCs that has shown success 
in microfluidic platforms and more traditional immunomagnetic separation techniques is 
the depletion of the non-CTC populations mainly composed of immune cells 56. Due to the 
heterogenous population of CTCs and the potential for an epithelial-to-mesenchymal 
transition, this approach attempts to capture a more complete population of CTCs in whole 
blood and minimize the potential for negative downstream side effects due to antibody 
binding. Lastly, a simplistic technique to capture CTCs involves the isolation of nucleated 
cells via density-based separation, such as Ficoll Paque. Although this does not separate 
immune cells from CTCs, during ex vivo culture these immune cells eventually die leaving 
an enriched CTC population 57. 
Ex vivo culture of CTCs is a challenging endeavor, and very few studies have been 
successful. Stable cell lines can take months to develop with low yield. Several groups 
have seen success using a cocktail of growth factors including EGF and FGF among others 
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to culture CTCs ex vivo 55, 58. Additionally, ex vivo CTC culture is commonly performed 
under hypoxic conditions of <5% O2 56. Those cells that were successful during initial 
culture were capable of expansion without growth factors. Another approach to culture 
CTCs includes the addition of tumor associate fibroblasts and extracellular matrix proteins. 
Three-dimensional culture was still necessary for effective expansion 54. Multiple reports 
indicate an enrichment of CD44+/CD24- CTCs which have been previously classified as 
cancer stem cells, a highly tumorigenic subpopulation 59.   
Even with advances in culture techniques, it is often challenging to expand primary 
cells in vitro. Drastic changes in nutrient availability, oxygen tension, cell-cell interaction, 
mechanical stiffness, extracellular matrix proteins can overwhelm cells and prevent 
proliferation. Human patient-derived xenografts in immunodeficient mice have yielded 
physiologically relevant maintenance of tumors. Similarly, CTCs have been 
xenotransplanted into murine hosts to enrich the population of cells that could form 
metastatic tumors 60. Similarly to in vitro studies, CD44 was frequently observed in 
metastatic disease. Interestingly the CTCs developed markers that were not present in the 
primary tumor. This phenomenon is frequently observed in the clinic and is believed to be 
a major driver of drug resistance and poor patient prognosis.  
In clinics, the capture of patient CTCs may be an important tool for diagnostics and 
aid in developing personalized therapeutic strategies to improve patient outcome. Current 
technology enables comprehensive CTC genotyping to identify mutations, however cells 
may not be fully receptive to drug candidates. CTC lines can be used to screen panels of 
single and combinatorial drug candidates. Additionally, better understanding of cells that 
can form metastases is also necessary. Data suggests that not all CTCs can form metastases. 
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Understanding the intrinsic factors that are unique to metastasis-initiating CTCs is another 
key area of study to prevent metastatic disease. Currently these approaches are limited by 
the lack of reliable methods to culture patient CTCs and the long periods of time required 
to generate cell lines. 
1.3.2 In Vitro Models to Study Disseminated Tumor Cells and Dormancy 
As techniques improve to isolate and characterize CTCs improve, there has also 
been considerable effort in understanding the DTC microenvironment. In vitro models 
have been developed to observe tumor cell behavior in controlled environments. Precise 
control of soluble molecules, cell ratios, substrate matrix, and external compressive, elastic, 
and shear forces can be applied reproducibly61-62. Additional benefits of in vitro systems 
include the high throughput nature, easy accessibility for real-time microscopic analysis, 
and fabrication with fully human cellular and extracellular components. A co-culture 
system of human stromal and endothelial cells was used to mimic lung and bone marrow 
microenvironments. Seeding with human cancer cells followed by a cocktail of laminin-
rich extracellular matrix and supplement-free media created a dormant 
microenvironment63. Endothelial cell derived thrombospondin-1 kept cancer cells in a 
dormant state by suppressing neovasculature and associated TGF-β1 and periostin. 
Another in vitro model utilized a microfluidic system to study human breast cancer 
extravasation into a human bone marrow microenvironment64. This model consists of a 
fibrin gel, seeded with human mesenchymal stem cells and osteoblasts, surrounded by flow 
channels separated by a layer of human endothelial cells. Human cancer cells are 
introduced in the flow channel and microscopically observed as they extravasate into the 
bone marrow mimic. This model demonstrated potential as a drug screening assay for 
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compounds that prevent extravasation and metastatic outgrowth. Although complex in 
vitro models have been developed, generating fully physiologically relevant models is 
challenging ex vivo. Additionally, as highlighted above with the culture of patient CTCs, 
certain primary cells are challenging to culture ex vivo. In vitro models have unmet 
potential in fully modeling DTC biology and still need time to reach the predictive value 
of in vivo models. 
1.3.3 In Vivo Models to Study Disseminated Tumor Cells and Dormancy 
In vivo models encompass the full complexity and dynamics of a living system and 
provide great insight on tumor biology 65-67. Mouse models have long been the gold 
standard to observe tumor progression from a primary tumor to a lethal metastasis. Mice 
are relatively cheap, easy to house and handle, and reproduce quickly. Due to the 
widespread use of mice in research laboratories a rich infrastructure of tools has been 
developed. Clinical imaging modalities such as x-ray, magnetic resonance imaging, and 
positron-emission tomography have all been adapted for use in preclinical studies68-69. In 
this section traditional mouse models and tissue engineering approaches to study metastasis 





Figure 1.5. Traditional methods to generate in vivo mouse models of metastasis. 
Primary tumors are commonly formed via cell line inoculation, patient-derived tissue 
transplantation, or genetic engineering to create spontaneous tumors. Each method presents 
its own unique benefits and drawbacks.  
 
The most common approach to modeling cancer in mice is the inoculation of in 
vitro cultured tumor cell lines. Injection of these cells can occur orthotopically, at the site 
of original primary tumor, ectopically, not at the site of original primary tumor, or 
systemically by directly injecting into circulation. These models benefit from rapid tumor 
generation and low cost, an attractive platform for preclinical therapeutic screening. 
Allogeneic transplantation into syngeneic immunocompetent hosts have been used for 
preclinical drug development since the 1950 and 1960s70-71. However, these models have 
shown low predictive value when translated to humans72. The discovery and widespread 
use of immunocompromised mice enabled xenotransplantation of human tissues into mice 
without host rejection73. Although these models utilize human cells, they still have low 
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predictive value for clinical outcomes74-75. The use of tumor cell lines has come under 
recent scrutiny as observations of altered in vivo tissue microenvironment development and 
irreversible gene expression changes due to culturing in vitro have been made76-77.  
Rather than digest tumor tissues, culture and expand the cells on two-dimensional 
substrates, and then introduce them into mice several models simply take pieces of tumor 
and implant them into mice. Engrafted tumors can be expanded by passaging to new mice 
and conserve histological and gene-expression features of the originating tumor78. When 
taken from human patients, these models are referred to as patient-derived xenografts 
(PDX). Co-clinical trials have been performed assessing the differences between PDX and 
patient responses to treatment. PDX models have been shown to accurately model clinical 
outcomes 87% of the time, including both positive and negative clinical outcomes79. Due 
to the personalized nature of these models, they have been proposed as powerful screening 
platforms to predict patient response80. Engraftment rates of patient tumor samples depends 
on several factors including sample quality and tumor type. The rate of engraftment can be 
on the order of months, making them impractical for personalized care and are additionally 
limited by logistical difficulties81. Over time or as the tumor is passaged to new mice, 
patient stroma and non-cancerous cells are eventually replaced with host cells.  
Another approach is to genetically engineer mice that develop de novo 
tumorigenesis in a spontaneous or controlled manner. In early models, oncogenes were 
inserted under control of a tissue-specific promoter82. One example of this is the MMTV-
PyMT mouse that develops a spontaneous breast cancer83. More recently, conditional 
models based on site-specific recombinase systems, like Cre-loxP, and CRISPR/Cas9 have 
been developed84. Due to de novo tumor generation, these models more accurately model 
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immune responses, develop heterogeneity, and progress toward metastatic disease in a 
more physiologically relevant manner. The ability to accurately predict patient response 
has also been studied extensively85. Genetically engineered models are limited by 
aggressive primary tumor burden, limiting their ability in studying metastasis84. 
Additionally, generation of new mouse models is time consuming and expensive81. 
The efforts described above were developed mostly to study the primary tumor, and 
their utilization in metastasis research is not as straightforward or effective. Mouse and 
human biology are ultimately different. The high frequency of metastasis in the lung, liver, 
brain, and bone observed in humans is not conserved in mice. For example, mice and other 
rodent models rarely develop bone metastases spontaneously 86. There have been various 
techniques developed to overcome the natural limitations of mouse models; however, these 
often involve direct injection into the tissue of interest such as intratibial injections for bone 
metastasis86. Although xenograft models have become more accessible and widespread, in 
the context of metastasis they lack relevant recipient human tissue stroma. Studying human 
DTCs in a mouse microenvironment may reduce the translational power of traditional 
mouse models. Although this is ultimately unavoidable when using a mouse host, strategies 
to incorporate human recipient tissue for CTCs have been successful.  
Early efforts to produce human relevant stroma involved the transplantation of 
human fetal lung and bone tissue into immunodeficient mice 87. These implanted tissues 
were successful in recruiting human tumor cells and displayed specific human-human cell 
interactions not observed in the native murine tissue. Of the nine human small cell lung 
carcinoma cell lines intravenously injected, only seven developed metastases and these 
only occurred in the human fetal lung implants. Additionally, these studies revealed that 
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the freshly implanted tissues were more receptive to generating metastases compared to 
implants that had been in the mice for 8-10 weeks. They attributed this to a decrease in 
cytokine secretion and expression of adhesion molecules over time. Interestingly, they 
were able to recover the ability to recruit CTCs by either sublethal irradiation or IL-1a 
treatment. Although this study provided early evidence that human-human cell interaction 
is an important factor with xenograft models, ethical considerations, and challenges in 
obtaining human samples have limited widespread adaptation of this technique. 
In recent years, tissue engineering strategies have been implemented to recapitulate 
human stromal microenvironments that attract CTCs from more readily available human 
sources. As mentioned above, the lack of metastases in the bone of mice is a critical 
challenge faced by the field. Formation of ectopic human bone and marrow tissues has 
been achieved via a combination of degradable polymers loaded with bone-inducing 
growth factors and seeding of human osteoblast precursors 88-89. Similar to the studies 
performed in fetal human tissues, human tumor cells homed to and proliferated within 
ectopic human bone implants 90-94. Besides bone, human liver microenvironments have 
also been developed in vivo, however they have not been utilized to study cancer 95. 
A secondary approach utilizes implantable biomaterials to study the metastatic 
niche 96-101. Pre-metastatic niches are transiently formed through inflammatory signaling 
from the primary tumor, instigating the recruitment of bone marrow derived cells to tissue 
microenvironments, priming the niche for CTCs. Interestingly, the implantation of various 
biomaterials has yielded niches with similar metastasis forming potential as traditionally 
discovered pre-metastatic niches. Work in our lab has utilized polyacrylamide hydrogel 
with an inverted colloidal crystal geometry to generate a highly porous, transparent, and 
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non-degradable biomaterial scaffolds 96-97, 101. When implanted subcutaneously these 
niches are receptive to CTCs derived from orthotopic and intravenously delivered tumors. 
These scaffolds are discussed in further detail in the following section. Similar efforts to 
engineer a pre-metastatic niche have been made with different biomaterial platforms. A 
porous poly-lactic and glycolic acid scaffold has been leveraged to identify haptoglobin as 
a key signaling molecule to recruit CTCs 99. These scaffolds have also been fabricated with 
polycaprolactone and used to track the dynamic immune response during cancer 
progression102. Their study revealed a detectable gene signature within the implantable 
niches that corresponded with disease progression and an opportunity to better understand 
myeloid derived suppressor cells. Besides the biological findings of this work, an exciting 
translational opportunity for implantable niches was presented that would enable 
diagnostic monitoring of the dynamic immunological profiles that occur during metastatic 
progression. Additional translational potential for implantable biomaterial 
microenvironments has also been explored with the goal of reducing DTC burden in native 
tissues by capturing circulating tumor cells within the tissue engineered niche 103-105.   
A secondary problem related to the use of mouse models is the challenge of 
studying DTC dormancy. Metastasis is inherently difficult to study regardless of model 
due to the nature of its single cell origin. Single DTCs and early stage metastases are 
difficult to detect and characterize in patients and mouse models. Following a DTC over 
long periods of time amplifies this challenge. Most cancer cell lines used in metastasis 
studies are generally aggressive and do not undergo dormancy for timescales observed in 
humans. In order to study disseminated cells in many models the primary tumor must be 
surgically removed. There have been reports that some primary tumors inhibit the 
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metastatic capability of DTCs, and removal activates proliferation106. This does not appear 
to affect all models, as several dormancy mechanisms have been discovered via primary 
tumor removal. One example is the discovery of p38α/β dormancy activation via TGFβ2 
signaling in DTCs in the bone marrow, which utilized a cell line xenograft surgically 
resected after reaching 500 mm3 45. The squamous cell carcinoma cell line, HEp3, used in 
this study and others, takes on a dormant phenotype after prolonged in vitro passage42. 
Another cell line commonly used in dormant DTC studies is the mouse breast cancer cell 
line D2.0R. When intravenously delivered these cells remain single and non-proliferative 
in the lungs for at least 240 days 107. Genetically engineered mouse models have also been 
utilized to study DTC biology. The discovery of early DTCs was made using MMTV-
HER2 and MMTV-PyMT mice108. As a larger emphasis is put on DTC biology, new tools 
and techniques are necessary to better understand dormancy and mechanisms that initiate 
proliferation. Implantable biomaterial scaffolds have demonstrated potential for being 
powerful tools to study DTCs. Engraftment of a dorsal skin-fold window chamber enabled 
imaging of CTCs extravasating into the scaffold niche97. The ectopic nature of the tissue 
engineered niche has been leveraged to transplant DTC containing scaffolds into secondary 
tumor-free hosts for long-term observation96. Together, the presented features of tissue 
engineered niches to study metastasis represent an exciting opportunity to better understand 
DTCs and their microenvironment in a new lens. One of the focuses of this dissertation is 
expanding the application of implantable biomaterial scaffolds for the investigation of 
DTCs as they progress from a single cell to an overt metastasis. 
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1.4 Inverted Colloidal Crystal Hydrogel Scaffolds and Implantable Biomaterial 
Niches 
Colloidal crystals are three-dimensional structures of ordered particles found in 
opal gemstones, bird feathers, beetles, sea creatures, and butterfly wings. Also known as 
photonic crystals, the structural geometry drives unique optical properties such as 
iridescent color. In nature these colloidal crystals consist of spherical particles in the 
nanometer scale109-110. Besides their attractive photonic properties, colloidal crystals are 
easily self-assembled across a wide range of diameters. Inverse colloidal crystal (ICC) 
structures have also been heavily studied for their photonic properties and more recently 
as a biomaterial scaffolding for tissue engineering applications111. ICC scaffolds are 
fabricated by filling the interstitial space of an initial colloidal crystal material with a 
polymer followed by selective removal of the colloidal crystals. The resulting structure 
consists of a reproducible interconnected spherical pore array with large surface area 
(Figure 1.6). These biomaterial scaffolds have been used in the tissue engineering of 




Figure 1.6. Inverted colloidal crystal hydrogel scaffold fabrication schematic. 
Uniform spherical beads are orderly packed and partially annealed to create a free-standing 
colloidal crystal template. A hydrogel precursor solution is added to the template and 
polymerized around the template structure. The template material is selectively removed 
to create a hydrogel scaffold with an inverted colloidal crystal geometry.   
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1.4.1 In Vivo Tissue Development 
Any material that enters the body undergoes a reaction known as the foreign body 
response. Initially soluble proteins in the host are adsorbed onto the material, accelerating 
the recruitment of innate immune cells such as macrophages. Prolonged exposure causes 
macrophages to form foreign body giant cells and recruit vasculature and fibroblasts to 
encapsulate the material with a fibrotic capsule that effectively seals the material off from 
the host. Experiments performed in the 1960s and 1970s found that subcutaneous 
implantation of porous poly(hydroxyethyl methacrylate) (pHEMA) sponges resulted in 
ingrowth of fibrous tissue, giant cells, blood vessels with a thin surrounding capsule112-113. 
Shortly after, an observation was made that pore size played a role in tissue infiltration, 
with 0.5 and 8 μm pores preventing infiltration while 40 μm allowing infiltration114. The 
introduction of sphere templated scaffolds enabled in depth analysis of tissue development 
within pHEMA and poly(methyl methacrylate) (PMMA) scaffolds as a function of tightly 
controlled pore size (20, 30, 40, 60, 80 μm)115-116. The effect of pore size on vascularization 
was further expanded when larger pore (79, 147, 224, 312 μm) poly (D, L-lactide-co-
glycolide) (PLGA) scaffolds were implanted subcutaneously116. Smaller pores drove the 
formation of high blood vessel density with poor penetration into the scaffold, whereas 
larger pores had larger vessels at lower densities that fully infiltrated the scaffold. A follow 
up study using multiscale photoacoustic microscopy and optical coherence tomography 
confirmed these findings in a comparison of scaffolds with 80 μm pores 200 μm pores117. 
Non-hydrogel, β-tricalcium phosphate scaffolds have been explored with larger pore sizes; 
300-400, 400-500, 500-600, and 600-700 μm118. Implantation of these scaffolds revealed 
that larger pore sizes are beneficial for blood vessel, however cellular infiltration is reduced 
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compared to scaffolds with smaller pores. Polyacrylamide ICC hydrogel scaffolds with 
250-300 μm pores were shown to have the highest cellular infiltration and complete 
vascularization when implanted subcutaneously97.  
Another interesting feature of ICC hydrogel scaffold implantation is the unique 
immune microenvironments that form within the pores. Lin-Sca-1+c-kit+ progenitor cells 
are recruited to polyacrylamide ICC scaffolds, and the number can be significantly 
enhanced by pre-seeding bone marrow stromal cells97. Investigation of the role of 
macrophages responding to ICC scaffolds has revealed specific cellular phenotypes arise 
at the material surface and within the pore119. Macrophages can be loosely categorized by 
their pro-inflammatory or alternative phenotypes. Pro-inflammatory, also referred to as M1 
or classically activated, macrophages are characterized by secretion of pro-inflammatory 
cytokines, reactive oxygen species, and nitric oxide. Alternatively activated, M2, have 
several functions including immunomodulation, matrix deposition, tissue remodeling and 
are associated with wound healing. M1 macrophages were found on the pore and outer 
scaffold surfaces whereas M2 macrophages were observed in the foreign body capsule and 
the central region of larger pores. This phenomenon appears to be driven by direct adhesion 
to the biomaterial as these cells occupy adjacent spaces. Physical size has been shown in 
non-ICC biomaterial systems to play an important role in modulating the immune 
response120. Further study into the immune microenvironments that forms within porous 
materials is necessary to better understand the differences observed in the foreign body 
response compared to bulk materials. Collectively these results indicate a unique foreign 




Figure 1.7. Host response to implanted biomaterials. 
Once a biomaterial is implanted, soluble proteins are adsorbed onto the surface. Local 
myeloid cells are recruited to the surface of the material and secrete pro-angiogenic 
molecules. Additional immune cells are recruited from systemic circulation through the 
vasculature. As the wound healing response resolves, a dense fibrous capsule is formed 
around the material. ICC hydrogel scaffolds do not undergo encapsulation and remain fully 
vascularized.  
 
My own observations with ICC scaffold implantation have aligned with previous 
studies in literature. However, the use of polyacrylamide has yielded some unique 
differences that warrant further investigation. Several factors change when altering the 
polymer composition and material properties. First, ICC scaffolds fabricated with 
polyacrylamide hydrogel yield more robust cell migration and infiltration within the pores 
compared to ICC scaffolds fabricated with polycaprolactone (Figure 1.8). Second, ICC 
scaffolds made with varying percentages of polyacrylamide concentrations (5-50 wt%) 
revealed limitations in scaffold stability and cellular recruitment. There was no significant 
difference in tissue development from 30-50 wt%, however scaffolds made with 5-15 wt% 
polyacrylamide mechanically collapsed after subdermal implantation and inter-scaffold 
tissue development was incomplete (Figure 1.9). Finally, 30 wt% polyacrylamide ICC 
scaffolds were examined with varying pore diameters from 75-500 µm. Blood vessel 
diameters increased with increasing pore sizes, but larger pores (400-500 µm) developed a 
more diverse range of vessels. Smaller pore sizes (75-150 µm) induced relatively 
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homogenous vascular development but restricted stromal and immune cell migration 
(Figure 1.10). These results demonstrate the tunable nature of ICC hydrogel scaffolds to 
drive different host responses to generate unique tissue microenvironments.  
 
Figure 1.8. ICC scaffolds fabricated with polyacrylamide and polycaprolactone.  
Hematoxylin and eosin staining of scaffolds composed of 30 wt% polyacrylamide and 





Figure 1.9. ICC polyacrylamide hydrogel scaffolds with four different polymer 
concentrations.  
Gross images of scaffolds after 4 weeks implantation, and hematoxylin and eosin stained 
images. Scale bar 200 μm. 
 
 
Figure 1.10. ICC polyacrylamide hydrogel scaffolds with four different pore sizes.  
Hematoxylin and eosin staining of 30 wt% polyacrylamide scaffolds fabricated with 
different bead sizes. Scaffolds were implanted for 4 weeks. Increasing pore size, resulted 




1.4.2 Modelling the Metastatic Cascade 
 ICC scaffolds made with polyacrylamide have shown robust performance modeling 
multiple aspects of the metastatic cascade. The first usage of these scaffolds aimed to 
mimic the bone marrow microenvironment97. Human bone marrow stromal cell seeded 
scaffolds enhanced the marrow-like environment of the implant and increased recruitment 
of intravenously delivered TF-1a cells, a human leukemia cell line. Extravasation was 
observed in real-time by surgical engraftment of a skin-fold dorsal window chamber. In 
addition to the kinetics of adhesion and extravasation of CTCs, the blood vessel diameter 
associated with adhered CTCs was also determined (Figure 1.11a). The second application 
of polyacrylamide ICC scaffolds in a metastasis study aimed to uncover cellular and 
molecular features of the early metastatic microenvironment96. In this model, scaffolds 
were subcutaneously implanted and allowed to fill with tissue before the orthotopic 
injection of human prostate cancer cells. Aggressive primary tumor growth required the 
removal of the scaffolds prior to the development of metastases. To prolong the study, 
scaffolds were transplanted to tumor-free hosts. Metastasis could be monitored 
noninvasively through luciferase imaging and showed a gradual increase in signal over a 
six week period (Figure 1.11b). The stromal cells in metastasis-positive and metastasis-
negative scaffolds was compared using a qPCR array and revealed upregulation in IL-1β, 
Mmp-9, Mmp-10, Mmp-13, Flt-4, Etv-4, and Mcam. The functional significance of stromal 
cell-derived IL-1β was confirmed in the same model using an FDA approved IL-1 receptor 
antagonist (Figure 1.11c). ICC hydrogel scaffolds for application in understanding DTC 
biology remains largely unexplored. My dissertation work utilized ICC hydrogel scaffolds 




Figure 1.11 Foundational work using inverted colloidal crystal hydrogel scaffolds in 
a metastasis model. 
a, Intravital imaging of extravasating cancer cells into scaffold microenvironment, adapted 
from Lee et al., P.N.A.S (2012)96. b, Long-term observation of DTCs and formation of 
advanced metastases, adapted from Cancer Research, 2014, 74/24, 7229-38, Bersani et al., 
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic 
cancer models, with permission from AACR97. c, Genetic analysis of stromal niche 
surrounding DTCs and functional reduction of metastatic relapse using ICC hydrogel 
scaffolds, adapted from Cancer Research, 2014, 74/24, 7229-38, Bersani et al., 
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic 









1.5 Dissertation Objectives 
This dissertation aimed to provide new tools and techniques to study DTCs and 
metastatic relapse in mice. As described to this point, mouse models struggle to fully 
reproduce patient-relevant metastasis, specifically organotropism and long-term dormancy 
behaviors. This work builds upon the use of a highly porous ICC hydrogel scaffold to 
assess niche evolution during metastatic progression in vivo. The reproducible and 
standardized tissue formation provides a unique platform to study DTCs with high 
analytical power. First, I aimed to engineer new scaffold microenvironments that can be 
used to elucidate critical niche components for recruitment and DTC proliferation. Second, 
I aimed to leverage the transplantable nature of ectopic scaffold tissue to investigate long-
term DTC niche evolution and potential activation mechanisms. Lastly, I aimed to improve 
the fabrication of ICC hydrogel scaffolds to make the process cheaper, safer, and faster. 
The aims of this dissertation are specified in further detail below. 
1.5.1 Aim 1: Engineer unique niches that enable the study of disseminated tumor cells 
in vivo 
 Mouse models are generally limited to the study of lung metastasis without 
specialized cell lines or injection techniques. Tissue engineered approaches have opened 
the door as an exciting opportunity to study DTCs in controlled environments. Previous 
work in our group has utilized a porous scaffold implanted subcutaneously to study 
extravasation and niche evolution during metastatic progression. The first focus explored 
the potential of altering the implantation site of the hydrogel scaffold in different 
anatomical locations to generate unique microenvironments. The hypothesis was that each 
tissue niche will have differing CTC recruitment and metastatic potential, enabling the 
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elucidation of cellular and molecular signals critical for metastasis. The findings of this 
study are presented in Chapter 2. 
A secondary approach to introduce new tissue microenvironments leveraging the 
unique tissue formation in ICC scaffolds is also presented. Here I aimed to transplant fully 
mature tissue from internal organs and transplant them subcutaneously. The rationale 
behind this approach was that the subcutaneous space provides greatly enhanced 
accessibility and transplantation can be leveraged for the study of human tissues in mice. 
The work corresponding to this sub-aim are presented in Chapter 3. 
1.5.2 Aim 2: Investigate long term niche evolution and potential triggers of metastatic 
relapse in scaffold microenvironments  
 The evolution of DTCs and their niche are largely unknown following 
extravasation. It is widely accepted that DTCs undergo varying periods of dormancy prior 
to entering a proliferative state. Previous work with ICC scaffold microenvironments 
revealed the capability to expand the observation of DTCs in their niche by transplanting 
them into tumor-free mice. The objective of this aim was to further explore the changes to 
the local microenvironment that occur as DTCs change from singular dormant cells to 
small tumor colonies and eventual overt metastases.  
 The first study investigated a humanized model consisting of human cancer, 
immune cells, and DTC-niche stroma and is described in Chapter 4. Human bone marrow 
cell seeded scaffolds were implanted in immunodeficient mice prior to the formation of an 
orthotopic human prostate tumor. Peripheral blood mononuclear cells were injected to 
instigate inflammatory signaling from human cells. Scaffolds were transplanted to tumor-
free mice and the niches were non-invasively monitored for 10 weeks. Histological 
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characterization revealed changes to local vascular and innate immune cells as DTCs 
progressed from singular cells to metastases.  
 Finally, a fully immunocompetent mouse model was used to investigate potential 
triggers of metastatic relapse. Recent reports have highlighted the possibility of enhanced 
risk of metastasis following adjuvant therapies. I aimed to explore the potential of 
biomaterial metastasis research to capture this phenomenon and uncover potential 
mechanisms of DTC activation. The corresponding work is found in Chapter 5. 
1.5.3 Aim 3: Improve fabrication process of ICC hydrogel scaffolds to increase 
scalability  
 Although ICC hydrogel scaffolds have demonstrated great potential as a tool for 
metastasis research, the fabrication process is suboptimal. The process is laborious, taking 
up to a week to manufacture a batch of polyacrylamide scaffolds starting from soda lime 
glass beads. When using glass beads as a starting material safety becomes a major concern 
as dissolution of the glass template requires highly toxic hydrofluoric acid. Finally, cost of 
fabricating bioactive scaffolds requires the use of expensive crosslinking reagents to 
covalently bond collagen to the surface. In Chapter 6 I highlight the work performed to 
improve fabrication using expanded polystyrene beads as the starting material and a 
polymerization strategy to embed collagen within the polymer matrix.  
1.6 Summary  
 As presented in this chapter, metastasis is a complex and dynamic process that 
stems from single cell interactions with their microenvironment and can take place over 
the course of months to years. Traditional mouse models designed to study cancer, 
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generally primary tumors, are poorly equipped to study the metastatic cascade due to 
technical limitations and human-mouse species differences. The work presented in this 
dissertation provides new tools to better understand metastasis. To achieve this, a 
biomaterial strategy was implemented to engineer receptive niches for circulating tumor 
cells. Specifically, inverted colloidal crystal scaffolds composed of polyacrylamide were 
used in a variety of ways to investigate circulating tumor cell recruitment, disseminated 
cell proliferation, and the cellular and soluble factor microenvironment changes that occur 




















DIVERSIFYING THE IMPLANTATION SITE OF POROUS BIOMATERIALS 
TO CREATE TISSUE-SPECIFIC MICROENVIRONMENTS 
2.1 Abstract 
The formation of metastatic tumors is the leading cause of cancer related deaths. 
Circulating tumor cells spread to several distal organs. However, disseminated tumor cells 
(DTCs) are reliant on their local tissue microenvironment to foster growth into overt 
metastases. Bone, brain, lung, and liver have been identified as favorable to metastatic 
growth, whereas tissues such as the muscle and intestine rarely develop metastases. Mouse 
models have been widely used to study various aspect of cancer biology, but they are 
limited to fully understand metastatic organotropism because metastasis mainly occurs in 
the lung. Identifying the common mechanisms that promote or suppress DTC growth 
across metastasis prone and resistive tissues is imperative to the development of better 
clinical strategies for metastatic disease. Recently, subdermally implanted porous 
biomaterials have demonstrated the ability to develop vascularized tissue 
microenvironments by recruiting near tissue cells and bone marrow derived cells. We have 
utilized these microenvironments to observe DTC progression from a single cell to an overt 
metastasis. Here, we report a new strategy to create tissue-specific microenvironment by 
altering the implantation site of porous biomaterials. In addition to subcutaneous 
implantation, porous scaffolds were inserted between liver lobes and within the intestinal 
mesentery. After 4 weeks in vivo, histological characterization confirmed recruitment of 
near tissue cells and significantly different immune cell profiles. Circulating tumor cells 
homed equally to the different implants, however metastasis was enhanced in scaffolds 
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implanted subcutaneously. High fibronectin and neutrophils in the subcutaneous scaffold 
microenvironment were identified as potential biomarkers of premetastatic niche signature, 
aligning with literature. We anticipate further microenvironment analysis using tissue 
engineered DTC niches may improve mechanistic understanding of metastatic 
development for the benefit of patient health. 
2.2 Introduction 
 More than 90% of cancer-associated death is caused by metastasis. Circulating 
tumor cells released from a primary tumor disseminate into distal tissues where they often 
lay dormant until their surrounding microenvironments become favorable for re-growth. 
In theory, circulating tumor cells can disseminate into a wide variety of tissue sites but 
subsequent metastatic relapse occurs non-randomly. Regardless of primary tumor types, 
metastasis frequently occurs in brain, liver, lung, and bone. Metastasis seldom takes place 
in skin, intestine, and muscle. Even with this knowledge it is challenging to predict the 
eventual site of metastasis. Genetically distinct metastasis can also arise simultaneously in 
multiple organs. Thus, it is imperative to understand common mechanisms across 
metastasis-prone organs and identify key differences among supportive and restrictive 
niches to develop therapies that reduce the burden of metastasis and maintain disseminated 
tumor cells (DTCs) in an inactive state.  
Mouse models are a critical tool for studying metastasis. Syngeneic, xenogeneic, 
and genetically engineered models are all limited by differences in their metastatic pattern 
compared to humans. The lung is a dominant site for metastasis while only a fraction of 
DTCs become metastases in the liver, bone, and brain. While these limitations can be 
addressed by directly injecting into target organs, the fidelity of these models is not clear. 
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There is a need for better models to study metastasis in mice in a variety of tissues. 
Recently, tissue engineering strategies have been exploited to address these limitations. 
Ectopic formation of bone containing human cells has had widespread success in recruiting 
human tumor cells in humanized mice. Additionally, several groups have identified the 
ability of implantable synthetic polymer biomaterials to recruit circulating tumor cells 
released from a primary tumor. Although there are reports of this phenomenon happening 
in both the subcutaneous and intraperitoneal cavity, the fate of the DTCs homed to implants 
located different anatomical sites has not been further investigated. Ultimately, the ability 
to monitor DTCs long-term has been challenging due to lethal tumor burden in the host. 
We have previously leveraged the ectopic nature of these DTC-containing niches and 
transplanted them to tumor-free mice for long-term observation and identified important 
niche components during evolution of early metastases. 
Here we report a comparative analysis of tissue development, CTC recruitment, 
and DTC proliferation in inverted colloidal crystal (ICC) hydrogel scaffolds implanted in 
three different anatomical locations. ICC geometry is characterized by a three-dimensional 
structure consisting of interconnected ordered spherical pores. Polyacrylamide ICC 
scaffolds have shown robust and reproducible vascularized tissue formation and the ability 
to capture CTCs and monitor their eventual metastatic outgrowth when implanted in a 
subcutaneous pocket. During the foreign body response local and systemic cells are 
recruited to initiate a wound healing response. We hypothesized that implantation in 
different anatomical locations may capture unique local signatures that may alter the 
metastatic potential of the tissue. Due to surgical restrictions, expansion of implant 
locations was limited to the intraperitoneal cavity. The liver and intestinal mesentery were 
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selected because of their rich vascularization and differing natural metastatic potential. 
Unique tissue microenvironments were developed at each of the implant sites, and the 
metastatic potential of each niche was assessed using an MMTV-PyMT spontaneous breast 
tumor model. We envision that this side-by-side comparative biomaterial strategy will open 
the door to future study of local and systemic factors that influence metastasis development 
in a standardized manner. 
2.3 Results 
2.3.1 Implantation of ICC scaffold in subcutaneous, hepatic, and mesentery sites 
generates unique tissue microenvironments 
 ICC scaffolds are fabricated with a sacrificial bead-based template to produce a 
highly ordered porous matrix (Figure 2.1A). In this study scaffolds were fabricated with 
polyacrylamide surface treated with rat tail collagen. Previous studies have identified 
scaffolds consisting of an average pore diameter of 300 ± 15 μm to have robust and 
reproducible tissue infiltration and vascular density101. Scaffolds were implanted in a dorsal 
subcutaneous pocket, sandwiched between the median and left caudate lobes of the liver, 
and wrapped within the small intestine in contact with the mesentery (Figure 2.1B). Gross 
images of the scaffolds revealed recruitment of large blood vessels and infiltration of local 
tissue cells, embedding the scaffolds within their local microenvironment (Figure 2.1C). 
Histological analysis was performed on the scaffolds at 1, 2.5, and 4 weeks post 
implantation (Figure 2.1D). Implants followed a similar pattern of tissue infiltration: 
extracellular matrix polymerization, initial cellular infiltration, followed by complete tissue 
infiltration. Interestingly cells infiltrated the liver scaffold faster than subcutaneous and 
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intestine scaffolds. Hepatocyte tissue infiltration was also observed on the outermost pores 
of the liver scaffold.  
 
Figure 2.1. Tissue development within the pores of ICC hydrogel scaffolds 
implanted in different anatomical locations.  
a, Fabrication schematic and brightfield image of ICC hydrogel scaffold. b, Schematic of 
implant locations. c, Gross images of ICC hydrogel scaffolds in subcutaneous, liver, and 
intestine sites four weeks after implantation. d, Hematoxylin and eosin staining of scaffolds 
implanted in different sites 1, 2.5, and 4 weeks after implantation. 
2.3.2 Fibronectin and Ly6G rich microenvironments develop in subcutaneous 
implants 
Scaffolds implanted for four weeks were screened with a panel of antibodies to 
evaluate the cellular and molecular components of the niche. Immunohistostaining was 
performed on scaffolds removed from the subcutaneous, liver, and intestine 
microenvironments (Figure 2.2A). Cell markers, αSMA (myofibroblasts), CD31 
(endothelial cell), Ly6G (neutrophils), F4/80 (macrophages), CD3 (T-lymphocytes), CD19 
(B-lymphocytes), and molecular markers, fibronectin and MMP9, were selected to assess 
the local vasculature, immune, and tissue remodeling activity. Tissue development within 
each of the niches was significantly different from one another. Notably Ly6G and 
fibronectin were significantly increased in subcutaneous implants and MMP9 was 
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significantly higher in implants located near the liver (Figure 2.2B). These results 
demonstrate that unique cellular and molecular microenvironments can be generated by 
changing the location of an implant.  
 
Figure 2.2. Immunohistological analysis of cellular and molecular niche components 
in subcutaneous, liver, and intestine implants.  
a, Immunohistostaining comparison of ICC hydrogel scaffolds implanted in different 
anatomical locations. b, Quantitative analysis of immunohistostaining images (*P<0.05).  
2.3.3 Bone marrow derived cells are recruited to ICC implants 
During the wound healing response bone marrow derived cells are activated and 
enter circulation to home to sites of inflammatory signaling. Parallels can be drawn 
between the inflammatory response that occurs at the site of a foreign object and that of a 
premetastatic niche. Previous studies with ICC scaffolds revealed the recruitment of bone 
marrow progenitor cells at the site of implantation, however the extent of other bone 
marrow derived cells was not investigated97. We hypothesized that bone marrow cells may 
be recruited to implants differently depending on the implant location. To test this 
hypothesis, we generated a chimeric mouse by performing a bone marrow transplant using 
eGFP bone marrow cells injected into a lethally irradiated C57BL/6 mouse. The bone 
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marrow was regenerated for 3.5 weeks before implantation of ICC hydrogel scaffolds in 
the subcutaneous, liver, and intestinal spaces (Figure 2.3A). Three weeks after 
implantation scaffolds were removed and cryosectioned to assess the eGFP cell population 
(Figure 2.3B). All implants recruited bone marrow derived eGFP+ cells, however liver 
implants had significantly higher tissue area coverage than implants in the subcutaneous 
and intestinal niches (Figure 2.3C). The increase in bone marrow derived cells may 
correlate to the increased MMP9 secretion observed in the liver implants since MMP9 is 
believed to be secreted specifically from bone marrow cells and not local stroma121.  
 
Figure 2.3. eGFP bone marrow cell recruitment to implantable biomaterial niches.  
a, Experimental schematic of eGFP bone marrow chimeric mouse generation and scaffold 
implantation. b, Fluorescent microscopy imaging of ICC hydrogel scaffolds for 
endogenous eGFP and DAPI. c, Quantitative image analysis of eGFP positive area in 




2.3.4 Circulating tumor cell recruitment comparable  
 Next, we examined the ability for the three different niches to recruit circulating 
tumor cells. A MMTV-PyMT spontaneous breast cancer model on the FVB background 
was used to generate CTCs in scaffold bearing mice. The MMTV-PyMT model was chosen 
because it is known to generate metastases and closely follow tumor progression observed 
in patients. Scaffolds were implanted at 4 weeks of age to maximize the CTC capture 
window. Eight weeks after implantation scaffolds were removed and analyzed via 
immunohistostaining (Figure 2.4A). Both single DTCs and small metastatic colonies were 
observed in scaffolds regardless of implantation site (Figure 2.4B). Quantification of 
DTCs revealed no significant difference in recruitment in the scaffolds from each of the 
tissues (Figure 2.4C). In this analysis small colonies were considered a singular DTC 
event. DTCs were found as colonies more frequently in subcutaneous and intestine 
scaffolds compared to liver scaffolds. Analysis of the proliferative status of the DTCs 
revealed 6.7% (2/30), 7.8% (4/51), and 15.4% (4/26) were Ki-67+ in subcutaneous, liver, 






Figure 2.4. Tumor cell recruitment to ICC hydrogel scaffolds in an MMTV-PyMT 
spontaneous breast cancer model.  
a, Experimental schematic of implantation strategy in MMTV-PyMT mice. b, 
Immunohistostaining of scaffold tissue reveals single DTCs and small micrometastases in 
subcutaneous, liver, and intestine scaffolds. c, Quantitative image analysis of DTC number 
in a single cryosection slice. d, Quantitative assessment of tumor colony number in a single 









2.3.5 Metastasis accelerated in subcutaneous microenvironment 
 Due to the high primary tumor burden in MMTV-PyMT mice, the maximum 
duration of scaffold implantation was limited to approximately 8 weeks. To prolong the 
observation window scaffolds were orthotopically transplanted into syngeneic tumor-free 
FVB mice (Figure 2.5A). The implants were left in the mice for 5 weeks before they were 
removed for immunohistostaining. Single DTCs and tumor colonies were observed in all 
implants regardless of location (Figure 2.5B). There were no significant differences in the 
number of DTCs or colonies in the implants (Figure 2.5C and 2.5D). However, colonies 
in the subcutaneously implanted scaffolds were the only ones to become large proliferative 
colonies (Figure 2.5E). These data suggest that unique microenvironments with different 
metastatic potential were generated by simply changing the site of the implanted ICC 
scaffold.  
 
Figure 2.5. Investigation of DTC outgrowth in different anatomical locations.  
a, Experimental schematic of transplantation model to extend experimental duration for 
the observation of DTC growth. b, Immunohistostaining of single DTCs and colonies in 
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scaffold niches. c, Quantitative analysis of DTC number in single cryosectioned tissue 
slice. d, Image analysis of tumor colony number in subcutaneous, liver, and intestine 
scaffolds. e, Quantitative analysis of tumor colony size in different scaffold tissues 
(*P<0.05).  
 
2.4 Discussion  
In vivo tissue engineered metastasis models have become an exciting area of 
research to probe hypotheses that traditional mouse models are inadequate to perform. For 
example, the generation of humanized ectopic bone has enabled the study of human cancer 
in a human bone-relevant microenvironment. Previously, we have demonstrated the 
potential of a porous ICC hydrogel scaffold to capture the long-term progression of DTCs 
and their local niche. Here we have provided a comprehensive analysis of the tissue 
formation, tumor cell recruitment, and DTC growth of three different tissue engineered 
niches generated by changing the implantation site of ICC hydrogel scaffolds. Although 
the scaffold microenvironment is driven by the foreign body response to the material, we 
found that the anatomical location drove unique tissue formation. Subcutaneous implants 
were characterized by high neutrophil recruitment and fibronectin. Liver and intestine 
scaffolds were similar in all markers analyzed except for MMP9, which was the highest in 
liver scaffolds. Interestingly bone marrow derived cells homed to the liver implants more 
than any other implant. Deeper analysis of the cellular niche via single cell RNA 
sequencing may provide additional information about the niche and reveal more intricate 
differences between the cellular populations.  
 Although it is believed that tissue engineered scaffolds enable metastatic tumor 
growth via premetastatic niche formation it has not been fully explored mechanistically. 
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Premetastatic niches are formed via systemic signaling derived from the primary tumor 
activation of bone marrow cells and priming of the local stroma to increase fibronectin 
secretion. Recruited bone marrow cells induce tissue remodeling by secreting matrix 
metalloproteinases. The foreign body response naturally induces several of these pathways 
without the need for priming by a primary tumor, including soluble fibronectin 
polymerization and recruitment of bone marrow derived cells. Here we provide evidence 
that metastatic growth in scaffold niches required fibronectin and Ly6G cells which were 
elevated in subcutaneous implants. Examination of the scaffold microenvironments over 
time may provide additional markers that correlate with metastatic niche development. The 
ability to tune the microenvironments by seeding engineered or tissue specific stromal cells 
onto the scaffolds prior to implantation may enable further mechanistic understanding of 
premetastatic niche development. Additionally, further examination of metastasis resistant 
scaffold niches may provide clues for keeping DTCs in a dormant state.  
 The results presented here demonstrate a new approach to engineer tissue 
microenvironments to study DTC biology and biomarkers for metastatic relapse. By 
utilizing a standardized ICC hydrogel scaffold reproducible tissues were generated and 
used for side-by-side analysis. This platform represents a high degree of control and 
tunability in tissue formation to address emerging hypotheses. Future studies may examine 
the role of biomaterial composition and physical features such as pore size have on driving 
tissue development. We believe this biomaterial driven approach will be an important tool 
in achieving mechanistic understanding of DTC behavior and yield therapies effective 
against metastasis.  
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2.5 Materials and Methods 
All chemicals and materials were purchased from Sigma Aldrich or Fisher 
Scientific unless specified. All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts-Amherst. 
2.5.1 Porous hydrogel scaffold fabrication 
ICC hydrogel scaffolds were fabricated as previously described101. Soda lime glass 
beads were sorted using an Advantech Sonic Sifter using 250 µm and 300 µm collection 
trays. Glass beads dispersed in deionized (DI) water were loaded into a 8 x 35 mm glass 
vial to a height of 2 mm. Vials were transferred to an oven set to 60 °C to remove the water. 
A glass template was made by annealing the beads in a 664 °C furnace for 4 hours. The 
annealed glass bead templates were infiltrated with a hydrogel precursor solution via 
centrifugation. The precursor solution was composed of 30 wt% acrylamide monomer, 1.5 
wt% bis-acrylamide crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine 
accelerator, and 0.2 vol% 2-hydroxy-2-methylpropiophenone photoinitiator in nitrogen 
purged DI water. The precursor solution was polymerized under a 15 W ultraviolet light 
source for 15 minutes. Glass beads were selectively dissolved in alternating washes of 
hydrofluoric and hydrochloric acid. Scaffolds were thoroughly washed with DI water to 
remove residual acid and lyophilized. Cracked or misshapen scaffolds were removed 
before proceeding. Scaffolds were sterilized with 70% ethanol and the scaffolds were 
surface treated with Sulpho-SANPAH to covalently crosslink rat-tail collagen. Scaffolds 




2.5.2 Mouse colony 
MMTV-PyMT mice on the FVB/N background (002374) and eGFP mice on the 
C57BL/6 background (006567) were bred in house from a colony initially obtained from 
the Jackson Laboratory. Wild type FVB/N were acquired from MMTV-PyMT breeding 
and C57BL/6 (000664) mice were purchased from the Jackson Laboratory. Mice were 
housed in sterile conditions with unrestricted access to food and water. 
2.5.3 Surgical implantation of scaffolds 
Mice used in this study were between 4-8 weeks old at the time of implantation. 
Mice were anesthetized with 2% isoflurane before removing the dorsal and ventral hair 
with electric clippers and Nair. The skin was sterilized using 70% isopropyl alcohol prep 
wipes. Mice received 2 mg meloxicam/kg mouse weight subcutaneously prior to surgery. 
For subcutaneous implants a pocket was created by making a 2 mm horizontal incision in 
the dorsal space followed by expansion of surgical scissors into the incision and expansion. 
The implant was placed into the pocket and the incisions were closed with Reflex 7 mm 
wound clips.  For liver and intestine implants, a 10 mm vertical incision was made in the 
lower abdomen and scaffolds were placed between the median and left caudate lobes of 
the liver,and wrapped within the small intestine in contact with the mesentery. The muscle 
layer was sutured and with polyglycolic acid sutures (Henry Schein), and the skin was 
closed with wound clips. 
2.5.4 Frozen tissue preparation and sectioning 
At the conclusion of the in vivo experiment, implants were frozen by embedding 
the tissue in Cryomatrix TM and snap-frozen in 2-methylbutane cooled on dry ice. Frozen 
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tissue was cut to 20 µm using a NX70 Cryostat. Frozen tissue blocks and sectioned slides 
were stored at -80 °C.  
2.5.5 Histology 
Hematoxylin and eosin staining was performed by fixing frozen tissue sections with 
10% neutral buffered formalin for 10 minutes. After washing with DI water, sides were 
transferred to hematoxylin for 30 seconds. Slides were then washed with DI water until 
dye was no longer present in the effluent and then transferred to eosin Y for 45 seconds. 
Slides were serially dehydrated in 70, 85, and 100% ethanol before xylene. Samples were 
mounted in Shandon-Mount and covered with a glass cover slide. Images were taken with 
a color camera on an EVOS FL Auto microscope.  
For immunohistostaining, frozen slides were fixed in -20 °C acetone for 10 minutes. 
Slides were washed with PBST solution 3 times before blocking in a solution containing 
10% normal goat serum, and 1% bovine serum albumin for 1 hour. Following blocking 
primary antibodies diluted in blocking solution were added to the slides and left in a 
humidified chamber overnight at 4 °C. Slides were washed 3 times with PBST and then 
incubated with secondary antibodies diluted in blocking solution for 2 hours at room 
temperature. Prior to imaging, slides were washed 3 times in PBST and stained with a 10 
ng/uL solution of DAPI. Fluorescent images were taken on a Zeiss Cell Observer SD. Α-
smooth muscle actin (ab5694), CD31 (550274), Ly6G (557445), F4/80 (565409), CD3 
(550277), CD19 (550284), fibronectin (MA5-11981), MMP9 (PA513199), PyMT 
(ab15085), and Ki67 (ab16667) primary antibodies and anti-rabbit Alexa Fluor Plus 488 
(A32731), anti-rat Alexa Fluor 647 (A21247), anti-hamster Alexa Fluor 488 (A21110), 
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and anti-mouse Alexa Fluor 660 (A21054), and anti-mouse Alexa Fluor 555 (A21424) 
secondary antibodies were used in this study. 
2.5.6 Bone marrow transplantation 
C57BL/6 mice were lethally irradiated with two doses of 6 Gy, four hours apart, 
from a cesium source. Twenty-four hours later, 20 x 106 bone marrow cells isolated from 
eGFP mice were intravenously injected. Engraftment was verified by microscopy for the 
presence of eGFP cells in blood collected via needle stick in the tail. Mice were given 
acidified antibiotic water (20 μg/mLtrimethoprim, 100μg/mL sulfamethoxazole, pH=3) for 
the duration of the experiment. 
2.5.7 Orthotopic scaffold transplantation 
Scaffolds were harvested from MMTV-PyMT mice and immediately transplanted 
to the same anatomical site in tumor-free FVB mice. The method for implantation was the 
same as initial surgery.  
2.5.8 Image Analysis 
All image processing and quantitative analysis was performed in ImageJ. Total 
tissue area was determined using the DAPI image for all relevant analysis.  DTC counts 
were tabulated by assuming small colonies were formed from a single DTC.  
2.5.9 Statistics 
Unpaired Student’s t tests were performed for comparison of the mean values 
between two groups. Statistical significance was determined if p<0.05 for two-tailed 





SCAFFOLD-ASSISTED ECTOPIC TRANSPLANTATION OF INTERNAL 
ORGANS AND PATIENT-DERIVED TUMORS 
 
Adapted with permission from Ryan Carpenter, Hye Jeong Oh, In-Hye Ham, Daeyoung 
Kim, Hoon Hur, and Jungwoo Lee. ACS Biomaterials Science & Engineering. 2019 5(12), 
6667-6678. DOI: 10.1021/acsbiomaterials.9b00978. Copyright 2019 American Chemical 
Society.  
3.1 Abstract 
Xenotransplantation of human tissues into immunodeficient mice has emerged as 
an invaluable preclinical model to study human biology and disease progression and 
predict clinical response. The most common anatomical site for tissue transplantation is the 
subcutaneous pocket due to simple surgical procedures and accessibility for gross 
monitoring and advanced imaging modalities. However, subcutaneously implanted tissues 
initially experience a sharp change in oxygen and nutrient supply and increased mechanical 
deformation. During this acute phase of tissue integration to the host vasculature, 
substantial cell death and tissue fibrosis occurs limiting the engraftment efficiency. 
Previously, we demonstrated the implantation of inverted colloidal crystal hydrogel 
scaffolds triggers pro-angiogenic and immunomodulatory functions without characteristic 
foreign body encapsulation. In this study we examine the use of this unique host response 
to improve the ectopic transplantation of tissues to the subcutaneous site. Scaffold-assisted 
tissues preserved morphological features and blood vessel density compared to native 
tissues, whereas Scaffold-free tissues collapsed and were less vascularized. Notably, the 
supporting biomaterial scaffold modulated the foreign body response to reduce localization 
of Ly6G+ cells within the transplanted tissues. Co-transplantation of patient-derived gastric 
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cancer with a scaffold resulted in a comparable level of engraftment to conventional 
methods, however detailed immunehistological characterization revealed significantly 
better retention of proliferative cells (Ki67+) and human immune cells (CD45+) by the end 
of the study. We envision that leveraging the immunomodulatory properties of biomaterial 
interfaces can be an attractive strategy to improve functional engraftment of 
xenotransplants and accelerate individualized diagnostics and the development of novel 
therapeutic strategies. 
3.2 Introduction 
Mice have been used as an important model to understand the basic biology of 
health and disease and serve as a vital link in the preclinical development of therapies for 
human diseases122-126. The development and advancement of immunodeficient mouse 
models has enabled the xenotransplantation of human cells and tissues, significantly 
improving the clinical relevance of animal studies127. For example, xenotransplantation of 
human tumor cell lines, patient-derived immune cells, fetal tissue, organoids, and tumor 
fragments have been performed to understand human cell and tissue biology in health and 
disease128-134. In particular, patient-derived xenograft (PDX) tumor models have 
demonstrated their capability to reflect the human tumor microenvironment, predict patient 
response to chemotherapy, and accelerate discovery and validation of preclinical drugs135-
138. A co-clinical trial in small lung cell cancer patients and corresponding PDX models 
showed consistency in responsiveness to cisplatin therapy, demonstrating the screening 
potential of PDX models139. Nevertheless, the fidelity, stability, engraftment efficiency, 
and engraftment kinetics of PDX tumors and mature tissues remain critical barriers to 
overcome for practical application140. For example, PDX models frequently fail to progress 
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to form metastatic lesions in mice141. Additionally, engraftment rates range widely between 
studies, from 10% to 95% depending on tumor type, and the time to reach initial 
engraftment can take several months to establish proliferative tumors130. 
Orthotopic transplantation of human tissues or tumors is most desirable but often 
limited by notable size difference between mouse and humans, and technical challenges to 
surgically access organs. The subcapsular region of the kidney is an attractive transplant 
site because of the richly vascularized environment, yet the small volume limits the size of 
transplanted tissues and requires technical expertise142. Alternatively, the subcutaneous 
space has been commonly used for transplantation because of the large tissue volume 
capacity, proximity to blood supply, simple surgical procedure and ease of accessibility for 
various imaging modalities143-144. However, engraftment efficiency of subcutaneously 
transplanted tissues remains suboptimal because of acute adaptation processes experienced 
by the donor tissue. First, the physical stresses beneath the skin caused by compressive 
forces from skin elasticity, and host motion can differ greatly from the donor tissue 
microenvironment145-146. This additional strain can cause soft tissue deformation and 
trigger abnormal mechano-transduction signaling147. Second, transplanted tissues suffer 
from limited oxygen and nutrient supply until blood vessels can reconnect to the host 
vasculature or neo-angiogenesis occurs. Delayed vascularization is accompanied by cell 
death and transformation of cellular phenotypes148. Third, the host wound response 
generates robust cellular recruitment from resident and systemic immune cells149. Acute 
local inflammation and fibrosis resultantly decreases donor tissue cell number and cellular 
heterogeneity as host cells infiltrate the graft and gradually replace donor tissue150. It is 
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imperative to develop strategies to overcome these acute detrimental effects on donor tissue 
to improve engraftment efficiency of current xenograft models to the subcutaneous space.  
Accumulating data indicate that biomaterial implantation is a compelling route to 
modulate the host immune response151-157. Implant geometry, surface topology and 
chemistry, material composition, and bioactive delivery of drugs or cells have been 
explored to reduce fibrosis around implants and improve the longevity of biomedical 
devices120, 158-161. For example, implantation of medical grade polymers with circular, 
triangular, and pentagonal shaped cross sections revealed a circular rod had the lowest host 
response162. The degree of foreign body response against spherical biomaterials was shown 
to be modulated as a function of implant size120. Synthetic biomaterials composed of 
zwitterionic hydrogels that alternate positively and negatively charged functional groups 
significantly delayed the foreign body response and resultant fibrotic encapsulation163. 
Mechanical properties of synthetic zwitterionic hydrogels have been identified as a potent 
parameter to modulate the foreign body response after subcutaneous implantation161. 
Extracellular matrix scaffolds have shown to trigger a notably different pattern of local and 
systemic immune response compared to synthetic materials by switching from fibrotic 
encapsulation to wound healing and tissue repair mechanisms164-165. Hydrogels embedded 
with mesenchymal stem cells attenuated macrophage response and reduced fibrotic capsule 
thickness166. These results collectively indicate that implantable biomaterials represent an 
opportunity to modulate the fate of implanted human tissues to support better functional 
engraftment while retaining original tissue complexity.  
In the presented work we hypothesized that an implantable biomaterial approach 
could be utilized to enhance the ectopic engraftment of mature tissue by improving 
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vascularization and altering the migration of immune cells. Furthermore, the biomaterial 
would act as a mechanical support to suppress mechanical deformation. We tested these 
hypotheses using inverted colloidal crystal (ICC) hydrogel scaffolds consisting of fully 
interconnected macroscale spherical pore arrays that have demonstrated mechanical 
robustness, and pro-angiogenic and immunomodulatory features after subdermal 
implantation96-97, 101. We first examined if co-implanted ICC hydrogel scaffolds promote 
the integration of liver and lung tissues retrieved from immunocompetent mice genetically 
engineered with DsRed fluorescent reporter protein to the immunodeficient NSG host 
mice. We also tested the impact of pre-seeded human bone marrow stromal cells (BMSCs) 
in ectopic tissue engraftment, which have been shown to further enhance angiogenesis and 
reduce inflammation96-97, 101, 167. Finally, we extended the study to examine the effects of 
stromal cell-seeded ICC hydrogel scaffolds on engraftment efficiency and cellular 
heterogeneity of human patient-derived gastric cancer samples. We envision this proof-of-
concept study for biomaterial assisted ectopic tissue and tumor transplantation may 
improve the usage of mouse models for preclinical cancer research. 
3.3 Results  
3.3.1. Subdermal co-implantation of mature liver tissue within an ICC hydrogel 
scaffold reduces tissue deformation.  
ICC scaffolds consist of an interconnected spherical pore array providing a high 
surface area-to-volume ratio and elicit a unique foreign body response that results in a 
vascularized tissue that does not undergo endogenous host rejection. We hypothesized that 
co-implantation of a mature tissue with an ICC hydrogel scaffold may improve the 
engraftment of transplanted tissues (Figure 3.1a). A 30 wt% polyacrylamide hydrogel 
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scaffold consisting of 300 ± 15 µm pores was used for this study, which has been shown 
to induce a richly vascularized tissue within 3 weeks of subdermal implantation101. To 
accommodate transplanted tissue samples, a cylindrical ICC scaffold (height = 2 mm and 
diameter = 6.5 mm) was modified by punching out a 3 mm diameter hole centrally. Human 
BMSCs were homogeneously seeded at a density of 5x105 cells/scaffold (Figure 3.1b). 
We employed DsRed immunocompetent mice as tissue donors and NSG immunodeficient 
mice as ectopic tissue recipients. Cells in DsRed mice ubiquitously express red 
fluorescence that facilitate rapid identification of surviving donor tissues in the recipient 
without staining. Immediately prior to surgery, a 3 mm piece of freshly harvested DsRed 
mouse liver tissue was collected using a biopsy punch and placed in the center of a scaffold 
prior to subcutaneous implantation. Three different groups of implants were used in the 
study, scaffold-free liver (Scaffold-free), unseeded scaffold-assisted liver (Blank-scaffold), 
and BMSC-seeded scaffold-assisted liver (BMSC-scaffold). Transplanted tissues were 
retrieved after one or two weeks of implantation (Figure 3.1c). Gross images of explanted 
tissue after 1 week implantation showed that the color of a liver tissue turned pale due to 
the significant loss of red blood cells whereas a liver tissue with a scaffold retained dark 
red color with a sign of vasculature (Figure 3.1d). Hematoxylin and eosin (H&E) staining 
revealed that Blank-scaffold and BMSC-scaffold transplanted hepatic tissue retained 
morphological features present in native liver such as portal veins. A fibrotic capsule was 
observed around all sides of Scaffold-free transplants and the host-transplant interface of 
Blank-scaffold and BMSC-scaffold transplants. Interestingly, liver tissue at the interface 
of the biomaterial scaffold showed less fibrotic tissue formation (Figure 3.1e-f). 
Characterization of albumin secretion via immunohistochemistry revealed maintenance of 
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liver function in all transplanted tissues (Figure 3.2). We repeated the experiment with 
DsRed mouse lung tissue that has more than 25-fold weaker mechanical strength than the 
liver tissue 168. The result revealed clear collapse of alveolar structures in Scaffold-free 
transplants (Figure 3.3). Collectively these results indicate that co-implantation of mature 
mouse tissues with an ICC hydrogel scaffold better preserve intrinsic tissue structure by 
preventing tissue collapse and reduction of fibrotic capsule formation directly at the 
transplant interface compared to control scaffold-free transplants.  
 
Figure 3.1. Scaffold-assisted transplants reduce tissue disruption.  
a, Schematic of general strategy to improve ectopic engraftment of mature tissues using 
ICC hydrogel scaffolds. b, Representative brightfield (top) and fluorescence (bottom) 
microscopy images of ICC hydrogel scaffold pore structure and homogeneous seeding of 
fluorescently labelled hBMSCs on the surface of the scaffold pores. c, Experimental 
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schematic of DsRed mouse liver tissue transplantation into NSG immunodeficient mice 
with an ICC hydrogel scaffold. d, Gross images of a liver tissue and a liver tissue integrated 
with a hydrogel scaffold and after one week of subcutaneous transplantation. e, H&E 
images of native mouse liver tissue structure. f, H&E images Scaffold-free, Blank-scaffold, 
and BMSC-scaffold transplants after 1 week implantation. White arrows highlight large 
portal veins, a key anatomical structure in the liver. 
 
 
Figure 3.2. Albumin secretion in transplanted liver tissues. 
a-b, IHS of mouse albumin in native liver (a) and transplanted liver tissues (b). 
 
 
Figure 3.3. Ectopic engraftment of mature mouse lung tissue into NSG mice using 
ICC hydrogel scaffolds. 
a, Gross images of ectopic subcutaneous lung tissue one week after transplantation. b, Low 
and high magnification images of mature lung tissue and transplanted tissues one week 
after transplantation. White arrows highlight large alveolar structures. 
 
3.3.2. ICC hydrogel scaffold promotes vascularization to transplanted tissue.  
We next examined if co-implanted ICC hydrogel scaffolds promote the formation 
of host blood vessels and vascular connection with the transplanted liver tissue. To validate 
functional vascular connection between transplanted liver tissue and the host, we 
intravenously perfused Evans Blue dye in mice carrying 1 week implants 20 minutes before 
sacrifice. Gross examination confirmed rich perfusion of Evans Blue dye in scaffold-
assisted transplants whereas limited perfusion was evident in Scaffold-free transplants 
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(Figure 3.4a). Spatial distribution of the perfused dye was substantiated with IVIS 
fluorescent imaging. In scaffold-assisted transplants, strong fluorescence was localized to 
the area containing liver tissue (Figure 3.4b). Quantitative analysis revealed scaffold 
assisted liver tissue implants showed at least 2.5-fold higher fluorescence signal than 
Scaffold-free implants. Blank-scaffolds showed 25% higher fluorescence than BMSC-
scaffolds (Figure 3.2c).  
 
Figure 3.4. Characterization of vascular perfusion using Evans Blue.  
a, Experimental schematic of Evans Blue perfusion experiment and gross image of 
transplanted liver tissue and surrounding subcutaneous tissue. b, Gross and fluorescent 
images of explanted tissues substantiating localized Evans Blue dye within transplanted 
liver tissue. c, Quantitative comparison of Evans Blue dye fluorescence in hepatic tissues 
one week after transplantation. (N=3 implants per group, *P<0.05) 
 
 Small sinusoidal blood vessels present in the transplanted liver tissues were 
visualized via endomucin antibody staining. In all transplants, intrinsic hepatic sinusoidal 
features were preserved. Blood vessels in the surrounding fibrotic capsule were less 
organized with branched morphology (Figure 3.5a-d). Quantitative analysis of endomucin 
expression in the liver tissue revealed that the overlapping region of endomucin and 
endogenous DsRed fluorescence in BMSC-scaffolds was 63 % and 35 % higher compared 
to Scaffold-free and Blank-scaffold transplants, respectively (Figure 3.5e). In the 
surrounding fibrotic tissue area, blood vessel density was significantly higher in scaffold 
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assisted transplants regardless of BMSCs and at least 2-fold higher than Scaffold-free 
controls (Figure 3.5f). The discrepancy between Evans blue characterization and 
immunohistostaining results may be due to immature vasculature and increased leakiness 
in Blank-scaffold samples. 
 
Figure 3.5. Vasculature staining in scaffold-free and scaffold assisted liver tissue. 
 a-d, Immunohistostaining (IHS) images of native DsRed liver (a), Scaffold-free (b), 
Blank-scaffold (c), and BMSC-scaffold (d) transplanted tissues. Higher magnification 
images show hepatic sinusoids and newly generated blood vessels that surround the 
transplanted tissue. e, Quantitative comparison of endomucin+ hepatic sinusoid retention 
in ectopic tissue transplants. f, Quantitative comparison of endomucin+ blood vessel 
density in surrounding host tissue. (N=3-5 implants per group, *P < 0.05)  
        
 We further characterized vascular reconnection via injecting MDA-MB-231 human 
breast cancer cells that stably express eGFP into mice bearing transplanted liver tissues. 
Three days after injection, tissue was removed and analyzed for dissemination to the 
transplanted liver tissue (Figure 3.6a). Imaging for endogenous eGFP disseminated tumor 
cells (DTCs) confirmed the presence of tail vein delivered human breast cancer cells in 
liver transplants in proximity to positively stained endomucin blood vessels (Figure 3.6b). 
Scaffold-free tissues had significantly fewer DTCs compared to Blank-scaffold and 
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BMSC-scaffold hepatic tissues (Figure 3.6c). Taken together these results demonstrated 
that BMSC-scaffolds improved preservation of intrinsic hepatic sinusoids and assisted in 
reaching stably reconnected vasculature compared to Scaffold-free and Blank-scaffold.   
 
Figure 3.6. Circulating tumor cell dissemination to ectopic liver tissue.  
a, Experimental schematic of functional vascular reconnection assay in scaffold-assisted 
ectopic transplant via intravenous delivery of human MDA-MB-231 cells. b, IHS of 
endogenous eGFP MDA-MB-231 cells, endomucin+ hepatic sinusoids, and endogenous 
DsRed+ hepatocytes. White arrow highlights DTC. c, Quantitative comparison of DTCs in 
transplanted liver tissues. (N=9 sections from 3 implants per group except Scaffold-free 
(N=2), *P < 0.05) 
 
3.3.3. Biomaterial scaffold modulates innate immune cell migration.  
Transplantation evokes a foreign body response, during which innate immune cells 
are recruited to the transplanted tissue and wound healing mechanisms act to resolve tissue 
disruption. We investigated the recruitment of mouse neutrophils and macrophages in the 
transplanted tissue microenvironments via IHS of Ly6G and F4/80, respectively (Figure 
3.7a-d). Ly6G+ neutrophils are early responders in the foreign body response. Ly6G+ cell 
infiltration was significantly higher in transplanted liver tissue compared to native liver 
regardless of the presence of a scaffold. However, Scaffold-free hepatic tissue had a 118-
fold increase in Ly6G+ cells over native tissue compared to 49-fold and 20-fold increase in 
Blank-scaffold and BMSC-scaffold groups, respectively. Samples collected two weeks 
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after transplantation had no significant differences in Ly6G+ cell infiltration indicating 
potential resolution of acute response by Ly6G+ cells. Interestingly, the surrounding tissue 
around Blank-scaffold and BMSC-scaffold transplants displayed a 10-fold and 21-fold 
increase in Ly6G+ cells compared to Scaffold-free transplants after one week, respectively. 
The surrounding tissue of BMSC-scaffolds had the highest infiltration of Ly6G+ cells one 
week after transplantation, however by week two the Ly6G+ cell significantly decreased 
and was not significantly different from Scaffold-free and Blank-scaffold values (Figure 
3.7e). Unlike neutrophils, macrophages are abundant in native liver tissue. Scaffold-free, 
Blank-scaffold, and BMSC-scaffold transplants contained at least 4-fold fewer F4/80+ cells 
than native liver tissue. There were no differences in macrophage recruitment to the 
surrounding tissue in any of the experimental groups. The skewed distribution of F4/80+ 
cells between the hepatic and the surrounding tissue remained in two weeks after 
transplantation (Figure 3.7f). Examination of transplanted lung tissue in Scaffold-free and 
BMSC-scaffold transplants showed similar modulation of Ly6G+ cell recruitment and 
macrophage response (Figure 3.8). These results demonstrate that the presence of the 
scaffold altered the pattern of Ly6G+ cell recruitment during the foreign body response, 




Figure 3.7. Scaffold derived immune modulation.  
a-d, IHS images of Ly6G+ neutrophils and F4/80+ macrophages with nucleus (DAPI) and 
hepatic tissue (DsRed) in native (a), Scaffold-free (b), Blank-scaffold (c), and BMSC-
scaffold (d). High magnification images show interface between hepatic tissue implant and 
host tissue. e, Quantitative comparison of Ly6G+ neutrophil density in native liver tissue 
and ectopic tissue transplants and their spatial distribution between transplanted liver and 
surrounding biomaterials 1 and 2 weeks after transplantation. f, Quantitative comparison 
of F4/80+ macrophage density in native liver tissue and ectopic tissue transplants and their 
spatial distribution between transplanted liver and surrounding biomaterials 1 and 2 weeks 
after transplantation. g, Proposed mechanism of improved ectopic tissue engraftment via  
pro-angiogenic and immunomodulatory scaffold that improves vascular reconnection 
while diverting immune cell recruitment to the biomaterial. (N=3-7 implants per group 




Figure 3.8. Immunomodulatory effects of ICC hydrogel scaffolds and immune cell 
migration on transplanted lung tissue. 
a-c, IHS of Ly6G+ and F4/80+ cells within native DsRed lung (a) and transplanted lung 
tissue without (b) and with BMSC-seeded scaffold (c). d, Quantitative analysis of Ly6G+ 
distribution within transplanted tissue. e, Quantitative analysis of Ly6G+ distribution in 
surrounding tissue. f, Quantitative analysis of F4/80+ distribution within transplanted 





3.3.4. Scaffold-assisted transplantation of patient-derived gastric cancers aids 
maintenance of intrinsic tissue heterogeneity.  
Next, we investigated the translational potential of scaffold-assisted 
xenotransplantation by transplanting seven human patient-derived gastric cancers into 
immunodeficient BALB/c nude mice. Patient-derived gastric cancer poorly engrafts when 
transplanted into immunocompromised mice with reported engraftment rates ranging from 
15-28 %169-171. As with most PDX models, non-cancerous human cells are often lost during 
xenotransplantation into mice. We hypothesized that the co-implantation of patient-derived 
gastric cancers with a biomaterial scaffold would assist in tissue engraftment, and in doing 
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so maintain intratumoral cellular heterogeneity (Figure 3.9a). To enhance the effect of the 
ICC scaffold, we seeded them with patient-derived cancer-associated fibroblasts (CAFs). 
CAFs have been documented to secrete numerous molecules that can stimulate cancer cells 
and non-cancerous cells in the tumor microenvironment172-173.  The ICC scaffold described 
above was altered to accommodate larger tissue pieces by increasing the diameter to 12 
mm while maintaining the same chemical composition, pore diameter and surface coating. 
Round, 2 cm pieces of gastric cancer tissue were removed from patients and stored in 
complete media with antibiotics. The tumor pieces were split into smaller 3-5 mm pieces, 
and then placed on top of the prepared scaffold. Scaffold material that exceeded the 
diameter of the tumor tissue was carefully removed using a razor blade. Placement on top 
of the scaffold rather than within the scaffold was chosen to increase the surface area 
between scaffold and PDX samples, increasing the effect of CAF-related soluble factors 
(Figure 3.9b). One scaffold-assisted or scaffold-free tumor was implanted into 4-6 week 
old male BALB/c nude mice (Figure 3.9c). In each PDX study, engraftment was checked 
after 2 weeks via palpation. If at least one tumor from the patient grew we continued the 
experiment for a maximum of 6 weeks (Figure 3.9d). Engraftment was considered 
successful if tumors remained by the end of the study. At the end of the experiment mice 
were sacrificed and the samples were prepared for histological evaluation. Tumor 
morphology appeared to be conserved following transplantation in successfully engrafted 
tissues (Figure 3.9e). Overall, 11 scaffold-free and 30 scaffold-assisted cancer pieces were 
transplanted into mice (Figure 3.9f). The frequency of transplanted tumors that displayed 
incremental growth was slightly higher in scaffold-free xenografts than scaffold-assisted 
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xenografts (43.3% vs 36.4%) but statistical analysis using a logistic regression did not show 
a significant effect of scaffold on PDX engraftment (P=0.5965) (Figure 3.6g). 
 
Figure 3.9. Patient derived tumor transplantation.  
a, Experimental schematic of scaffold-assisted human gastric tumor xenograft strategy. b, 
Gross images of scaffold-assisted patient gastric tumor biopsy and subcutaneous 
 transplantation into Balb/c nude mice. c, Gross images of PDX implants beneath the skin 
with and without scaffold. d, Gross image of successful PDX engraftment and extracted 
sample with scaffold removed. e, Histological comparison of gastric tumor tissue structure 
between primary and PDX tumors with H&E staining. f, Table of patient tumor 
information, implantation duration and engraftment success. g. Summary of PDX 
engraftment with and without scaffold.  
 
 Multiple microenvironment (mLy6G, endomucin, alpha-smooth muscle actin), 
human tumor (hVimentin, hCytokeratin, hCD45, hCD44) and mitogenic (Ki67) markers 
were evaluated in scaffold-assisted and Scaffold-free tumor transplants (Figure 3.10a). 
Alpha-smooth muscle actin (αSMA) is expressed by activated fibroblasts174. Vimentin and 
cytokeratin are mesenchymal and epithelial cell markers, respectively175. hCD45 is a pan-
leukocyte marker, and hCD44 is a marker associated with cancer stem cells176. Tumors 
implanted with a scaffold had significantly more proliferative cells (Ki67+), and human 
immune cells (hCD45+) (Figure 3.10b). There was no difference in other tumor related 
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markers between the two groups indicating scaffold-assisted transplantation did not 
negatively affect the tumor phenotype compared to control. Proliferative human immune 
cells (i.e. double positive Ki67 and hCD45) were rare in both scaffold-free and scaffold-
assisted PDX transplants (Figure 3.11). Taken together, IHS results demonstrate higher 
mitogenic and human immune cell activity in human tumors co-implanted with 
biomaterials compared scaffold-free controls. 
 
 
Figure 3.10. Histological analysis of PDX tissue.  
a, IHS comparison of mouse cells, human cells, and mitogenic marker expression of 
patient-derived gastric tumor microenvironments engrafted without and with scaffolds. b, 
Quantitative comparison of each marker in PDX tumors transplanted without and with 





Figure 3.11. Proliferative status of hCD45 cells in PDX samples. 
IHS of mitogenic status (Ki67) of tumor resident human immune cells (CD45) 
transplanted without and with scaffold.  
3.4 Discussion 
The ability to modulate the biomaterial-host immune response is an exciting 
enabling step in the realization of many biomedical technologies154, 156. For example, 
biomaterials have widespread success in modulating osteoblast and osteoclast activity 
during bone tissue repair177. Biomaterial encapsulation of islet cells has shown promise in 
being a functional treatment for diabetic patients178. Immunomodulatory nanomaterials 
have been developed to target inflammatory monocytes and alter lymph node activity in 
vivo179. Implantable biomaterial-based cancer vaccines take advantage of the influx of 
dendritic cells to boost the host immune response against cancer180-181. A removable 
biomaterial strategy after subcutaneous implantation leaves behind a fibrotic tissue pocket 
that has been exploited for islet cell delivery143. Implantable polymeric biomaterials that 
attract circulating tumor cells have shown the feasibility to reduce the risk of metastasis in 
vital organs103-104. The inversed spherical pore geometry of ICC hydrogel scaffolds directs 
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the formation of distinct inflammatory microenvironments, with a pro-inflammatory milieu 
at the pore surface and an immune-suppressive niche within the pore cavity119. This 
phenomenon enables enhanced vascularization with reduced fibrotic encapsulation while 
maintaining pro-inflammatory immune cell activity116, 182-183. Previously we exploited 
these features in creating humanized metastatic tumor microenvironments consists of 
human immune, stromal and tumor cells to study systemic investigation of humanized 
tumor microenvironment and identify critical events in metastatic relapse96-97, 101. In the 
present study, we demonstrate a new translational opportunity of biomaterials to improve 
ectopic and xenogeneic transplantation of tissues and tumors. The findings of this work 
can be leveraged to improve preclinical mouse models to better reflect human biology and 
disease.  
A foreign body reaction is a physiological host response to a foreign object within 
the tissue, whereby the object is encapsulated with a fibrotic capsule, effectively sealing it 
off from the host149. We intended to exploit the angiogenic activity of the foreign body 
response to improve the transplantation of mature tissue into the subcutaneous space by 
co-implanting a porous biomaterial scaffold. The effects of this co-implantation strategy 
were three-fold. First, mechanical deformation of the transplanted tissue was minimized 
due to the structural stability of the scaffold. ICC scaffolds composed of at least 30 wt% 
polyacrylamide do not deform when implanted101. This property enabled the preservation 
of original tissue structures, maintaining tissue complexity and heterogeneity compared to 
collapsed Scaffold-free transplanted tissues. Second, increased inflammatory signaling due 
to the presence of the biomaterial scaffold modulated the recruitment of innate immune 
cells by attracting them to the biomaterial rather than within the transplanted tissue. Third, 
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implantation of biomaterials accelerated vascularization to the transplant by increasing pro-
angiogenic signaling molecules such as molecules such as VEGF184. The pro-inflammatory 
and pro-angiogenic milieu generated by co-implanted biomaterial demonstrated a distinct 
advantage over scaffold-free transplants. The addition of hBMSCs on the surface of the 
ICC hydrogel scaffolds further enhanced the results of the scaffold-assisted approach. 
hBMSCs are known to secrete various immunomodulatory and angiogenic molecules101, 
167. We have previously demonstrated hBMSCs can maintain secretory function after long-
term (12 week) subcutaneous implantation49. The large surface area of ICC hydrogel 
scaffolds permits the accommodation of a high density of stromal cells. Seeding of tissue-
specific stroma may provide further supportive functions to transplanted tissues. 
Neutrophils and macrophages are innate immune cells that play an important role 
in inflammation, tissue remodeling, and fibrosis. As an early responder, neutrophils create 
an inflammatory environment through release of cytokines, chemokines, reactive oxygen 
species, and neutrophil extracellular traps (NETs)185-186. Release of reactive oxygen species 
and tissue digesting enzymes can be particularly disruptive and cause graft tissue 
damage187. However, neutrophil derived matrix metalloproteases and NETs have been 
implicated in enhancing angiogenesis188-189. Synthetic polymer scaffolds have been shown 
to elicit a strong immunological response compared to extracellular matrix scaffolds155. In 
the presented study scaffold-assisted samples have benefited from pro-angiogenic features 
of neutrophils without direct, potentially disruptive physical interaction. A recent report 
suggests that hBMSCs alter neutrophil response toward an immunosuppressive phenotype, 
which in the context of this study may have further enhanced the viability of transplanted 
tissues190. Our findings suggest hBMSCs were the cause of increased neutrophil 
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recruitment compared to biomaterial alone, but it is difficult to conclude if this was linked 
to the increase in angiogenesis. Further transient studies of neutrophils and biomaterial may 
elucidate their biological function. Macrophages are another important innate immune cell 
type in the foreign body response and secrete a variety of inflammatory signals that can 
lead to fibrotic encapsulation191. Here macrophages were predominantly localized to the 
surrounding tissues regardless of the presence of biomaterial. Interestingly, we observed a 
notable reduction in macrophages derived from donor liver tissue after transplantation, 
which is potentially due to a migratory response to the strong inflammatory signals in the 
surrounding tissue. The functional consequence of macrophage attrition in ectopically 
engrafted liver remains to be determined as tissue resident macrophages play diverse roles 
in liver function. 
In the presented study we explored the application of scaffold-assisted 
transplantation to improve human PDX models in mice. Due to technical challenges, 
orthotopic transplantation of PDX tumors is rarely performed therefore subcutaneous 
implantation is primarily utilized. Although engraftment can still occur, the difference in 
the local stroma can change tumor behavior and growth. PDX models are also hampered 
by the rate of engraftment and overall engraftment efficiency. The rate of engraftment 
normally takes between 2-8 months before developing a preclinical model130. The 
efficiency of gastric cancer engraftment is also low, with over 70 % of xenografts failing 
to grow169-171. Finally, the local stroma of PDX models gradually becomes replaced with 
mouse cells, leading to a loss of heterogeneity which can skew preclinical testing and result 
in poor patient efficacy. Based on the ectopic mouse liver tissue transplant experiments we 
adjusted the strategy for the scaffold-assisted PDX model. First, we utilized nude mice, 
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which are only deficient in mature T cells to minimize the loss of immunological response 
on the tumor. A recent study showed that mice reconstituted with human immune 
progenitor cells prevented genetic drift within engrafted PDX tumors by better 
recapitulating the tumor microenvironment133. Second, we changed the configuration of 
biomaterial and transplant to increase the interface and subsequent effect of CAFs. The 
presence of CAFs seeded on the scaffold may have provided supportive cytokines and 
growth factors to resident human immune cells in addition to tumor cells to maintain a 
heterogeneous microenvironment. Although the presented results of gastric cancer 
engraftment were sub-optimal, as tumor engraftment between the two groups was 
comparable, detailed IHS characterization distinguished higher percentages of hCD45+ and 
Ki67+ cells within the tumor tissue in scaffold-assisted transplants compared to scaffold-
free controls. We believe further exploration into biomaterial strategies of co-implantation 
with PDX tumors is warranted.  
3.5 Conclusion 
Our results demonstrate a new approach to aid in the transplantation of mature tissues to 
an ectopic, subcutaneous location. By leveraging the acute host response to biomaterial 
implantation, we improved vascularization while keeping potentially disruptive immune 
cells away from the transplant. The presented biomaterial strategy may be applicable for 
the xenotransplantation of human tissues such as the liver and lung potentially enabling the 
study of human disseminated tumors in the context of fully mature human tissues. 
Additionally, we have highlighted a modulatory effect on the tumor microenvironment of 
human gastric cancer PDXs via this co-implantation strategy. We anticipate this approach 
 
 71 
is an important step in expanding the preclinical value of mouse models and achieve better 
understanding of human disease and the discovery of effective therapies. 
3.6 Materials and Methods 
All chemicals and materials were purchased from Sigma Aldrich or Fisher 
Scientific unless specified. All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts-Amherst and Ajou 
University Medical Center. Patient-derived samples were approved by the institutional 
review board of Ajou University Hospital. Informed consent was received from all patients.  
3.6.1 Porous hydrogel scaffold fabrication 
Interconnected porous hydrogel scaffolds were fabricated as previously 
described101. Soda lime glass beads were sorted using an Advantech Sonic Sifter using 250 
µm and 300 µm collection trays. The resulting beads had an average diameter of 275 ± 21 
µm. Glass beads were dispersed in deionized water and gradually loaded into an 8 x 35 
mm or 12 x 35 mm glass vial to a height of 2 mm. A dense lattice structure was achieved 
utilizing an ultrasonic water bath. Water was removed in a 60 °C oven prior to thermal 
annealing of the glass beads in a 664 °C furnace for 4 hours. The annealed glass bead 
templates were infiltrated with a hydrogel precursor solution via centrifugation. The 
precursor solution was composed of 30 wt% acrylamide monomer, 1.5 wt% bis-acrylamide 
crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine accelerator, and 0.2 vol% 2-
hydroxy-2-methylpropiophenone photoinitiator in nitrogen purged DI water. The precursor 
solution was immediately polymerized under a 15 W ultraviolet light source for 15 
minutes. The next day, excess hydrogel was removed by scraping the glass bead template 
with a razor blade on all surfaces. Glass beads were selectively dissolved in alternating 
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washes of an acid solution containing a 1:5 dilution of hydrofluoric acid in 1.2 M 
hydrochloric acid, and 2.4 M hydrochloric acid. Washes were performed on a shake plate 
and the solutions were changed every four hours until the beads were removed. Scaffolds 
were washed with DI water to remove residual acid and lyophilized. Cracked or misshapen 
scaffolds were removed before proceeding. Scaffolds were sterilized with 70% ethanol and 
the scaffolds were surface treated with Sulpho-SANPAH to covalently crosslink rat-tail 
collagen. Scaffolds were stored at 4 °C in sterile phosphate buffered saline.  
3.6.2 Cell culture of hBMSCs and seeding onto ICC scaffold 
Human bone marrow aspirates were acquired from Lonza and isolation was 
performed as previously described101. Cells were cryogenically frozen in media containing 
10% dimethyl sulfoxide (DMSO). Cells were cultured with alpha modified, minimal 
essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 2% 
penicillin-streptomycin, 0.2% gentamicin, and 1 µg/L recombinant human fibroblast 
growth factor.  Half a million hBMSCs were seeded onto partially dehydrated scaffolds 
and kept in culture for up to one week prior to use. hBMSCs were not used beyond passage 
4 and media was changed every 3 days.  
3.6.3 Sterile DsRed tissue collection and integration into hBMSC scaffold 
A breeding pair of DsRed (005441) was obtained from Dr. Barbara Osbourne. Mice 
were housed in sterile conditions with unrestricted access to food and water. Mice used in 
this study were between 6-13 weeks old. DsRed mice were euthanized via carbon dioxide 
and the liver and lung tissues were harvested in a biosafety cabinet and kept in sterile 
phosphate buffered saline (PBS) over ice. A sterile 3 mm biopsy punch was used on the 
harvested liver and lung to generate tissue inserts. Additionally, a 3 mm hole was created 
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in the center of the hBMSC-seeded scaffolds. The tissue piece was gently inserted inside 
the hole of the scaffold using sterile forceps. Completed scaffold-assisted implants were 
kept in PBS on ice until implantation surgery. 
3.6.4 Subdermal transplantation into NSG mice 
A breeding pair of NOD-scid IL2Rgnull mice (005557) was initially obtained from 
the Jackson Laboratories. Mice were housed in sterile conditions with unrestricted access 
to food and water. Mice used in this study were between 6-13 weeks old. NSG mice were 
anesthetized with 1.5 % isoflurane before removing the dorsal hair with electric clippers 
and Nair. The skin was sterilized using 70 % isopropyl alcohol prep wipes. Mice received 
2 mg meloxicam/kg mouse weight subcutaneously prior to surgery. A subcutaneous pocket 
was created by making a 2 mm horizontal incision in the dorsal space followed by 
expansion of surgical scissors into the incision and expansion. One Scaffold-free or 
scaffold-assisted tissue with or without hBMSCs was inserted into the pocket and the 
incisions were closed with two 7 mm wound clips. Each mouse received four implants. 
Wound clips were removed after 1 week. 
3.6.5 Evans Blue perfusion and quantitative imaging 
Prior to euthanization, mice were injected with a 2 wt% Evans Blue dye at a dosage 
of 2 mL/kg mouse weight. Dye was allowed to perfuse for 20 minutes before euthanization 
via carbon dioxide. Tissues were harvested from the mice and imaged on an IVIS Spectrum 
CT using an excitation wavelength of 640 nm and emission wavelength of 680 nm. 
3.6.6 MDA-MB-231 cell culture and intravenous injection 
MDA-MB-231 human breast cancer cells were cultured with Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin. 
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For intravenous cell injections 2 x 106 cells were suspended in 200 µL of PBS and injected 
into the lateral tail vein using a 27 gauge needle. 
3.6.7 Frozen tissue preparation and sectioning 
At the conclusion of the in vivo experiment, implants were frozen by embedding 
the tissue in Cryomatrix TM and snap-frozen in 2-methylbutane cooled on dry ice. Frozen 
tissue was cut to 20 µm using a NX70 Cryostat. Frozen tissue blocks and sectioned slides 
were stored at -80 °C.  
3.6.8 Immunohistostaining 
Frozen slides were fixed in -20 °C acetone for 10 minutes. Slides were washed with 
a wash buffer consisting of 0.5 % Tween 20 in PBS (PBST) 3 times before blocking in a 
solution containing 10 % normal goat or donkey serum, and 1 % bovine serum albumin for 
1 hour. Following blocking, primary antibodies diluted in blocking solution were added to 
the slides and left in a humidified chamber overnight at 4 °C. Slides were washed 3 times 
with PBST and then incubated with secondary antibodies diluted in blocking solution for 
2 hours at room temperature. Prior to imaging, slides were washed 3 times in PBST and 
stained with a 10 ng/µL solution of DAPI. Fluorescent images were taken on a Zeiss Cell 
Observer SD. A table of primary and secondary antibodies used in this study has been 













Table 3.1. List of antibodies used for immunohistostaining 
Target Vendor Catalog Number 
Rat – anti-Endomucin Invitrogen 14-5851-81 
Rat – anti-Ly6G Becton Dickinson 557445 
Rat – anti-F4/80 Becton Dickinson 565409 
Mouse – anti-CD44 Becton Dickinson 550392 
Mouse – anti-CD45 Becton Dickinson 550539 
Mouse – anti-Vimentin Dako M072529-2 
Guinea pig – anti-Cytokeratin Lifespan Biosciences LS-C193787 
Rabbit – anti-Ki67 Abcam Ab16667 
Donkey – anti-Albumin Bethel Laboratories A90-134A 
Rabbit – anti-α-Smooth Muscle 
Actin 
Abcam Ab5694 
Goat – anti-rat AF488 Life Technologies A11006 
Goat – anti-mouse AF660 Life Technologies A21054 
Goat – anti-mouse AF488 Life Technologies A32723 
Goat – anti-guinea pig AF647 Life Technologies A21450 
Goat – anti-rabbit AF568 Life Technologies A11011 
Donkey – anti-goat AF488 Life Technologies A11055 
 
 
3.6.9 Human cancer and fibroblast isolation and transplantation 
Human gastric cancer specimens were obtained from patients undergoing tumor 
resection surgery at the Ajou University Hospital as previously described172. Fibroblasts 
were isolated from gastric cancer tissues and were used within six passages. 2.5 x 105 cells 
were seeded onto 12 mm scaffolds. A human gastric cancer specimen (3-5 mm) was placed 
on top of cancer associated fibroblast-seeded scaffolds. After removing excess hydrogel 
matrix, implants were inserted into a subcutaneous pocket made on the dorsal side of Balb/c 
nude mice. The incision was closed using sutures.  
3.6.10 Tissue histology 
Formalin-fixed paraffin-embedded tissue samples from PDX experiments were 
sectioned using a microtome. Sections were cut to a thickness of 6 µm. To deparaffinize 
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sections, slides were treated sequentially with xylenes, 100 % ethanol, 95 % ethanol, and 
50 % ethanol before washing with deionized water. For antigen retrieval, citrate buffer (10 
mM, pH 6.0) was preheated to 90-95 °C on a hotplate before slides were immersed and 
incubated for 20 minutes. The antigen retrieval solution was then removed from the 
hotplate and allowed to cool to room temperature. Slides were washed with PBST solution 
before beginning the standard blocking and antibody staining procedure. Hematoxylin and 
eosin (H&E) staining were performed as previously described101. Brightfield images were 
taken on an EVOS FL Auto microscope. 
3.6.11 Image analysis 
All image processing and quantitative analysis was performed in ImageJ. For 
overlapping quantification, DsRed images were used to identify the transplanted tissue 
area.  
3.6.12 Statistics 
Unpaired Student’s t tests were performed for comparison of the mean values 
between groups in mouse tissue implantation studies. A logistic regression analysis was 
used to evaluate the effect of scaffold on PDX engraftment. Mann Whitney U test was 
performed to analyze the statistical significance of immunohistostaining measurements of 
markers in PDX tumor experiments. Statistical significance was determined if p < 0.05 for 






IMPLANTABLE PRE-METASTATIC NICHES FOR THE STUDY OF THE 
MICROENVIRONMENTAL REGULATION OF DISSEMINATED HUMAN 
TUMOR CELLS 
 
Adapted with permission from Ryan Carpenter, Jun-Goo Kwak, Shelly Peyton, and 
Jungwoo Lee. Nature Biomedical Engineering. 2018 2, 915-929. DOI: 10.1038/s41551-
018-0307-x. Copyright 2018 Springer Nature.   
4.1 Abstract 
Cancer survivors often carry disseminated tumor cells (DTCs), yet owing to DTC 
dormancy they do not relapse from treatment. Understanding how the local 
microenvironment regulates the transition of DTCs from a quiescent state to active 
proliferation could suggest new therapeutic strategies to prevent or delay the formation of 
metastases. Here, we show that implantable biomaterial microenvironments incorporating 
human stromal, immune and cancer cells can be used to examine the post-dissemination 
phase of the evolution of the tumor microenvironment. After subdermal implantation in 
mice, porous hydrogel scaffolds seeded with human bone marrow stromal cells form a 
vascularized niche and recruit human circulating tumor cells released from an orthotopic 
prostate tumor xenograft. Systemic injection of human peripheral blood mononuclear cells 
slowed the evolution of the active metastatic niches but did not change the rate of overt 
metastases, as the ensuing inflammation promoted the formation of DTC colonies. 
Implantable pre-metastatic niches might enable the study of DTC colonization and 




Tumor cell dissemination and subsequent metastatic relapse is the leading cause of 
death from nearly all cancers. This insidious event has often already occurred when a 
patient is first diagnosed with a tumor. However, not all disseminated tumor cells (DTCs) 
develop lethal metastases within the lifetime of the patient because the formation of 
aggressive secondary tumors is inefficient and lengthy 192. Only a few circulating tumor 
cells (CTCs) disseminate successfully to vital organs, and the majority of these DTCs 
undergo apoptosis or clearance by immune cells 193. Often, CTCs that survive extravasation 
do not immediately proliferate, but instead lay dormant for months to decades until the 
surrounding milieu becomes favorable for regrowth 194-195. Emerging evidence suggests 
that metastatic relapse may not be explained solely by intrinsic genetic instability of DTCs, 
instead bi-directional interaction with the surrounding microenvironment needs to be 
considered 22, 196-197. Understanding how the local milieu surrounding DTCs prevents or 
aids in regaining proliferative phenotypes is imperative to developing better therapeutic 
strategies to prevent or delay lethal metastasis. 
CTCs theoretically spread to a wide range of distant organs, but metastasis limitedly 
occurs in a subset of target organs including the lung, bone, liver, and brain. This non-
random development of metastasis has been recognized as the “Seed and Soil” hypothesis 
198. Recently the “Pre-metastatic Niche” hypothesis further posits that CTCs are actively 
attracted to transiently formed pro-inflammatory microenvironments, driven by signaling 
from the primary tumor, in these distant organs that better support the survival and growth 
of DTCs 21. The key microenvironmental signatures of the pre-metastatic niche include (i) 
a vascular network 48, 63 and associated oxygen tension (i.e. hypoxia) 199, (ii) altered local 
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deposition of extracellular matrix 200-202, (iii) recruitment of bone marrow-derived cells 21, 
29, and (iv) pro-inflammatory immune cell activity 50-51, 203-204. These niche factors are 
believed to attract CTCs and subsequently direct the fate of DTCs to remain in a dormant 
state or proliferate 205. However, the detailed mechanisms through which dormant DTCs 
regain their aggressive phenotype while interacting with the local microenvironment have 
remained uncertain due to the lack of relevant experimental models that can faithfully 
simulate the post-dissemination phase of a dormant-to-active transition of DTCs with high 
analytical power. 
Mouse models have been widely used to understand various aspects of cancer 
biology. For example, spontaneous and experimental metastasis models simulate invasion, 
circulation and dissemination of cells from solid tumors in a physiologically relevant 
manner 65-67. The development of immunodeficient NOD-scid IL2Rgnull (NSG) mice has 
improved the ability to study the biology of human cancer cells in the context of living 
systems 73.  This has greatly advanced knowledge about early stage events in human tumor 
metastasis and the functional interplay between human DTCs and the local stromal 
microenvironment 96. However, there are major limitations in current models to study 
metastatic relapse of dormant human DTCs. First, experimental metastasis models always 
induce both active and dormant DTCs simultaneously, restricting the study of late stage 
metastatic tumor recurrence. Second, rare dormant DTCs are impractical to detect. 
Metastatic relapse becomes evident only after reactivated DTCs establish a clinically 
detectable tumor mass. Third, immunodeficient mice cannot capture the role of the immune 
system in microenvironmental regulation of DTC survival and outgrowth. Fourth, most of 
these mouse models rely on xenografts wherein human tumor cells interact with mouse 
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stromal cells, which does not fully recapitulate human disease. Lastly, these systems offer 
little opportunity to manipulate individual properties of the niche, constraining the ability 
to distinguish the role of individual factors of the tumor microenvironment in regulating 
DTC biology. 
Recently, tissue engineering strategies have been applied to address the 
fundamental limitations of conventional murine metastasis models 160, 206-207. These efforts 
can be divided into two different aspects based on the target tissues. Among the four major 
metastatic prone tissues, bone has been the most successful in tissue engineering. A 
combination of bone inducing biomaterial selection, porous scaffold design, and 
osteogenic growth factors have successfully been applied to generate ectopic bone and 
marrow, mostly beneath the skin 88-89. The addition of human bone marrow stromal cell 
(hBMSC)-derived osteogenic cells and subsequently introduced human tumor cells 
recapitulate humanized bone-specific metastasis 90-94. The second approach exploits the 
transient foreign body response triggered by biomaterials that attract immune cells along 
with CTCs to the site of implantation 96-100. These approaches have been utilized to 
distinguish common biological processes that support aggressive metastatic tumor 
formation 96, 99. Engineered tumor cell attracting niches have also demonstrated 
translational potential as they have been shown to significantly reduce metastatic burden 
in vital organs and resultantly extend the lifespan of tumor bearing mice 103-104, 208. 
However, tissue engineered microenvironments have not been applied for detailed 
investigation of the post-dissemination phase of cancer biology.  
In this report, we introduce a new experimental metastasis model to study the 
evolution of early humanized DTC niches in immunodeficient NSG mice. Functional pre-
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metastatic niches can arise in multiple tissue sites and share pro-inflammatory features 
observed during wound healing and tissue remodeling processes 209. A recent study 
demonstrated that repeated injection of tumor-derived exosomes induced a pre-metastatic 
niche in the liver and lung of mice 210, indicating that a pre-metastatic niche can be 
generated by exogenously delivered factors. Based on this premise, we have developed a 
tissue engineered pre-metastatic niche by subdermally implanting inverted colloidal crystal 
(ICC) hydrogel scaffolds that induce vascularized and pro-inflammatory tissue 
microenvironments. This niche was humanized with hBMSCs preseeded on the scaffolds, 
followed by recruitment of CTCs released from an orthotopic human tumor xenograft. The 
established humanized pre-metastatic niche was applied to determine the long-term impact 
of inflammation triggered by human peripheral blood mononuclear cells (hPBMCs) in 
directing the fate of DTCs. Many solid tumor patients suffering metastasized lesions 
receive chemotherapy and/or radiation therapy and subsequent bone marrow 
transplantation. In these patients, graft-versus-tumor effects have been clinically observed, 
whereby grafted cells reduce tumor burden of the recipient 211. Therefore, we hypothesized 
that the introduction of hPBMCs would reduce long-term metastatic relapse by decreasing 
DTCs. Serial transplantation of early humanized DTC niches into syngeneic naive mice 
permitted prolonged evolution of the tumor microenvironments. Over a 10-week period, 
the kinetics of metastatic relapse were quantitatively monitored under whole body 
bioluminescent imaging. At the end of the study, we identified early, intermediate, and 
overt stages of the metastatic cascade. Deep multiplex imaging and quantitative analysis 
captured the ability of hPBMCs to reduce the number of single DTCs but did not affect the 
incidence of overt metastatic tumor development. Additionally, the importance of 
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vasculature and innate immune cells in regulating the stable-to-active transition of human 
DTCs was substantiated. The presented tissue engineered, humanized, and analytical niche 
model may serve as an enabling tool for the study of microenvironmental regulation of the 
post-dissemination phase of cancer biology and development of targets for anti-metastatic 
therapies. 
4.3 Results  
4.3.1 hBMSC-seeded inverted colloidal crystal hydrogel scaffolds induce a 
vascularized tissue microenvironment in vivo 
We hypothesized that engineered implantable biomaterials could create pre-
metastatic niche-mimicking tissue microenvironments by directing the foreign body 
response to promote angiogenesis and maintain a pro-inflammatory milieu. An isotropic 
porous ICC structure fabricated by a simple and tunable procedure was chosen to 
systematically investigate the role of biomaterial design in directing host tissue response 
by orthogonally manipulating its physical and chemical properties 212-215. ICC geometry 
consists of fully interconnected spherical pore arrays and provides maximal surface area in 
the given volume, increasing the biomaterial-tissue interface to direct the foreign body 
response 216. Cavity diameter and mechanical integrity of the hydrogel matrix were 
recognized as important parameters to direct angiogenesis and subsequent systemic 
recruitment of cells including immune and bone marrow cells. Ultimately, we determined 
that a 6.5 mm diameter, 1 mm thick cylindrical ICC scaffold consisting of 300 ± 15 µm 
pores with 30 wt% synthetic PAA hydrogel was optimal to generate a controlled 





Figure 4.1. Subdermally implanted hBMSC-seeded ICC hydrogel scaffolds develop 
vascularized humanized niches in immunodeficient NSG mice.  
a, Schematic of microsphere template-based fabrication of ICC geometry polyacrylamide 
hydrogel scaffolds. Bright-field image shows ICC structure through transparent hydrogel 
matrix (top), and SEM images show interconnecting junctions and surface immobilized 
type I collagen (bottom). b, Confocal images of tiled top and cross-sectioned scaffolds 
demonstrate homogeneously seeded fluorescently labeled hBMSCs into 3D ICC hydrogel  
scaffolds with typical mesenchymal morphology after adhesion. c, Representative gross 
and histological images of subdermally implanted hBMSC seeded scaffold after 4 weeks 
in NSG mice. H&E (top) and trichrome staining (bottom) shows recruitment of stromal 
and immune cells, and organized collagen architecture, respectively. d, 
Immunohistostaining (IHS) of hVimentin and mCD31 for analyzing spatial characteristics 
of hBMSCs and vasculature within the scaffold. e, f, Quantitative analysis of blood vessels 
(e), and hBMSC localization (f) (n=3 independent scaffolds). g, Comparison of key human 
cytokine secretion from hBMSC-scaffolds before and after implantation for 4 and 12 weeks 
(n=3 independent scaffolds). *P<0.05. 
 
A humanized stromal niche was created by seeding 5x105 hBMSCs onto an ICC 
hydrogel scaffold coated with type I collagen. hBMSCs are adherent fibroblastic cells 
isolated from the human bone marrow that carry multilineage capabilities and high 
secretory activity (Figure 4.2) 167. Confocal imaging confirmed deep and homogeneous 
distribution of hBMSCs, displaying a spindle-like cellular morphology (Figure 4.1b). We 
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previously demonstrated that subdermally implanted ICC scaffolds preseeded with 
hBMSCs significantly enhanced vascularization and hematopoietic cell recruitment 97. 
Four hBMSC-scaffolds were implanted in the dorsal subcutaneous space apart from each 
other in a NSG mice. ICC hydrogel scaffolds facilitated rapid and deep migration of mouse 
immune cells, which was in turn followed by near tissue cell migration and inter-scaffold 
angiogenesis. After 4 weeks, complete inter-scaffold tissue development was confirmed 
under scanning electron microscopy (Figure 4.3). Histological analysis revealed that pores 
were filled with organized dense collagen extracellular matrix and populated with various 
types of hematopoietic cells on the pore surface (Figure 4.1c). Immunohistostaining (IHS) 
for mouse endothelial cell marker, mCD31, and human mesenchymal marker, hVimentin, 
revealed a richly vascularized tissue throughout the scaffold with hBMSCs (Figure 4.1d). 
There was no overlap between mCD31 and hVimentin, indicating that blood vessels were 
mouse tissue derived and hBMSCs did not incorporate with mouse vessels. Interscaffold 
angiogenesis was directed by the biomaterial geometry as vasculature took on branched 
morphology between the scaffold cavities (Figure 4.4). Quantitative analysis revealed that 
most blood vessels and hBMSCs resided at the outer regions of the scaffold, gradually 
decreasing in number toward the center (Figure 4.1e,f). This indicates that the survival of 
hBMSCs was dependent on the rapid formation of inter-scaffold blood vessels. To 
determine whether engrafted hBMSCs remained functional, we examined ex vivo secretion 
of cytokines from hBMSCs remaining in implanted scaffolds 4 and 12 weeks post 
implantation. Explanted scaffolds were cultured ex vivo for 36 hours before conditioned 
media was collected and analyzed for a subset of human cytokines (VEGF, IL-6, and IL-
8) that have implicated importance in angiogenesis and inflammation 21, 217-219. Human 
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cytokine secretion gradually diminished overtime in vivo but was still detectable by ELISA 
(>35 pg/mL) 12 weeks after implantation (Figure 4.1g). The directed foreign body 
response and hBMSC secretome in ICC hydrogel scaffolds reproducibly form an analytical 
tissue microenvironment that recapitulates three key features including (i) vascular 
networks, (ii) bone marrow derived cells, and (iii) inflammatory immune cells. 
 
Figure 4.2. Human bone marrow stromal cell (hBMSC) multilineage potential.  
hBMSCs isolated from human bone marrow aspirate have capability to differentiate into 
adipogenic, osteogenic, and chondrogenic lineage. Undifferentiated, adipogenic, and 
osteogenic images are representative brightfield images displaying changes to 






Figure 4.3. Scanning electron microscope images of complete tissue infiltration into 
PAA ICC hydrogel scaffolds.  
a, Complete tissue infiltration with minimal fibrotic encapsulation of the PAA scaffold. b, 




Figure 4.4. Branched vascular morphology through interconnecting pore in the ICC 
scaffold.  
a, Representative immunohistostaining (IHS) of mCD31 through the scaffold. Blood 
vessels have a branched morphology. b, Vascular branching only occurred in the scaffold 
pores and not at interconnecting junction indicating the vasculature is directed by the 
biomaterial geometry.  
 
4.3.2 Humanized stromal niches attract human CTCs and permit colonization 
We employed an orthotopic xenograft tumor-based experimental metastasis model 
with PC3 human prostate tumor cells that has demonstrated robust engraftment and 
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subsequent metastasis 220-222. After 3 weeks, hBMSC-scaffold implantation, we performed 
an intra-prostate injection of 2x106 PC3 human prostate tumor cells expressing green 
fluorescent protein (GFP) and luciferase (Luc). Engraftment and metastatic spread of 
human tumor cells was non-invasively monitored via whole-body bioluminescent imaging 
(BLI). The efficiency of successful orthotopic engraftment based on BLI was above 90%. 
Unsuccessfully engrafted mice were excluded from experiments. BLI+ mice were 
sacrificed at 8 weeks because mice became moribund due to continuous growth of the 
primary tumor and aggressive metastasis in vital organs (Figure 4.5a). Previous 
characterization demonstrated that by this time point, primary tumors grew in weight to 
about 400 mg and generated roughly 10-50 CTCs per mL of blood 96. At the end of the 
study, gross examination of internal organs confirmed overt metastatic tumor nodules in 
the liver (Figure 4.5b). IHS of explanted tissues confirmed the formation of micro-
metastases in the liver and lung whereas DTCs remained individually in the bone marrow 
and spleen (Figure 4.5c). IHS of humanized stromal niches revealed CTCs had 
successfully disseminated. DTCs were mostly observed in a single cell state but there were 
few colonized DTCs (Figure 4.5d). These results verified that the implanted humanized 
stromal niches recapitulated the microenvironmental complexity, tumor cell attracting, and 






Figure 4.5. Humanized implantable microenvironments recapitulate tumor cell 
receptive and supportive functions of the pre-metastatic niche.  
a, Experimental schematic describing establishment of an orthotopic xenograft tumor and 
subsequent metastasis. b, Gross images of the orthotopic xenograft PC-3 human prostate 
tumor and liver metastasis. Arrows indicate overt metastatic nodules. c, IHS images of 
dissemination and colonization of DTCs in vital organs including the liver, lung, bone 
marrow and spleen. Micrometastatses commonly appeared in the liver and lung while 
DTCs remained mostly in an individual state in the bone marrow and spleen. d, IHS of 
implantable pre-metastatic niche showed both single and colonized DTCs. Green arrow 





4.3.3 Intravenously delivered hPBMCs increased human immune cell complexity 
Immune cells, both innate and adaptive, are important components of the pre-
metastatic niche 21, 223. To add human immune cell complexity, we intravenously injected 
1 x 107 hPBMCs isolated from healthy adult donors into mice bearing hBMSC-scaffolds 4 
weeks after implantation (Figure 4.6a). Initial distribution of hPBMCs was characterized 
24 hours after injection. As expected, hPBMCs were primarily localized to the spleen and 
lung. A relatively low and comparable level of hPBMCs was confirmed across hBMSC-
scaffolds, bone marrow, and liver (Figure 4.6b and Figure 4.7). At the same time point, 
we also determined whether systemically migrated immune cells initiated local tissue 
inflammation. After 36 hours of ex vivo culture, conditioned media for human cytokines 
representative of inflammation (TNF-α, IL-6, and IL-10) were compared to non-hPBMC 
injected controls. Increased inflammatory cytokine secretion was observed in the lung, 
liver, and spleen but not in the bone marrow. hBMSC-scaffolds showed significantly 
increased pro-inflammatory IL-6 but decreased anti-inflammatory IL-10 compared to 
hPBMC-free controls (Figure 4.6c). We then examined the long-term effect of human 
immune cells on tissues and hBMSC-scaffolds by IHS for the pan-leukocyte marker, 
hCD45, 6 weeks after injection of hPBMCs. hCD45+ cells displayed a single cell 
morphology and were observed widespread across the scaffold (Figure 4.6d and Figure 
4.8). Sublineage analysis of human immune cells confirmed both hCD4 and hCD8 T-
lymphocytes were present in the scaffold (Figure 4.9). Diffuse mCD31 endothelial staining 
in hPBMC-injected mice compared to controls indicated leaky and permeable vasculature, 
which is the representative vascular morphology in inflamed tissues 224. Further 
quantitative image analysis confirmed a significant increase in vascular density in the 
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scaffold tissue with hPBMCs compared to controls (Figure 4.6e). Taken together, 
implantable humanized niches gained enhanced inflammatory characteristics after the 
introduction of hPBMCs, however the host animals developed symptoms of systemic graft-
versus-host-disease and became moribund 10-12 weeks post hPBMC injection 225-226. 
 
Figure 4.6. Implantable humanized stromal niches attract systemic hPBMCs.  
a, Experimental schematic describing systemic introduction of hPBMCs followed by 
functional and immunohistological characterization. b, Flow cytometry analysis of 
hPBMC distribution 24 hours after intravenous injection (n=3 mice). c, Analysis of 
inflammatory human cytokine secretion from ex vivo cultured tissues and scaffolds 
retrieved 24 hours after injection. Dotted line indicates cytokine levels from control tissue 
and scaffolds without hPBMCs (n=3 mice). d, IHS of hCD45 and mCD31 in scaffolds 6 
weeks after hPBMC injection with quantitative characterization of hCD45+ cell 
distribution within the scaffolds (n=4 independent scaffolds). e, IHS of mCD31 6 weeks 
after hPBMC injection shows leaky vascular morphology when compared to non-injected 
control and quantitative analysis confirms significantly increased vascular density 




Figure 4.7. Flow cytometry plots of hPBMC migration across various tissue.  





Figure 4.8. Distribution of hCD45 cells in primary mice liver, lung, and implanted 
hBMSC- scaffold 6 weeks after hPBMC injection.  
IHS shows more human immune cells in native mouse tissues than hBMSC-scaffolds. 





Figure 4.9. Human CD4 and CD8 IHS 6 weeks after hPBMC injection. 
 Human CD4 and CD8 cells in hBMSC scaffolds.  
 
4.3.4 Systemic delivery of hPBMCs instigates early stage humanized DTC niches 
Next, we challenged humanized early DTC niches with hPBMCs under the 
hypothesis that mature, functional human immune cells would decrease metastasis. After 
subdermal implantation hBMSC-scaffolds for 3 weeks, 2x106 eGFP-Luc PC3 cells were 
injected into the mouse prostate to form an orthotopic human prostate tumor xenograft. 
The primary tumor grew for 6 weeks before intravenous injection of 1x107 hPBMCs to 
introduce human immune cells to the implanted microenvironments. By this point, the host 
animals carried substantial primary and metastatic tumor burden. Thus, 5 days after 
hPBMC injection, we euthanized mice and characterized the establishment of the early 
humanized metastatic niche in the scaffolds (Figure 4.10a). IHS revealed coexistence of 
human stromal (hVimentin), human immune (hCD45), and human tumor (hCytokeratin) 
cells residing in the same microenvironment (Figure 4.10b). BLI analysis of explanted 
scaffolds revealed 8% of scaffolds produced positive signal from both control (3/36) and 
hPBMC (4/44) injected mice. There was no significant difference in overall bioluminescent 
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signal intensity between hPBMC-injected and control mice (Figure 4.10c). We expected 
hPBMC-induced inflammation of humanized DTC niches altered DTC fate, but these 
results indicated that a longer period of implantation was necessary to substantiate the 
functional consequence. 
 
Figure 4.10. Instigation of humanized pre-metastatic niches with hPBMCs and long-
term monitoring of DTC niche evolution via serial transplantation.   
a, Experimental schematic describing the establishment of early stage humanized DTC 
niches and subsequent instigation by systemic introduction of hPBMCs.  b, Representative 
IHS of humanized early DTC niche including hCytokeratin (tumor), hCD45 (immune), 
hVimentin (stroma) and mCD31 (vessel). Arrows indicate human immune (white) and 
tumor (green) cells. c, Representative ex vivo BLI of explanted scaffolds from primary 
mice and quantified bioluminescent signal with and without hPBMCS. The dotted line 
represents a threshold used to define BLI+ and BLI-. d, Experimental schematic describing 
a strategy to monitor the long-term evolution of humanized DTC niches via serial 
transplantation of intact early metastatic niches to naïve secondary syngeneic mice. e, 
Representative whole body BLI of primary and secondary mice at different time points. 
Gross image of explanted scaffolds from secondary mice showing an overt metastasis. f, 
Quantitative analysis of human DTC growth in scaffolds after transplantation into 
secondary mice via weekly BLI. Scaffolds were classified as BLI-, BLI+, or overt based 





4.3.5 Serial transplantation of humanized DTC niches allowed for long-term 
monitoring of metastatic evolution 
We hypothesized that evolution of the early humanized DTC niches could be 
continued by intact transplantation of the microenvironment to the same anatomical site of 
syngeneic mice. We followed the aforementioned experimental schedule to generate 
humanized DTC niches with and without hPBMCs. Bioluminescent signal from scaffolds 
retrieved from primary mice was checked ex vivo, and BLI negative scaffolds were 
transplanted immediately to naïve NSG mice 6-12 weeks of age. Subsequent metastatic 
relapse was non-invasively monitored on a weekly basis via BLI starting 4 weeks after 
transplantation and continued up to 10 weeks (Figure 4.10d). We did not observe 
noticeable necrotic tissue areas in histological analysis of serially transplanted scaffolds 
(data not shown). Gross observation 3 and 7 days after transplantation showed large blood 
vessels surrounding the scaffolds (Figure 4.11). By the end of the study, serially 
transplanted microenvironments captured a broad range of the metastatic cascade (Figure 
4.10e). Based on bioluminescent intensity and outgrowth beyond the scaffold, we 
categorized scaffold microenvironments into three groups: (i) BLI-, (ii) BLI+ and (iii) 
Overt. BLI+ microenvironments were defined by signal at least 3 times greater than the 
background signal, and the rest were defined as BLI- microenvironments. Background BLI 
signal was determined from mice without injection of luciferin. Overt growth, a 
subcategory of BLI+, described aggressive metastases where the tumor expanded outside 
of the boundary of the scaffold (Figure 4.10f). hPBMC-free mice displayed a gradual 
increase in the number of BLI+ scaffolds over the 10-week period whereas in mice with 
hPBMCs the number of BLI+ scaffolds stabilized 8 weeks after transplantation. By the end 
of the study, 53% (17/32) and 23% (9/40) of scaffolds became BLI+ in hPBMC-free and 
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hPBMC-injected mice, respectively. There was no significant difference in the percentage 
of scaffolds with overt metastasis between the two groups; 6.3% (2/32) in hPBMC-free 
and 10% (4/40) in hPBMC-injected mice. Our results signify the ability of hPBMCs to 
suppress human DTC growth but did not affect the incidence of aggressively growing 
metastases. 
 
Figure 4.11. Large blood vessel recruitment to the transplanted scaffold after 3 and 
7 days in secondary mice. 
  
 
4.3.6 Complete optical sectioning of BLI- scaffolds captured the impact of hPBMCs 
on early DTCs  
We hypothesized that BLI- scaffolds still attracted CTCs, but the number of DTCs 
were low and the cells entered a dormant state. Conventional IHS and flow cytometry may 
not effectively detect rare DTCs due to the technical difficulties of probing entire tissue 
volumes and representative cell recovery after tissue digestion, respectively. To overcome 
these challenges, we adapted the recently introduced CLARITY technique through which 
optically cleared fixed tissues permit microscopic detection of rare cell populations while 
retaining spatial resolution in the tissue microenvironment 227 (Figure 4.12a). A PAA 
hydrogel meshwork (4 wt%) between fixed cellular proteins was formed before removal 
 
 96 
of light scattering lipids, achieved by passive washing with sodium dodecyl sulfate and 
boric acid at 37 °C. Transparency dramatically improved in the scaffold, but light scattering 
was still present, possibly due to ICC geometry, or mismatched hydrogel density between 
the pore cavities and scaffolds (Figure 4.12b). We cut the scaffolds to a thickness of 250 
µm using a cryostat, which allowed complete optical imaging (Figure 4.12c). Sliced 
scaffolds were stained with antibodies for mouse α-smooth muscle actin and human 
cytokeratin to visualize vasculature and tumor cells, respectively. Analysis of the images 
revealed abundant (80-400) single DTCs as well as few (5-30) colonized DTCs throughout 
the BLI- scaffolds (Figure 4.12d). DTCs were detected in all characterized BLI- (6/6) 
scaffolds regardless of hPBMC injection. Complete counts of single and colonized DTCs 
did not show a significant difference between hPBMC-injected and hPBMC-free mice 
(Figure 4.12e). Further spatial analysis revealed widespread distribution of DTCs across 
inner and outer regions of the scaffolds (Figure 4.13). The frequency of colonized DTCs 
in total tumor counts, was two times higher in implants with hPBMCs compared to 
hPBMC-free implants (Figure 4.12f). There was no significant difference in DTC colony 
size among BLI- scaffolds with an average size of 3,700 μm2 (Figure 4.14). These results 
suggest that the implantable pre-metastatic niches effectively attract CTCs and 
subsequently maintain the long-term viability of DTCs. hPBMC injection disrupted DTC 
survival but did not decrease colonization events.  
We then extended cytological profiling of the DTCs to determine intrinsic tumor 
cell properties and proliferative state using standard immunohistostaining. First, we 
examined CD44 expression in DTCs to identify potential cancer stem cells 228-229. About 
29% of primary tumor cells (N=3 primary tumors) co-expressed hCD44 and hCytokeratin 
 
 97 
whereas all observed DTCs (97 DTCs from 4 independent scaffolds) were double positive 
regardless of being in single or colonized states (Figure 4.15). To confirm cellular 
dormancy, we examined the functional status of the DTCs. Several studies have reported a 
subset of markers that are expressed while DTCs are in a dormant state. These markers 
have been shown to be dependent on the microenvironment 43-45, 230. For example, NR2F1 
was shown to promote dormancy in the lung and spleen, however did not play the same 
role in DTCs found in the bone marrow 42. Additionally, the expression of these markers 
is transient and relative, therefore not necessarily informative to distinguish the functional 
state of dormancy 40, 231-232. Thus, we focused on expression of the cell proliferation marker 
Ki67. All singular DTCs found in the scaffold microenvironments (N=107) were Ki67-, 
confirming that these cells were not in a proliferative state. In DTCs that formed colonies, 
only 8.3% (24/252) contained at least one Ki67+ cell. We did not observe any colonies in 
which all cells expressed Ki67. These results suggest that the majority of initial 
proliferating DTCs stop growing and enter dormancy indicating that intrinsic properties of 
early DTCs may be important to initiate metastatic colonization but not sufficient to lead 
to continuous growth. Comparison between scaffolds with and without hPBMCs revealed 




Figure 4.12. Detection of rare dormant DTCs via whole scaffold tissue clearing and 
optical sectioning.  
a, Schematic of tissue clearing process describing hydrogel embedding, tissue clearing, 
thick sectioning (250 µm), and antibody staining of explanted scaffolds. b, Gross images 
of whole scaffold before and after tissue clearing. c, Tiled confocal z-stack images of an 
entire scaffold sectioned into 4 slices. d, Representative tissue cleared scaffold images of 
DTCs as singular and micro-colonies. e, Comparison of complete single and colonized 
DTC counts between BLI- scaffolds with and without hPBMCs. f, Comparison of 
normalized frequency of DTC colony per 100 DTCs in BLI- scaffolds with and without 
hPBMCs. g, Representative HIS of Ki67+ tumor colony (left) and quantitative comparison 
of Ki67+ of single and colonized DTCs between scaffolds with and without hPBMCs 
(right). White arrows identify Ki67+ cells (n= 3 independent scaffolds from mice without 










Figure 4.13. Spatial dissection of DTCs in BLI- scaffolds.  
a, Schematic of BLI- scaffold processing and region designation. b, Normalized 










Figure 4.15. IHS of Ki67, hCD44 and hCytokeratin in a primary tumor and an 
implanted hBMSC-scaffold.  
a, Human CD44 and human cytokeratin do not have high overlap in primary tumor. 
Proliferative regions of the primary tumor had higher overlap than non-proliferative 
regions. b, Nearly all single and colonized DTCs had overlapping human CD44 and human 
cytokeratin. 
 
4.3.7 Comparative analysis of niche factors identifies key microenvironmental 
regulation of DTCs in single-to-colony transition 
Next, we characterized how early DTC niches evolved by probing the local tumor 
microenvironments in single and colonized DTCs. By leveraging the uniform pore 
geometry of the scaffold, we generated a standardized imaging analysis of the 
microenvironment (Figure 4.16a). Antibodies for IHS were chosen to determine the role 
of blood vessels (mCD31), human stromal cells (hVimentin), human immune cells 
(hCD45), and innate mouse immune cells in the single-to-colony transition of DTCs. 
Snapshots were collected in the tumor microenvironment of single cell and tumor colonies 
from at least 4 independent scaffolds (Figure 4.16b). We first determined the proximity of 
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human immune cells to single and colonized DTCs. hCD45+ cells located significantly 
closer to colonized DTCs. About 25% of tumor colonies were infiltrated with hCD45+ 
cells. However, colocalization of single tumor cell and human immune cells was rare 
(Figure 4.16c). Next, we analyzed the correlation between single and colonized DTCs with 
respect to the distance from blood vessels. In general blood vessels were found within 50 
µm of a tumor cell. Without hPBMCs, over 50% of tumor colonies had at least one 
infiltrating blood vessels, but this phenomenon was observed in less than 35% of tumor 
colonies in scaffolds with hPBMCs (Figure 4.16d). As expected, the average colony size 
infiltrated with blood vessels was significantly larger than those without, but there existed 
no significant correlation between tumor colony size and hPBMCs (Figure 4.16e). 
Functional characterization between Ki67+ tumor colonies and blood vessel availability 
revealed that nearly all (8/9) proliferative colonies had infiltrating vasculature. However 
infiltrating vasculature did not guarantee proliferation, only accounting for 26% (9/35) 




Figure 4.16. Quantitative comparison of vascular, stromal and immune niches 
between single and colonized DTCs in single pore microenvironment.  
a, Representative images of dormant human DTC bearing scaffold and schematic of pore 
imaging targets. b, Representative IHS of microenvironments surrounding single and 
colonized DTCs with vascular and cellular niche components including hCD45, hBMSCs, 
mLy6G, and mF4/80. Scale bars 100 µm. c, Comparison of distribution profiles of 
neighboring hCD45+ cells to hTumor cells between single and colonized DTCs (top) and 
frequency mapping of hCD45+ cells (bottom). d, Comparison of distribution profiles of 
nearest mCD31+ cells to hTumor cells with and without hPBMC injection (top) and 
frequency mapping of mCD31+ cells (bottom). e, Comparison of tumor colony size with 
and without infiltrating mVessel. f, Comparison of distribution profiles of mCD31+ cells 
to hTumor with and without neighboring hBMSCs (top) and frequency mapping of 
mCD31+ cells (bottom). g, Comparison of distribution profiles of neighboring mLy6G+ 
cells to hTumor cells with and without hPBMCs (top) and frequency mapping of mLy6G+ 
cells (bottom). Representative values were plotted, selected by ordering datasets and 
averaging every 10 points, when N>100. Data collected from 5 biologically independent 




Figure 4.17. Correlation between tumor infiltrating vessels and proliferative tumor 
colonies.  
Proliferative tumor colonies were always within 25 um of mouse blood vessel. *P<0.05  
 
We extended quantitative analysis of IHS images with other microenvironmental 
components. First, the distance between tumor cells and blood vessels was considered 
when in the proximity of hBMSCs. Although the existence of DTCs and hBMSCs in the 
same pore was rare, as cellularity of hBMSCs decreased over the implantation period, 
tumor colonies that formed near hBMSCs were more likely to be infiltrated with a blood 
vessel than those not closely associated with human stroma (Figure 4.16f). Next, we 
characterized the recruitment and distribution of endogenous mLy6G+, mLy6C+, and 
mF4/80+ cells to determine the role of innate immune cells. Abundant mLy6C+ and 
mF4/80+ cells were observed at the pore periphery in nearly every pore regardless of 
experimental condition indicating that their response was dominantly triggered by the 
biomaterial rather than tumor or human immune cell activities (Figure 4.18). Both 
mLy6C+ and mF4/80+ cells are known critical players in tissue remodeling, secreting 
protease enzymes including matrix metallopeptidase 9 (MMP-9) 233. IHS of MMP-9 
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confirmed localized tissue remodeling activity at the pore surface (Figure 4.19). 
Interestingly, mLy6G+ cells were preferentially localized within tumor colonies, compared 
to single DTCs (Figure 4.16g). The distribution of mLy6G+ cells in tumor colonies was 
independent of their proliferative status confirmed by Ki67 staining (Figure 4.20). Taken 
together these results indicate that increasing vascular connection and recruitment mLy6G+ 






Figure 4.18. HIS of mouse F4/80 and Ly6C in hBMSC-scaffold.  
a, Representative IHS images of mF4/80 and b, mLy6C staining in disseminated tumor 





Figure 4.19. IHS of MMP-9 in hBMSC-scaffolds. 
Representative IHS images of a, mLy6G, b, mLy6C, and c, mF4/80 staining in scaffold 
microenvironment.  High amounts of MMP-9 at the biomaterial scaffold interface. d, 
Quantification of MMP-9 source reveals mF4/80 and mLy6C cells are main producers.  
 
 
Figure 4.20. Correlation between mLy6G and proliferative tumor colonies.  
No change in local mLy6G cell distribution between proliferative and non-proliferative 
tumor colonies. Addition of hPBMCs did not influence distribution. Characterization was 




4.3.8 Multiplex IHS of overt metastasis substantiates the importance of innate 
immune cell influx in continuous outgrowth of DTCs 
To understand how the early DTC microenvironment evolved during metastatic 
relapse, we characterized tumors that had progressed beyond the initial awakening events. 
A panel of 9 different antibodies, hCytokeratin, hVimentin, mCD31, hCD45, Ki67, hCD4, 
hCD8, mLy6G, and mF4/80, and the nucleus stain DAPI were used to visualize and 
quantify cellular signatures in the tumor microenvironment (Table 4.1). Eight consecutive 
histological sections, 20 µm thick, were stained with sets of 3-5 antibodies to generate a 
multiplexed and comprehensive view of the metastatic tumor heterogeneity (Figure 4.21). 
Using ImageJ, individual image channels were centered and overlaid. From these 
cumulative images, eight zones were manually identified that highlighted regions of 
diversity (Figure 4.22a).  






Figure 4.21. IHS of eight consecutive overt metastasis slices with different antibody 
staining. 
Individual monochrome images showing individual antibody staining results on eight 




Figure 4.22. Multiplex IHS imaging-based characterization of heterogeneity in overt 
metastatic microenvironments.  
a, Overlaid IHS images from eight consecutive 20 µm thick slices and manually defined 
zones representing distinct microenvironment profiles with a list of antibodies and their 
associated targets. b, Representative IHS images of each zone with quantitative cellular 
complexity. Bar graphs display intra-zone composition of quantified antibody staining. 
Radial plots represent inter-zone comparison of cellular markers normalized to the zone 
with the highest signal. Top panel highlights human stromal, tumor, and immune 
celllocalization. Bottom panel highlights human and mouse immune cell subset. c, Five 
functional zones capturing different states of metastatic tumors: (1) necrotic tumor, (2) 
active tumor, (3) host tissue, (4) dormant tumor, and (5) intermediate tumor. d, IHS images 
of hCD45 cells found within early DTC colonies (n=5) and overt scaffold metastases (n=3) 
with quantitative representation of overlapping hCD45+ cell coverage. Arrows show 
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 infiltrating hCD45+ cells (white). e, IHS image of mLy6G+ cell localization at the 
boundary of an actively growing overt metastasis and quantitative comparison of Ki67 
stain overlap with human tumor and mLy6G+ cells (n=3). f, Quantitative comparison of 
overlapping mLy6G+ cells in early DTCs and overt scaffold metastases (n=3). *P<0.05. 
 
To quantitatively determine cellular and functional signatures of each zone, we 
developed an imaging analysis pipeline. Two different characterizations were considered 
for quantifying the selected regions (Figure 4.23). The first analysis compared the absolute 
pixel number of each stain within each zone to highlight the makeup of each region, which 
was displayed as a bar graph. The second was a comparative analysis between zones, which 
was plotted on a radial chart broken into two panels; (i) a general overview of cellularity, 
and (ii) the diversity of immune cells (Figure 4.22b). Comparison of the different zones 
revealed similar phenotypes that were categorized into five separable regions. Zone 1 
highlighted a typical necrotic tumor region consisting largely of weak human tumor and 
immune cell markers. Mouse macrophages were present but relatively low compared to 
other regions. A pocket of mouse tissue, zone 4, was characterized by a low signal in human 
cell markers and weak Ki67 signal. Zones 5 and 6 exhibited similar tissue 
microenvironments to a dormant DTC niche; a high number of human stromal and immune 
cells with relatively few mLy6G+ cells were observed, and overall Ki67 signal was weak. 
On the periphery of the scaffold, zones 7 and 8, an increase in vessels and immune cells 
was observed (Figure 4.22c). In contrast to our observation of micro-metastases, the 
frequency of human immune cells in overt tumor regions was significantly lower (Figure 
4.22d). This result was possibly caused by reduction in human immune cells, but IHS of 
spleens revealed the presence of hCD45+ cells suggesting that a subset of human immune 
cells systemically migrate and proliferate in the secondary host. The frequency of hCD45+ 
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cells in the spleen was not significantly different between secondary mice with and without 
overt tumors (Figure 4.24). Zone 2 and 3 contained actively growing tumors indicated by 
high DAPI and Ki67 staining. Zone 2 had higher hCytokeratin signal than zone 3 but only 
half the relative Ki67. High hVimentin in zone 3 suggests a more mesenchymal tumor 
phenotype, which was linked with higher proliferation compared to the more epithelial 
tumor phenotype in zone 2. Colocalization analysis confirmed that Ki67 staining was 
mostly derived from tumor cells and not mLy6G+ cells that were also observed in these 
actively growing tumor zones (Figure 4.22e). mLy6G+ cells limitedly infiltrated overt 
tumor regions and remained on the tumor periphery, opposite to what was observed during 
the early stages of colonization (Figure 4.22f.). Considering the relatively short lifespan 
of mLy6G+ cells, about 1 day 234, this result indicates that mLy6G+ cells continuously 
migrated to actively growing tumors. This phenomenon was repeatedly observed in three 
independent overt metastatic tumors (Figure 4.25). Together these results demonstrate that 
the tumor microenvironment evolves during progression to an overt tumor, including 
phenotypic changes of tumor cells to a more mesenchymal phenotype, and continual 






Figure 4.23. Active tumor microenvironment imaging analysis pipeline.  
1) Images were centered and canvas size equalized.  
2) Scaffold images discretized into 24x24 grid of subimages.  
3) For each antibody positive signal separated from background noise. Total tissue 
area was calculated by increasing background to include autofluorescent tissue. 
4) Positive signal from each subimage was normalized to total tissue area and 
displayed as a heatmap.  
5) Visual inspection of images revealed 8 zones that housed unique features.  
6) Manually determined zones of interest translated to 24x24 grid.  
7) The 8 translated zones were overlaid on images with normalized signal. Normalized 
signal was recalculated for each of the 8 zones.  
8) Intra-zonal composition was performed by dividing the positive pixels for each 
stain and dividing by the summation of all positive pixels from all staining except 
Ki67 and DAPI. Stain compositions were plotted on a bar plot.  
9) Inter-zonal comparison was performed by taking normalized signal from each zone 
and dividing by the largest value for each stain. Thusly, the zone with the highest 
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value for a particular stain would have a value of 1. Quantitative results were 
displayed on a radial plot broken into two different panels.  








Figure 4.24. Human PBMCs enter circulation in secondary mouse host. 
Spleens taken from non-injected (control) and hPBMC-injected mice. Non-overt spleens 
taken from mice without overt-metastasis bearing scaffolds. Overt spleen taken from mice 




Figure 4.25. IHS of mLy6G, Ki67, and hCytokeratin in independent over metastasis.  
IHS of Ki67 and mLy6G localization in independent actively growing overt tumors beyond 





Accumulating evidence suggests that systemic spread of DTCs may be unavoidable 
235, but metastatic relapse can be preventable. For example, low-dosage aspirin 236, 
canakinumab 237, metformin 238, and cabozantinib 239 have demonstrated significantly 
reduced risk for metastasis. It is imperative to develop detailed understanding of how these 
molecules suppress revitalization of dormant DTCs in distant tissue sites. The lack of 
relevant experimental models that can faithfully determine the long-term functional 
consequence of therapeutic intervention in the context of humanized tissue 
microenvironments has been a critical challenge. The presented tissue engineered pre-
metastatic niche model represents a new opportunity to study the post-dissemination phase 
of human cancer biology from three distinct aspects. First, the use of biomaterials to create 
a pre-metastatic niche allowed controlled and analytical experimentation to quantitatively 
distinguish key features of microenvironmental regulation in dormant-to-active transition 
of DTCs. The standardized structure of ICC scaffolds generated reproducible tissue 
microenvironments and streamlined multiplex imaging and comparative analysis of DTC 
niches. Additionally, optical transparency of PAA hydrogel permitted whole tissue clearing 
and complete optical sectioning of tumor microenvironments to detect rare DTCs while 
retaining spatial resolution. Implantation of biomaterials in a subcutaneous pocket enables 
easy accessibility to various functional characterizations including direct measurement of 
tumor growth, BLI, and possible intravital imaging via surgical engraftment of a skinfold 
window chamber 97, 184. The tunable design of ICC hydrogel scaffolds permits easy 
manipulation of physical and geometrical parameters. Recently there has been a substantial 
progress in understanding the interaction between implantable biomaterials and host tissue 
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and immune cells 240. For example, poly-lactic and glycolic acid (PLGA) scaffolds 241 and 
methacrylated alginate cryogels 242 manipulate dendritic cell homing and immune 
response; scaffolds composed of extracellular matrix proteins have modulated pro-
regenerative systemic immune environments 164; physical dimensions of biomaterials 
influence foreign body response 120. These efforts can further empower an implantable pre-
metastatic niche model to study human tumor metastasis.  
Second, in vitro seeding of stromal cells provided additional capability to create 
defined and functional implantable pre-metastatic niches. Here hBMSCs were introduced 
into the scaffold to create humanized stromal niche and modulate foreign body response 
and interscaffold angiogenesis. hBMSCs are known to secrete immunomodulatory and 
proangiogenic molecules, which resultantly attenuate foreign body response 166 and 
enhanced angiogenic activity 97 in previous studies. Similarly, different types and 
combinations of stromal cells can be introduced into biomaterials to induce defined 
functionality of microenvironments. For example, genetically engineered stromal cells that 
secrete specific human cytokines were used to create defined humanized soluble 
microenvironments 134.  
Finally, the transplantation strategy separated early metastatic niches from 
advanced tumors and prolonged the microenvironment evolution to substantiate functional 
mechanisms behind metastatic relapse. Serial transplantation has been commonly 
conducted to maintain intrinsic characteristics of human blood cancer cells and solid 
tumors (e.g. patient derived xenograft tumors) in the context of living system for extended 
periods 243-244. Applying this concept to metastatic tumor microenvironments overcame the 
fundamental limitation of mouse model for long-term evolution of the DTC niche beyond 
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the lifespan of primary host mice, which enabled observation of the full spectrum of post-
disseminated tumor progression. Here we exploited this feature to determine the functional 
consequence of acute inflammation triggered by hPBMC injection. Even though the 
experiment was halted 10 weeks after transplantation, dormant DTC microenvironment 
studies could continue for longer experimental duration. This capability will facilitate 
observation of the long-term dormant DTC niche and the screening of drugs for metastasis 
prevention.  
Intravenous injection of hPBMCs instigated early humanized DTCs niches and 
subsequent metastatic relapse became evident 6 weeks after serial transplantation. The 
incidence of metastasis was significantly lower and stabilized when compared to hPBMC-
free scaffolds. This phenomenon is reminiscent of a graft-versus-tumor response 211, 245-246. 
Comparative analysis of single and colonized DTCs revealed a correlation between human 
immune cells and colonized DTCs, whereas single DTCs did not directly interact with 
human immune cells (Fig. 4.16c, d). Given the observation of reduced DTCs in mice that 
received hPBMCs, direct contact between human immune and tumor cells could be a 
potential mechanism in the elimination of DTCs. Indeed, a previous study showed that 
systemic delivery of hPBMCs prior to the subcutaneous injection of human PC3 tumor 
cells in NSG mice significantly decreased ectopic tumor development with increased 
primary tumor-infiltration of T-lymphocytes 247.  Additional studies reported that T-
lymphocytes within patient-derived xenografts continually proliferated and systemically 
spread to the host NSG mouse 248. Similarly, we confirmed the presence of hCD45+ cells 
in the spleens of secondary mice, indicating that a subset of human immune cells migrated 
out from the scaffolds and potentially continued growth. This could be the mechanism that 
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leads to long-term stabilization of DTC growth in secondary hosts. Although hPBMCs 
reduced overall metastatic relapse, the incidence to develop overt metastasis was not 
changed. Additionally, complete optical sectioning of BLI- scaffolds revealed an increased 
frequency of colonized DTCs in total DTC counts in mice that received hPBMCs (Fig. 
4.12f). These results suggest that although hPBMCs decreased DTC burden, during this 
process they may also increase the chance to initiate colonization of DTCs possibly due to 
local tissue inflammation. However, detailed mechanisms by which human immune cells 
promoted colonization of DTCs remains an open question.  
Previous studies have highlighted vasculature and immune cell interaction as 
critical for reactivation of dormant DTCs 32, 63, 249-252. Our results provide additional 
evidence to support these findings and quantitatively capture the changes in the local DTC 
microenvironments from single, to colonized to overt metastasis. The vasculature is 
initially used by tumor cells to migrate to distant tissues, however during the period of 
dormancy, DTCs remain distant from the vasculature. Quantitative analysis of the blood 
vessels surrounding DTCs revealed that tumor cells begin to proliferate without immediate 
contact with a blood vessel, but their growth could not exceed a cross-sectional area of 
roughly 4,000 µm2 without the connection to a blood vessel. It remains unclear if DTCs 
migrate toward a blood vessel, a vessel is recruited by DTCs, or DTCs and vessels meets 
opportunistically. Recent studies suggest the source of angiogenic signaling may be 
derived from local immune and stromal cells that release proinflammatory or 
proangiogenic factors that initiate endothelial tip cell sprouting 63, 253-254, induce phenotypic 
switching of perivascular cells to a less differentiated state 28, or transiently enhance 
vascular remodeling activity.  
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Additionally, our results substantiate the important role of continuously recruited 
innate immune cells in forming a supportive microenvironment for awakening dormant 
DTCs. mLy6G+ cells consist of several myeloid cells including monocytes, granulocytes, 
and neutrophils. Recent studies have shown that neutrophils are associated with playing a 
key role in initiating metastatic outgrowth 32, 249-252. Deep optical characterization of the 
metastatic niche demonstrated their presence within awakening DTC colonies during initial 
tumor colonization, however it is unclear how the host neutrophils seek out early stage, 
reactivated DTCs and their role in promoting or inhibiting growth. Once a tumor colony 
became an advanced large metastasis, mLy6G+ cells no longer infiltrated but remained on 
the periphery where they were continually recruited. The lack of infiltrating neutrophils 
within overt tumors indicates that the tumor may produce a repulsive microenvironment 
once it has formed a large enough mass. The varying activities of mLy6G+ cells within the 
different stages of tumor development demonstrate the need for deeper understanding of 
myeloid cell biology such as neutrophils in the tumor microenvironment, which may lead 
to more effective anti-metastatic strategies 255. It is possible, and likely that many budding 
metastases fail to evade immune response at the initial stages of outgrowth and become 
terminated. Tumors that can evade microenvironmental control will continue to proliferate 
and gain control of the microenvironment and dictate bi-directional interactions with 
surrounding cells. From our data, we demonstrated that overt tumor cell proliferation 
occurs together with vascularization and exclusion of innate and adaptive immune cells, 
while selectively attracting a subset of innate immune cells to the actively proliferative 




Figure 4.26. Proposed microenvironmental regulation of DTCs during initial 
dormancy, reactivation, and overt metastasis along with the experimental 
transplantation strategy from primary to secondary mice for long-term observation.  
 
The presented implantable pre-metastatic niche model has demonstrated enabling 
features for detailed observation of awakening dormant DTCs in vivo, yet there is still room 
to improve. First, since the established humanized microenvironments are comprised of 
three different donors, human immune interactions are allogeneic, which limits the study 
of adaptive immune system mediated tumor microenvironment regulation. Creating donor-
matched microenvironments is possible by obtaining different tissue cells from the same 
patient but this involves clinical and ethical considerations 256. One alternative solution is 
to use induced pluripotent stem cells that can differentiate into stromal, hematopoietic, and 
tumorigenic cells 257. While the current study has focused on humanized tumor 
microenvironments keeping in mind translational opportunity, for mechanistic studies the 
experimental system could be adapted to an entirely mouse-based model. Second, hPBMC 
injection delivers fully functional human immune cells but the innate immune cell effect is 
restricted to a short-term period due to their limited lifespan; the average lifespan of 
monocytes and neutrophils are about 1 week and 24 hours, respectively 234, 258. Instead, 
repeated injection of human granulocytes into the humanized mice could replenish short-
lived immune cells. Alternatively, the transplantation of human hematopoietic stem cells 
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could stably provide human innate immune cells, but differentiated human immune cells 
in the mouse bone marrow may not carry full functionality 259. Emerging data including 
our own has demonstrated that innate immune cells play a critical role in regulating the 
tumor microenvironment 260-262. Innate immune cell activity does not strictly rely on the 
highly specific binding required for adaptive immune cells, and thus human tumor and 
mouse innate immune cell interaction may be clinically relevant.  Third, the prolonged 
local foreign body unnaturally elevated macrophage activity and may not accurately reflect 
physiological situations. Recent studies have shown that locally implanted biomaterials 
modulate systemic immune response and host regenerative potential 164, 263-264. 
Additionally, biomaterial-induced myeloid cell responses were shown to be tunable by 
incorporating macrophage selective drugs e.g. clodronate for macrophage depletion 184. 
Finally, transplantation of the intact microenvironments possibly caused brief temporal 
oxygen and nutrient deprivation. Aside from intrinsic changes to DTCs, their fate can be 
critically influenced by the secondary host cells, especially immune cells. We minimized 
this potential effect by using syngeneic mice and implanted the microenvironments to the 
same anatomical locations. However, a similar clinical scenario has been reported in the 
field of organ transplantation where dormant DTCs in the donor organ developed 
metastasis in the recipient 49, 265. Indeed, this feature may provide a new opportunity to 
investigate the role of local and systemic tissue microenvironments by altering the recipient 
host animal in terms of age, immune competence, and implantation site. 
Mouse models play a critical role in advancing our understanding of cancer 
metastasis, however their capability to capture the long-term evolution of the metastatic 
niche and their relevance to humans remains questionable. Tissue engineered humanized 
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metastasis models can reduce the pre-clinical gap and potentially uncover new biological 
interactions between human tumors and the surrounding microenvironment. Studies can be 
readily extended to characterize the extracellular matrix, and molecular and genetic 
profiles. One promising future direction is to combine comparative analysis based on 
endpoint IHS characterization with temporal observation of cellular processes via intravital 
or ex vivo imaging, which will enable deeper mechanistic understanding of the DTC niche 
evolution. The established metastasis model can also be applied to screen the effectiveness 
of drugs targeting DTCs and secondary outgrowths. Taken together, we envision that tissue 
engineered strategies will provide an invaluable tool to answer provocative hypotheses 
emerging in the cancer field and advance clinical translation of anti-metastatic therapeutic 
strategies. 
4.5 Materials and Methods 
All chemicals and materials were purchased from Sigma Aldrich or Fisher 
Scientific unless specified. All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts-Amherst. 
Experiments and handling of mice were conducted under federal, state and local guidelines.  
4.5.1 Type I collagen coated inverted colloidal crystal hydrogel scaffold fabrication 
 Inverted colloidal crystal hydrogel scaffolds were fabricated following the 
previously reported methods (33). Soda lime glass beads were sorted using an Advantech 
Sonic Sifter for each range with ~8% deviation. Beads dispersed in deionized (DI) water 
were gradually loaded into a glass vial (8 x 35 mm) to a height of 2-2.5 mm and were 
mechanically packed into a lattice structure in an ultrasonic water bath. Orderly packed 
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glass beads were dried in a 60 °C oven and then thermally annealed between 650 and 680 
°C depending on the bead size for 4 hours in a furnace. A hydrogel precursor solution 
composed of 5, 15, 30, and 50 wt% acrylamide monomer, 1.5 wt% bis-acrylamide 
crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine accelerator, and 0.2 vol% 2-
hydroxy-2-methylpropiophenone photoinitiator in nitrogen purged DI water was prepared 
immediately before use. 150 µL of precursor solution was infiltrated into the glass bead 
template and centrifuged in a microcentrifuge at 9,000 RPM for 15 min and subsequently 
polymerized under a 15 W ultraviolet light source for 15 minutes. Polyacrylamide 
hydrogel-glass templates were removed from the glass vials the next day to ensure 
complete polymerization. Excess hydrogel was removed by scraping the glass bead 
template with a razor blade on all surfaces. Glass beads were selectively dissolved in 
alternating washes of an acid solution containing a 1:5 dilution of hydrofluoric acid in 1.2 
M hydrochloric acid and 2.4 M hydrochloric acid (Caution: These chemicals are corrosive 
and must be used in a fume hood with proper protective gear). Washes were completed on 
a shake plate and solutions were changed every four hours until the beads were removed. 
Scaffolds were thoroughly washed with DI water to remove residual acid and lyophilized. 
Following lyophilization, scaffolds were resuspended in CryomatrixTM embedding resin 
and cut to 1 mm thickness on a CryoStar NX70. After thorough washing in DI water, 
scaffolds were sterilized with 70% ethanol and stored at 4 °C in sterile phosphate buffered 
saline solution (PBS). The final pore dimension of the optimized scaffolds used for the 
remainder of the study was 300 ± 16 µm. To support stromal cell adhesion on 
polyacrylamide hydrogel scaffolds, type I collagen extracted from rat tails was covalently 
immobilized on the pore surface using Sulfo-SANPAH conjugate chemistry. 
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4.5.2 Human BMSC isolation and culture expansion 
50 mL of bone marrow aspirate obtained from a healthy donor was purchased from 
Lonza. Mononuclear cells were isolated via density gradient based centrifugation using 
Ficoll Paque (GE) at 1500 RPM for 30 minutes using minimum acceleration and no brake. 
Mononuclear cells were plated on T-225 flasks with Minimum Essential Medium Eagle, 
alpha modified (αMEM) supplemented with 20% FBS, 2% penicillin-streptomycin, 0.2% 
gentamicin, and 1 µg/L recombinant human fibroblast growth factor. After 1 week, 
colonies of adherent cells were harvested, cryogenically frozen in media containing 10% 
DMSO, and stored in a cryotank. The multilineage differentiation potential of hBMSCs 
were tested using standard protocols.  
4.5.3 Human BMSC seeding and culture on a 3D hydrogel scaffold 
Collagen coated ICC hydrogel scaffolds were partially dehydrated by removing 
excess PBS and drying in a biosafety cabinet. 5 x 105 hBMSCs suspended in 20 µL of 
growth media were dropped on top of a partially dehydrated scaffold. The cell suspension 
was drawn into the dried scaffold, facilitating deep and homogenous cell seeding in the 3D 
scaffolds. Cell loaded scaffolds were incubated for 20 minutes in a CO2 incubator to allow 
initial cell adhesion. Cell-scaffolds were transferred to a 48-well plate containing 500 µL 
of media and allowed to grow for up to one week prior to use. Media was changed every 3 
days.  
4.5.4 Subdermal implantation of hBMSC-scaffolds in NSG mice 
A breeding pair of NOD-scid IL2Rgnull mice (005557) was initially obtained from 
the Jackson Laboratories. NSG mice were housed in sterile conditions with unrestricted 
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access to food and water. In this study 6-13 week age mice were used for implantation. 
Mice were anesthetized with 1.5% isoflurane and dorsal hair was removed with electric 
clippers and Nair. The skin was sterilized using 70% isopropyl alcohol prep wipes. Prior 
to surgery, 2 mg meloxicam/kg mouse weight was subcutaneously injected. 2 mm 
horizontal incisions were made in the upper and lower dorsal spaces. A subcutaneous 
pocket was formed by inserting surgical scissors into the incision and expanding. One 
scaffold per subcutaneous pocket was implanted and the incisions were closed with 2 
Reflex 7 mm wound clips. Four scaffolds were implanted per mouse. Wound clips were 
removed after 1 week.  
4.5.5 Characterization of cytokine secretion of implanted hBMSC-scaffolds 
Implanted hBMSC-scaffolds were retrieved at 4 and 12 weeks from NSG mice. 
Explanted scaffolds were cut into 1-2mm pieces using surgical scissors and cultured in 500 
µL of αMEM media supplemented with 1% mouse serum and 1% penicillin-streptomycin 
for 36 hours. For control samples, 1 week in vitro cultured hBMSC-scaffolds were used. 
Conditioned media was collected and used immediately for characterization human VEGF, 
IL-6 and, IL-8 secretion by DuoSet® ELISA kits (R&D Systems).  
4.5.6 Tail vein injection of human PBMCs 
Whole blood was obtained from 3 healthy male donors age 20-38 in BD Vacutainer 
K2 EDTA blood collection tubes. Mononuclear cells were isolated via density gradient-
based centrifugation using Ficoll Paque at 1500 RPM for 30 minutes using minimum 
acceleration and no brake. From roughly 30 mL of whole blood we extracted 25-30 million 
PBMCs. Isolated mononuclear cells were counted and re-suspended in PBS to a density of 
10x106 or 20x106 cells per 100 µL PBS. Scaffold bearing or scaffold and tumor bearing 
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mice were warmed under a heat lamp to dilate the tail vein, placed in a restrainer, and 
intravenously delivered by tail vein injection using a 27 Gauge needle.  
4.5.7 Human PBMC distribution and cytokine secretion 
Mice 6-13 weeks of age were implanted with BMSC seeded scaffolds. 20x106 
PBMCs suspended in 100 µL of PBS were intravenously delivered 5.5 weeks after scaffold 
implantation. Mice were euthanized 24 hours after PBMC injection. Lung, liver, spleen, 
bone, and scaffolds were retrieved. Tissue samples were aliquoted for analysis via flow 
cytometry or ELISA. For flow cytometry experiments, freshly harvested tissue samples 
were minced with scissors in a 40 µm cell strainer and further digested with Collagenase, 
Type II. Stock solution (100 U/µL) was diluted in PBS to 200 U/mL and added to the tissue 
for 15 minutes. Tissue pieces were pushed through the 40 µm cell strainer using the back 
side of a 1 mL syringe plunger. DMEM media containing 10% FBS was added to quench 
the enzymatic reaction before spinning down in a centrifuge at 1500 RPM. Cell pellets 
were resuspended in FACS buffer (PBS containing 1% bovine serum albumin (BSA)) and 
counted. Cells were spun down again and resuspended to a final concentration of 107 
cells/mL in FACS buffer. 100 µL of the cell suspension was added to a U-bottom 96 well 
plate. 100 µL of FACS buffer containing 2.5 µg of Fc Block was added to each well and 
incubated for 10 minutes at room temperature. The plate was spun down and supernatant 
removed before adding mouse anti-human CD45-PE diluted in FACS buffer 1:100. 
Samples were incubated for 30 minutes at room temperature in the dark. Samples were 
washed 3 times with FACS buffer before being transferred to FACS tubes and analyzed 
with a BD LSRFortessa. BD FACSDiva software was used for both collection and analysis. 
For human cytokine secretion, retrieved tissues were kept relatively equal in size and cut 
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into 1-2 mm pieces using surgical scissors. Conditioned media was prepared 36 hours after 
plating in 500 µL of αMEM media supplemented with 1% mouse serum and 1% penicillin 
and streptomycin. Conditioned media was used immediately for characterization using 
DuoSet® ELISA kits for human TNF-α, IL-6 and IL-10 (R&D Systems) 
4.5.8 Orthotopic xenoengraftment of human prostate tumor 
 Luciferase (Luc) and green fluorescent protein (GFP) transduced PC-3 Human 
Prostate Cancer cells were obtained from the Center for Engineering in Medicine, 
Massachusetts General Hospital. Luc-GFP PC3 cells were cultured with DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin. Scaffold bearing mice were 
anesthetized with 2% isoflurane followed by ventral hair removal with Nair. Skin was 
sterilized with 70% isopropyl alcohol prep wipes. Prior to surgery 2 mg meloxicam/kg 
mouse weight was subcutaneously injected. A 10 mm vertical incision was made in the 
lower abdomen of the mouse. The bladder was externalized through the opening to expose 
the prostate. 2 x 106 Luc-GFP PC-3 cells suspended in 50 µL of matrigel were injected to 
the prostate using a 27 G needle. The bladder was returned to the intraperitoneal cavity, 
the muscle layer was sutured using polyglycolic acid sutures (Henry Schein), and the skin 
was clamped with Reflex 7 mm wound clips. Clips were removed after 1 week. 
4.5.9 Monitoring human tumor engraftment and metastasis by bioluminescent 
imaging 
Two weeks after orthotopic injection of Luc-GFP PC3 tumor cells, whole body 
bioluminescent imaging was performed to confirm engraftment and metastasis to distant 
organs using an IVIS SpectrumCT (Perkin Elmer). Luciferin was prepared by dilution in 
PBS to a concentration of 15 mg/mL in PBS. Mice were anesthetized with 2% isoflurane 
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and injected intraperitoneally with 10 µL luciferin solution/g of body weight before being 
placed in the imaging chamber. Images were taken every 5 minutes until peak values were 
achieved. 6 weeks after orthotopic tumor injection, mice were euthanized, and scaffolds 
were retrieved and placed in a 48-well plate. Luciferin stock solution was diluted 1:100 in 
PBS and 300 µL were loaded into each well. Bioluminescent imaging was performed every 
2 minutes until reaching peak values.  
4.5.10 Non-invasive long-term monitoring of metastasis in serially transplanted 
scaffolds 
Metastatic tumor microenvironments primed in primary mice were retrieved and 
immediately transplanted to the same anatomical site in naïve male NSG mice 6-12 weeks 
of age following the same method as initial scaffold implantation. Wound clips were 
removed after 1 week. Whole body bioluminescent imaging was started 4 weeks after serial 
transplantation and continued for an additional 6 weeks with measurements taken weekly. 
Images were taken every 5 minutes until peak values were achieved. 
4.5.11 Scanning electron microscopy imaging 
Microfabricated scaffolds coated with type I collagen were fixed with 2% 
glutaraldehyde, serially dehydrated with 50, 70, 90, and 100% ethanol and lyophilized 
overnight. The prepared dehydrated samples were deposited with a thin gold film using a 
sputter-coating machine (208HR, Cressington) and observed using a Zeiss Ultra55 Field 
Emission Scanning Electron Microscope. 
4.5.12 Immunohistological staining and imaging 
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At the end of in vivo experimentation, tissue and scaffold samples were frozen by 
embedding tissue in CryomatrixTM and snap-frozen in a metal beaker containing 2-
methylbutane cooled by dry ice. Frozen samples were sectioned using a Cryostat (NX70). 
Scaffolds were cut to 20-25 µm, while native tissue were cut to 10 µm thickness and 
attached to ColorMarkTM Plus glass slides. Remaining frozen tissue blocks and sectioned 
slides were stored at -80 °C. Frozen tissue was briefly fixed in pre-chilled acetone for 10 
minutes. Following 3 wash cycles in 0.05% Tween-20 in PBS (PBST), samples were 
outlined with a hydrophobic marker and blocked with 10% goat serum and 1% BSA in 
PBST for 2 hours at room temperature. Primary antibodies were added at a dilution ratio 
of 1:200 in blocking solution and left overnight in 4 °C. Samples were washed 3 times with 
0.05% PBST followed by secondary antibodies at a dilution ratio of 1:200 in blocking 
solution and left for 2 hours at room temperature. Samples were washed 3 times with PBST 
prior to addition of 1 µg/mL DAPI solution and a cover slide. When required, streptavidin 
conjugated Qdot was added to the samples and left for 1 hour prior to the final washing 
cycle. 10 µL of 10 ng/µL DAPI solution was added to samples before imaging. Images 
were obtained using a Zeiss Cell Observer SD with 10x and 20x objectives. Tiling was 
performed with 10% overlap. Human antibodies were validated against relevant mouse 
tissue to rule out cross-reactivity (Figure 4.27). For hematoxylin & eosin and trichrome 
staining, frozen tissue sections were fixed with 10% neutral buffered formalin for 10 
minutes. After washing with DI water, sides were stained with dye solutions following the 




Figure 4.27. IHS of hVimentin, hC45, and hCytokeratin against relevant mouse tissue 
to rule out cross-reactivity. 
 
4.5.13 Optical tissue clearing and complete optical sectioning of the scaffolds 
Mice were transcardially perfused with 20 mL of ice cold PBS followed by 20 mL 
of ice cold monomer solution containing 4% acrylamide, 0.05% bis-acrylamide, 0.25% 
VA-044 (thermal initiator) and 4% paraformaldehyde in PBS. Tissue samples were 
collected and incubated in fresh monomer solution at 4 °C for 48 hours. Air in the tubes 
was replaced with nitrogen gas prior to incubation at 37 °C for 3-4 hours to polymerize the 
monomer solution. Excess polymer was removed and samples were left in either PBS or 
tissue clearing solution (4% SDS, 200 mM boric acid, pH 8.5). Scaffold samples required 
thick sectioning to achieve whole tissue imaging. Samples were frozen in CryomatrixTM 
and cut to a thickness of 250 µm with a cryostat for a total of 4 slices per scaffold. Sections 
were washed thoroughly in 0.1 vol% Triton X-100 in PBS prior to antibody staining. All 
of the staining procedures were performed at room temperature. Samples were blocked 
with 10% normal goat serum (NGS) and 1% BSA in PBST overnight. Samples were 
incubated for 36 hours in primary antibody solution containing chicken anti-human 
cytokeratin and rabbit anti-mouse smooth muscle actin diluted 1:200 in blocking solution. 
Samples were washed thoroughly with Triton X-100 PBS for 24 hours. Samples were 
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incubated in secondary antibody solution containing goat anti-chicken Alexa Fluor 647 and 
goat anti-rabbit Alexa Fluor 568 diluted 1:200 in blocking solution for 36 hours. Samples 
were washed thoroughly with Triton X-100 PBS before imaging. Refractive index 
matching solutions did not enhance scaffold imaging depth, so samples were imaged in 
PBS. Samples were transferred to a glass slide with silicone isolators and covered with a 
cover slip. Whole tissue Z-stack images were taken with a Zeiss Cell Observer SD with a 
10x objective at a 10 µm z-step. Optical slices were observed and compiled in ImageJ. 
Single cells and tumor colonies were manually counted and concentric circles were drawn 
as previously described. Nikon Elements AR v4.5 was used for 3D rendering and creation 
of videos. The videos were annotated in Adobe Premiere Pro CC 2014 and encoded in 
Adobe Media Encoder CC 2014. 
4.5.14 Image analysis 
For characterization of mCD31 and hVimentin distribution in 4-week in vivo 
scaffolds, concentric circles were drawn in ImageJ. Three circles were drawn with 1/3 R-
Total (Total Radius), 2/3 R-Total and R-Total. Background signal of each individual 
channel were removed before measuring the pixel density. Values were normalized by the 
zone area and the signal measured from the entire scaffold to generate a relative distribution 
across the scaffold. The same analysis was performed for hCD45 distribution in hPBMC 
injected mice 6 weeks after intravenous injection. Percent coverage analysis (mCD31, 
hCD44, hCD45, Ki67, and mLy6G) was calculated by measuring the overlap between 




For in depth characterization of the local tumor microenvironment, single cell and 
tumor colonies were manually identified by examining tiled images of stained tissue 
sections. Nearest vessel, vessel diameter, tumor colony diameter, and nearest cell distance 
were measured in ImageJ for all of the identified tumor cells. Data was binned to generate 
histograms. 
4.5.15 Multiple antibody staining of overt metastatic tumor bearing scaffold 
8 consecutive tissue slices, each 20 µm thick, from a single scaffold were stained 
with multiple combinations of antibodies, for a total of 11 different stains. All of the images 
were aligned in ImageJ. Images were then divided into a grid of 24x24 images, thresholded 
and pixel density was measured for each channel. Total tissue area was determined by 
setting a low threshold to include background signal. Values from each individual channel 
were normalized by total tissue area within each and plotted in a 24x24 heatmap. 10 color 
images were generated by combining images from different staining combinations. From 
these composite images, regions of interest were manually determined to highlight 
heterogeneity. Regions of interest were translated to the 24x24 heatmaps and pixel density 
was recalculated for the 8 zones. Pixel densities from each of the zones of interest were 
normalized to the maximum value from the 8 zones. Channels that had more than one 
replicate were averaged together before plotting on a radar chart. Cellular composition 
within each zone was achieved by normalizing the absolute pixel count of each channel by 






Unpaired Student’s t tests were performed for comparison of the mean values 
between two groups. Statistical significance was determined if p<0.05 for two-tailed 





INVESTIGATION OF THERAPY-INDUCED METASTATIC RELAPSE VIA 
ENGINEERED DISSEAMINTED TUMOR CELL NICHES 
5.1 Abstract 
The treatment of most primary tumor types has greatly improved, however metastatic 
disease remains a substantial clinical hurdle. Disseminated tumor cells (DTCs) are 
impractical to detect in patients and can develop resistance to treatment options that 
successfully treated the primary tumor. It is widely accepted that DTCs undergo periods of 
dormancy that can last years to decades after primary tumor treatment. However, several 
clinical and preclinical studies have shown greatly accelerated metastatic recurrence after 
the administration of chemotherapy and surgical intervention. The direct causes of 
metastatic relapse remain largely unknown and represent a critical gap in understanding to 
produce effective treatments. Here we present a biomaterial scaffold driven in vivo model 
to understand the implications current treatment strategies have on DTCs and their local 
microenvironment. Tissue engineering approaches have been shown to enable the long-
term observation of non-metastatic DTCs and provide high analytical assessment of the 
cellular and molecular factors that drive metastatic relapse. Investigation of implantable 
niches shortly after an adjuvant chemotherapy regimen suggested that DTCs were 
eradicated in 50% of treated samples, however long-term analysis revealed all niches had 
undergone relapse to the same degree as non-treated implants. Secretome analysis of the 
scaffold tissue revealed significant increases in SDF-1 and leptin, and decreases in 
proMMP9, MMP8, VEGF, IP-10, IL-10, IL-15, and IFNy following chemotherapy. Direct 
surgical manipulation of long-term dormant niches revealed a significant increase in tumor 
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burden and an increase in angiogenic and inflammatory cell recruitment. These results 
demonstrate the translational potential of implantable niches to uncover mechanisms of 
DTC activation in a clinically relevant manner. 
5.2 Introduction 
Although primary tumor treatments have improved, the overall five-year survival 
rate for patients diagnosed with cancer remains under 70%. The main cause of this is the 
dissemination of tumor cells to distant tissues and the eventual relapse into metastatic 
disease. Treatment of the metastatic disease is challenging due to several factors. First, 
metastatic disease can be asymptomatic and is usually detected late into tumor progression. 
Second, disseminated tumor cells (DTCs) can develop new mutations and interact with 
different stromal cell populations that may aid in resistance to therapies. Third, metastatic 
tumors generally proliferate in organs vital to survival, specifically the lung, liver, bone, 
and brain. A better understanding of DTC biology is needed to create effective treatments 
against metastasis. 
Chemotherapeutic agents have been used for the last few decades with successful 
application across several tumor types. Chemotherapies aim to interfere with the 
proliferation pathways of cancer cells. Following tumor removal, adjuvant chemotherapy 
may be administered with the goal of removing residual tumor cells. The ability to monitor 
the success or failure of these therapies is difficult in patients. Clinical studies examining 
the efficacy of adjuvant therapies tend to demonstrate marginal increases in reducing 
remission and prolonging survival266-267. The nature of chemotherapies is not tumor 
specific, and the systemic delivery of these drugs yields several off-target effects268-270. A 
recent study demonstrated that administration of chemotherapeutic agents in a neoadjuvant 
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regimen mobilized bone marrow derived cells and increased angiogenesis leading to tumor 
regrowth and relapse271. The local microenvironment has been shown to plays a critical 
role in regulating chemosensitivity during adjuvant therapy and can be targeted to improve 
treatment effectiveness272. These provocative findings have led to the questioning of 
adjuvant and neoadjuvant therapies and their potential negative responses in accelerating 
metastatic relapse. 
Metastatic recurrence is commonly observed shortly after the surgical removal of 
the primary tumor. The act of surgery triggers a wound healing response that can activate 
systemic inflammation, and in turn awaken dormant DTCs in distant tissues. A recent study 
has demonstrated that surgery can lead to the outgrowth of immunologically restricted 
tumors by increasing circulating neutrophils and inflammatory monocytes through IL-6, 
G-CSF, and CCL2 signaling. The increased monocyte activity was shown to directly 
counter T cell-mediated growth restriction of the tumor273. Additional evidence suggests 
that primary tumors themselves may prevent metastatic relapse by releasing systemic 
factors106. Although these studies provide mechanisms of escape for larger tumor colonies, 
it is unclear how surgery or the wound response to surgery may aid in changing the 
phenotype of DTCs that are actively dormant.  
Chemotherapy and surgery provide substantial clinical benefits, however they both 
induce systemic immune responses that may trigger metastatic relapse. Specifically, we 
hypothesized that these treatments stimulate systemic inflammatory pathways and cause 
dormant DTC niches to undergo tissue remodeling and trigger metastatic relapse. Mouse 
models that are capable of investigating DTC dormancy generally utilize specialized cell 
lines that may misrepresent patient phenomenon. We have recently developed a tissue-
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engineered metastasis model using micro-fabricated porous hydrogel scaffolds 
subdermally implanted into mice. The scaffold induces the formation of vascularized tissue 
microenvironments that recruit bone marrow-derived cells, an emulating key feature of the 
premetastatic niche. Circulating tumor cells are attracted to the implants and DTC niches 
can be retrieved intact and re-implanted to a secondary tumor-free mouse enabling the 
observation of the full spectrum of the metastatic cascade from single DTCs to a fully 
metastasized tumor. Isolation of the DTC niche provides high experimental control without 
confounding factors such as multiple metastases or diminishing health of the host. The 
standardized 3D structure and synthetic hydrogel impart high analytical power when 
combined with conventional immunohistostaining and recently introduced tissue-clearing 
techniques for whole tissue imaging. Here we use this biomaterial approach to investigate 
the impact of adjuvant chemotherapy and local surgery on long-term dormant DTCs.  
5.3 Results 
5.3.1 Circulating tumor cells from an orthotopic MMTV-PyMT transplant model 
home to implantable biomaterial niches 
 Four ICC hydrogel scaffolds were implanted subcutaneously into 
immunocompetent FVB mice to begin niche tissue development. Two weeks later a 
fragment of syngeneic MMTV-PyMT breast tumor was orthotopically transplanted into 
the mammary fat pad. This approach was taken to increase the experimental throughput, 
as one MMTV-PyMT primary tumor could be split into 15-20 pieces (Figure 5.1A). The 
primary tumor was grown until a critical size of 1,000 mm3 was reached. Only tumors that 
achieved this size within 10 weeks of implantation (82.1%) were considered for further 
experiments (Figure 5.1B). Scaffolds were removed and analyzed for the presence of 
 
 137 
DTCs. Immunohistostaining revealed 100% of scaffolds were positive for DTCs, however 
colony development was rare at the time of sacrifice (Figure 5.1C). These results suggest 
implantable scaffold niches retain their tumor cell capture abilities in fully 
immunocompetent syngeneic tumor models. 
 
Figure 5.1. Orthotopic MMTV-PyMT tumor transplant model generates DTCs in 
implantable niches.  
a, Experimental schematic of scaffold implantation and orthotopic breast tumor 
generation. b, Orthotopic primary tumor growth kinetics and engraftment efficiency. c, 




5.3.2 Adjuvant chemotherapy reduces initial DTC burden but does not prevent 
relapse 
 DTC-containing scaffolds were transplanted to secondary tumor-free FVB hosts to 
prolong the observation window of cancer cell progression. One week after transplantation, 
adjuvant chemotherapy, consisting of doxorubicin and cyclophosphamide, or PBS was 
administered intraperitoneally once a week for three weeks (Figure 5.2A). Twenty-four 
hours after the final dose of chemotherapy scaffolds were removed from mice to assess the 
short-term results of therapy. Microscopic analysis of the scaffolds revealed the presence 
of single DTCs and early stage colonies in both experimental groups (Figure 5.2B). 
Quantification of DTCs in the scaffolds revealed a significant decrease in cancer cells in 
mice given chemotherapy (Figure 5.2C). Additionally, 50% of chemotherapy-treated 
scaffolds did not contain any DTCs.  
 A separate group of mice were sacrificed 10 weeks after the final dose of 
chemotherapy to assess long-term impact of adjuvant therapy on DTCs. Surprisingly all 
analyzed scaffolds contained an increased tumor burden regardless of treatment (Figure 
5.2D). Quantification revealed no significant difference between the final tumor burden 





Figure 5.2. Short and long-term effects of adjuvant chemotherapy in transplantable 
niche model.  
a, Experimental schematic to investigate the role of adjuvant chemotherapy on DTC 
niches. b, Immunohistostaining of samples retrieved 24 hours after the final dose of 
adjuvant chemotherapy. c, Quantitative image analysis of DTCs in scaffolds retrieved 24 
hours after the final dose of adjuvant chemotherapy. d, Immunohistostaining of samples 
after long-term, 10 week, observation. e, Quantitative analysis of total tumor positive area 
in long-term samples. (*P<0.05) 
5.3.3 Chemotherapy alters soluble factors in local microenvironment 
 Next, we assessed changes to the soluble microenvironments within the scaffolds 
following chemotherapy. Four scaffolds were subcutaneously implanted into FVB mice 
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and left for three weeks before starting chemotherapy. Twenty-four hours after the final 
dose of chemotherapy scaffolds were harvested and cultured ex vivo for 36 hours (Figure 
5.3A). Conditioned media was analyzed with a panel of 45 cytokines (Figure 5.3B). 
Secretion of SDF-1 and leptin were significantly increased, while proMMP-9, MMP-8, 
VEGF, IP-10, IL-15, IL-10, and IFNγ were significantly decreased (Figure 5.3C). SDF-1 
is a ligand connected to immune cell homing. Leptin has been implicated as leading to 
chronic inflammation and a pro-tumor factor. The decreases observed appear likely due to 
a decrease in immunogenic activity within the scaffold niche due to therapy. The change 
in soluble factors may lead to altered immune cell homing and trigger rapid tissue 
remodeling once the effects of chemotherapy subside.  
 
Figure 5.3. Secretome analysis of implantable niche tissue following chemotherapy.  
a, Experimental schematic of procedure to generate conditioned media for multiplex 
secretome analysis. b, Secretion profile of scaffold niches from mice without and with 
chemotherapy. c, Subset of cytokines that displayed significant up- or downregulation 
following therapy compared to control.  
5.3.4 Local surgical intervention increases tumor growth 
 Surgical intervention was modeled by performing a 4mm biopsy in the center of 
the implant tissue and replacing it with an empty ICC hydrogel scaffold. Long-term DTC 
niches were generated using the transplantation strategy described above, however 
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scaffolds were untreated and left for 15 weeks prior to intervention (Figure 5.4A). Two of 
the four scaffolds underwent biopsy surgery and the remaining two remained untouched 
(Figure 5.4B). Five weeks after the surgery scaffolds were explanted and analyzed via 
immunohistostaining (Figure 5.4C and 5.4D). Tumor burden was over three-fold higher 
in scaffolds that underwent surgical intervention (Figure 5.4E). Characterization of the 
local microenvironment revealed increases in vasculature (CD31), leptin, MMP9 and 
Ly6G in the surgically activated scaffolds (Figure 5.4F). Analysis on the biopsy samples 
was performed on the original tissue area and did not include the area accounting for the 
newly implanted scaffold. Collectively these results indicate that local surgical intervention 
significantly increased tissue remodeling and tumor burden from DTCs.  
 
Figure 5.4. Surgical intervention of long-term DTC niches.  
a, Experimental schematic of procedure to generate controlled surgical disruption using a 
4 mm biopsy punch. b, Gross images of surgical procedure and explanted scaffolds 5 
weeks after surgery. c, Immunohistostaining of long-term control DTC niches. 
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d, Immunohistostaining of samples that received surgical intervention. e, Quantitative 
analysis of PyMT+ tumor burden in scaffolds without and with surgery. f, Quantitative 
image analysis of tissue nice components found in the original scaffold area. (*P<0.05) 
5.4 Discussion 
 The observation that metastatic relapse can occur years after the removal of primary 
tumors has provoked extensive research into the understanding of DTC biology. Multiple 
efforts have been made to uncover pathways that enabled DTCs to escape a quiescent state 
and proliferate into a metastatic tumor. However, this is a challenging phenomenon to 
model and reproduce consistently in traditional mouse models. Here we provide evidence 
that implantable scaffold niches can reduce this gap and enable the long-term analysis of 
DTCs. Transplantation of scaffold niches housing DTCs to tumor-free mice enables 
complete isolation of the microenvironment with the added benefit of niche control via 
tissue engineering principles. In this study we have applied two stimuli to the niches, 
adjuvant chemotherapy and surgery, to provide mechanistic insight toward metastatic 
relapse. Although adjuvant chemotherapy showed promise in removing DTCs in the short-
term, long-term observation following the end of adjuvant therapy suggests a substantial 
number of DTCs were able to survive and proliferate. In modeling local tissue surgical 
intervention, we demonstrated a robust increase in tumor growth in the surrounding tissue 
via activation of inflammatory signaling.  
Adjuvant chemotherapy given after the resection of a primary tumor is a common 
strategy to remove residual DTCs. These methods have recently come under question as 
treatment is ultimately unsuccessful over time274. Chemotherapy by nature of the drug 
mechanism of action relies on interfering with the proliferative state of the tumor cells. 
Most DTCs are believed to be held in a dormant state making these therapies only effective 
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once they start growing. However, evidence has been provided that demonstrates 
chemotherapy can have negative side-effects such as increased remodeling and 
inflammation271. Secretome analysis performed on scaffold microenvironments confirmed 
the upregulation of SDF-1 and leptin following chemotherapy. Both molecules have been 
implicated as pro-tumor and may accelerate metastatic relapse275-276. The local 
microenvironment is believed to be a key regulator in maintenance of DTC dormancy, and 
disruption may have unexpected effects107, 272, 277. Short- and long-term histological 
characterization following chemotherapy may provide clues as to how the niche evolves 
over time with and without therapy. However, it may be challenging to capture key 
biological events without increasing the sampling rate following the end of therapeutic 
intervention. The heterogeneous makeup of tumor cells can also lead to drug resistance as 
tumor cells can gain resistance to therapy once disseminated278. The findings in this study 
confirm the notion that adjuvant chemotherapy is not effective in the prevention of long-
term DTC relapse. However, additional factors such as increasing the length of treatment 
may yield significant decreases in relapse. An additional aspect that remains unexplored is 
the cyclical nature of adjuvant therapy and the associated fluctuations of immune cell 
populations. Myeloid and myeloid precursor cells are dramatically reduced during 
chemotherapy. Interestingly, the onset of neutropenia after therapy is correlated with 
antitumor efficacy and good patient prognosis279. A recent study has shown that repeated 
dosing of inflammatory lipopolysaccharide was necessary to aggressively reactivate DTCs 
in the lung251. Understanding how the body changes on a systemic level after subsequent 
doses of chemotherapy may unveil new drivers of metastatic relapse107.  
 
 144 
 Clinical observation of patients after tumor resection has revealed a sharp increase 
in risk of metastatic recurrence shortly after surgery280. This early spike in relapse appears 
to undermine the concept of DTC dormancy, yet the act of surgery provokes wound healing 
responses that may reactivate DTCs. This notion is confirmed by patients that undergo 
elective surgeries and an observed increase in metastatic relapse281-282.  Aside from surgery, 
reports that the primary tumor can maintain dormancy have also been made106. A recent 
study however has shown that surgical wounding can disrupt immunologically regulated 
tumor dormancy by altering systemic immune cell responses273. Here we demonstrate local 
metastatic relapse due to proinflammatory signaling due to surgery including increased 
vascular density, leptin, MMP9 and Ly6G. Additional work is necessary to validate the 
role of the increased soluble factors. Due to the broad nature of the response stemming 
from tissue remodeling, targeting these factors with pan anti-inflammatory molecules may 
reduce metastatic spread. In addition to systemic administration of anti-inflammatory 
molecules, replacement scaffold inserts can be loaded with drug to increase the effect on 
the local tissue.  
Additional questions regarding DTCs and potential mechanisms that activate 
relapse remain. For example, the effect of aging and senescence of local tissue cells and 
hematopoietic cells has not been fully explored. New therapeutic approaches to combat 
relapse have been made but will require further investigation before application in patients. 
Antibodies have been developed against remodeled laminin to prevent α3β1 integrin 
signaling and DTC proliferation107. Direct blocking of integrin function has also achieved 
better adjuvant chemotherapy results272. Previously we used ICC hydrogel scaffolds to 
demonstrate the modulation of inflammatory signaling with an IL-1 antagonist altered the 
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fate of DTCs within the niche96. In addition to understanding fundamental mechanisms, 
the standardized tissue-engineered metastasis model presented in this study provides a 
unique opportunity to screen anti-metastatic drug candidates. We believe implantable DTC 
microenvironments will serve as an indispensable tool across several aspects of metastatic 
relapse. 
5.5 Materials and Methods 
All chemicals and materials were purchased from Sigma Aldrich or Fisher 
Scientific unless specified. All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts-Amherst. 
5.5.1 Porous hydrogel scaffold fabrication 
ICC hydrogel scaffolds were fabricated using soda lime glass beads with sizes 
ranging from 250 µm to 300 µm as previously described101. The polyacrylamide hydrogel 
was made from a precursor solution composed of 30 wt% acrylamide monomer, 1.5 wt% 
bis-acrylamide crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine accelerator, 
and 0.2 vol% 2-hydroxy-2-methylpropiophenone photoinitiator in nitrogen purged DI 
water. The solution was polymerized under an ultraviolet light. Beads were removed with 
alternating acid washes of hydrofluoric and hydrochloric acid. Scaffolds were thoroughly 
washed with DI water to remove residual acid and lyophilized. Scaffolds were sterilized 
with 70% ethanol before they were surface treated with Sulpho-SANPAH to covalently 






5.5.2 Mouse colony 
MMTV-PyMT mice on the FVB/N background (002374 bred in house from a 
colony initially obtained from the Jackson Laboratory. Wild type FVB/N were acquired 
from MMTV-PyMT breeding. Mice were housed in sterile conditions with unrestricted 
access to food and water. 
5.5.3 Orthotopic MMTV-PyMT tumor model implantation of scaffolds 
FVB mice at an age between 6 and 12 weeks old were implanted with four scaffolds 
subcutaneously. Mice were anesthetized with 1.5% isoflurane before removing the dorsal 
hair with electric clippers and Nair. The skin was sterilized using 70% isopropyl alcohol 
prep wipes. Mice received 2 mg meloxicam/kg mouse weight subcutaneously prior to 
surgery. A subcutaneous pocket was formed and implanted with an ICC hydrogel scaffold. 
The incisions with Reflex 7 mm wound clips. Two weeks after scaffold implantation mice 
were given a fragment of primary tumor from an MMTV-PyMT mouse. Large tumors were 
retrieved from 8 to 12 week old MMTV-PyMT mice and chopped into 2-3 mm pieces using 
a scalpel. Tumor fragments were immediately implanted into a subcutaneous pocket 
located at the right abdominal mammary gland. Incisions were closed with wound clips. 
Tumor measurements were taken weekly using digital calipers and volume was calculated 
using the formula V = (Width2 x Length)/2. Once the primary tumor reached 1,000 mm3 
scaffolds were harvested for immunohistostaining or orthotopically transplanted to 






5.5.4 Adjuvant chemotherapy regimen 
Doxorubicin was dissolved in phosphate buffered saline to a final concentration of 
0.2 mg/mL. Cyclophosphamide was dissolved in 0.9% NaCl to a final concentration of 12 
mg/mL. Drug solutions were stored at -80 °C. One week after transplantation mice received 
intraperitoneal doses of doxorubicin (2 mg/kg) and cyclophosphamide (60 mg/kg) once a 
week for three weeks.  
5.5.5 Multiplex soluble factor analysis 
FVB mice were implanted with four scaffolds subcutaneously as described above. 
Three weeks after implantation, mice received the adjuvant chemotherapy regimen. 
Twenty-four hours after the final dose scaffolds were harvested and cultured ex vivo in 
serum-free alpha-Modified Eagle Medium supplemented with 1% penicillin-streptomycin. 
Conditioned media was harvested thirty-six hours later and stored at -80 °C. Samples were 
shipped on dry ice to Eve Technologies for multiplex cytokine analysis (MD31, MAGP-
08-107, and MMO-C,O).  
5.5.6 Surgical intervention of DTC niches 
Fifteen weeks after transplantation DTC niches were subjected to surgical 
disruption. An incision was made close to the implant and the connective tissue was broken 
on the muscle side of the implant. The scaffold was carefully exposed through the incision 
and a 4 mm biopsy punch was used to remove the central region of the implant. A new 4 
mm ICC hydrogel scaffold was placed in the void and the scaffold was carefully returned 





5.5.7 Frozen tissue preparation and sectioning 
At the conclusion of the in vivo experiment, implants were frozen by embedding 
the tissue in Cryomatrix TM and snap-frozen in 2-methylbutane cooled on dry ice. Frozen 
tissue was cut to 20 µm using a NX70 Cryostat. Frozen tissue blocks and sectioned slides 
were stored at -80 °C.  
5.5.8 Immunohistostaining 
Frozen slides were fixed in -20 °C acetone for 10 minutes. Slides were washed with 
PBST solution 3 times before blocking in a solution containing 10% normal goat serum, 
and 1% bovine serum albumin for 1 hour. Following blocking primary antibodies diluted 
in blocking solution were added to the slides and left in a humidified chamber overnight at 
4 °C. Slides were washed 3 times with PBST and then incubated with secondary antibodies 
diluted in blocking solution for 2 hours at room temperature. Prior to imaging, slides were 
washed 3 times in PBST and stained with a 10 ng/uL solution of DAPI. Fluorescent images 
were taken on a Zeiss Cell Observer SD. PyMT (ab15085), Ki67 (ab16667) Α-smooth 
muscle actin (ab5694), CD31 (550274), Leptin (PA1-052), MMP9 (PA513199), and Ly6G 
(557445) primary antibodies. Anti-rabbit Alexa Fluor Plus 488 (A32731), and anti-rat 
Alexa Fluor 647 (A21247) secondary antibodies were used in this study. 
5.5.9 Image analysis 
All image processing and quantitative analysis was performed in ImageJ. Total 
tissue area was determined using the DAPI image for all relevant analysis.  DTC counts 






Unpaired Student’s t tests were performed for comparison of the mean values 
between two groups. Statistical significance was determined if p<0.05 for two-tailed 
























FABRICATION OF BIOACTIVE INVERTED COLLOIDAL CRYSTAL 
SCAFFOLDS USING EXPANDED POLYSTYRENE BEADS 
 
Adapted with permission from Ryan Carpenter, Dalton Macres, Jun-Goo Kwak, Katherine 
Daniel, and Jungwoo Lee. Tissue Engineering Part C: Methods. 2020. DOI: 
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6.1 Abstract 
Inverted colloidal crystal (ICC) hydrogel scaffolds have emerged as a new class of 3D cell 
culture matrix that represents a unique opportunity to reproduce lymphoid tissue 
microenvironments. ICC geometry promotes the formation of stromal cell networks and 
their interaction with hematopoietic cells, a core cellular process in lymphoid tissues. When 
subdermally implanted, ICC hydrogel scaffolds direct unique foreign body responses to 
form a vascularized stromal tissue with prolonged attraction of hematopoietic cells, which 
together resemble lymphoid tissue microenvironments. While conceptually simple, 
fabrication of ICC hydrogel scaffold requires multiple steps and laborious handling of 
delicate materials. Here, we introduce a facile route for ICC hydrogel scaffold fabrication 
using expanded polystyrene (EPS) beads making the process cheaper, faster, and safer. 
EPS beads shrink and fuse in a tunable manner under pressurized thermal conditions, which 
serves as colloidal crystal templates for ICC scaffold fabrication. Inclusion of collagen in 
the precursor solution greatly simplified preparation of bioactive hydrogel scaffolds. The 
resultant EPS-templated bioactive ICC hydrogel scaffolds demonstrate characteristic 
features required for lymphoid tissue modeling in both in vitro and in vivo settings. We 
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envision that the presented method will facilitate widespread implementation of ICC 
hydrogel scaffolds for lymphoid tissue engineering and other emerging applications.  
6.2 Introduction 
Three-dimensional (3D) cell culture matrices also known as scaffolds are an 
essential component of tissue engineering that provide the biophysical framework and 
biochemical complexity to reproduce essential tissue structure and function160. As each 
tissue represents different cellular and extracellular matrix (ECM) composition and 
organization, biomaterial selection and structural design of scaffolds have been specialized 
to reproduce key cellular processes in target tissues283-285. Inverted colloidal crystal (ICC) 
hydrogel scaffolds have been developed to reproduce lymphoid tissue 
microenvironments286-288. ICC geometry consisting of fully interconnected spherical pore 
arrays provides a large surface area for adherent stromal cells and the formation of an 
intricate stromal network289. Spherical cavities connected via small channels transiently 
entrap hematopoietic cells and facilitate their intimate interactions with stromal cells290, 
which is a core cellular process in lymphoid tissues. ICC hydrogel scaffolds have 
demonstrated biological significance in simulating bone marrow291-292, thymus293 and 
lymph nodes214 in vitro. When subdermally implanted in mouse models, ICC hydrogel 
scaffolds rapidly induced interscaffold vascularization and attract local and systemic 
hematopoietic cells97, 101, 294, which together function as a lymphoid tissue analogue.  
 The fabrication of ICC scaffolds involves four steps: (i) preparation of colloidal 
crystal templates via partial fusion of microspheres with narrow size distribution, (ii) 
infiltration of a hydrogel precursor solution and subsequent polymerization, (iii) selective 
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removal of the template microbeads, and (iv) if necessary, modification of the pore surface 
to support stromal cell adhesion295 (Figure 6.1A). The most critical consideration is the 
selection of template bead material as it determines the possible range of pore sizes and 
conditions for template preparation and dissociation. Current ICC scaffold fabrication can 
be categorized into five groups based on template materials (Figure 6.2B). The first group 
is solid polymeric beads synthesized by emulsion polymerization including 
poly(methylmethacrylate) (PMMA) and polystyrene (PS) 291, 293, 296-301. ICC geometry was 
initially developed for nanostructured photonic crystal materials using submicron PMMA 
and PS beads. By increasing the bead size, ICC structures can be utilized for 3D cell culture 
experiments. While PMMA and PS beads are commercially available, they are expensive 
and limited in size selection, with an upper limit of 160 µm due to the decreasing stability 
of emulsions with increasing size. Addition of crosslinkers allows synthesis of larger beads, 
but cross-linked beads cannot be dissolved. The second group is polymeric beads prepared 
by solvent evaporation from emulsion droplets including polycaprolactone (PCL)302. 
Polymers dissolved in organic solvents are microfluidically processed into uniform size 
emulsion droplets that in turn solidify as the solvent evaporates303. This method increases 
template bead sizes in a cost-effective manner, but the resultant polymeric beads exhibit a 
narrow window for thermal and mechanical stability, requiring exceptional care to process 
into colloidal crystal templates and ICC scaffold fabrication. The third group is hydrogel 
beads generated by in situ gelation including alginate and gelatin. Formation and 
dissociation of alginate beads are exploited by ionic cross-linking and a chelating agent, 
ethylenediaminetetraacetic acid, respectively304-305. Synthesis and solubilization of gelatin 
beads take advantage of their temperature-dependent reversible sol-gel transition306-309. 
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Although hydrogel beads made from biocompatible materials are removable without using 
toxic chemicals, their weak mechanical properties make them difficult to process and 
handle. The fourth group is microbubbles including air and nitrogen gases310-313. 
Microbubbles suspended in a precursor solution generated by a flow-focusing microfluidic 
device are collected in a confined container and solidified under negative pressure, which 
opens the closed pores and enables formation of an open porous ICC structure. This method 
is simple, fast, and essentially non-toxic, but requires significant optimization due to the 
intrinsic instability of the microbubbles. The last group is glass beads. Glass beads are 
commercially available with a broad range of sizes and represents high thermal and 
mechanical stability that facilitates streamlined fabrication of ICC hydrogel scaffolds96-97, 
101, 134, 314-316. However, requirement of toxic chemicals (i.e. hydrofluoric acid) to dissolve 
the glass beads has been a critical issue. Currently there exists no practical and cost-
effective method to produce ICC hydrogel scaffolds at high scale under good 
manufacturing practices. The development of a better fabrication method remains an active 
area of research. 
Here, we introduce a simple and robust method to fabricate bioactive ICC hydrogel 
scaffolds using expanded polystyrene (EPS) beads, the raw material commonly used for 
packaging and insulation products. EPS beads are a closed cell foam material composed of 
95-98% air, with robust mechanical and thermal stability317. We have developed a method 
to shrink and fuse EPS beads into a free-standing construct that functions as a colloidal 
crystal template for fabrication of ICC hydrogel scaffolds. Pore size is tunable by adjusting 
the degree of EPS bead shrinkage. Surface modification for bioactive ICC hydrogel 
scaffolds was simplified by introducing collagen fibers into the hydrogel precursor solution 
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and polymerizing in a single step. The biological significance of EPS-templated ICC 
hydrogel scaffolds was demonstrated in vitro via conducting a hematopoietic colony-
foaming assay in the presence of bone marrow stromal cells (BMSCs). The ability to form 
vascularized tissue and attract hematopoietic cells after subdermal implantation was 
comparatively demonstrated using glass bead-templated ICC hydrogel scaffolds. We 
envision that this simple and cost-effective fabrication strategy will facilitate usage of ICC 
hydrogel scaffolds for lymphoid tissue modeling and other emerging novel biological 
applications. 
 
Figure 6.1. Summary of the state-of-the-art inverted colloidal crystal hydrogel 
scaffold fabrication methods.  
(A) Schematic illustration of the procedure to fabricate bioactive inverted colloidal crystal 
hydrogel scaffolds starting from microbead-based colloidal crystal templates. (B) The 
fabrication of ICC hydrogel scaffolds can be divided into five groups based on microbead 




6.3.1 Preparation of colloidal crystal templates using expanded polystyrene (EPS) 
beads 
For some polystyrene foam products, EPS beads are subjected to steamed 
mechanical compression to make a densely packed foam structure without interstitial 
space. We hypothesized that EPS beads with increased interstitial space could serve as 
colloidal crystal templates for ICC hydrogel scaffold fabrication. To test this hypothesis, 
we used a pressure cooker to apply vapor phase water and ethanol solutions to EPS beads 
without mechanical compression (Figure 6.2A). Water and ethanol were used as the source 
of vapor because they are cheap and relatively safe for scaled operation. EPS beads 
(diameters = 1.6 ± 0.19 mm) were placed in a perforated metal container and processed in 
an electric pressure cooker for 5, 10, 15, and 30 min. The perforated metal container was 
elevated to prevent contact with the liquid phase at the bottom of the cooker. Electronic 
pressure cookers are regulated by a pressure setpoint. On the Chefman unit used for these 
experiments a gauge pressure of roughly 0.5-0.7 bar is achieved during operation. 
Evaluation of the vapor pressure as a function of temperature reveals that the chamber 
reaches a temperature of 110-114 °F with water compared to 89-93 °C with pure ethanol. 
Pressurized thermal conditions directed shrinkage and fusion of EPS beads to create a free-
standing colloidal crystal-like structure. The shape of the template remained identical, 
indicating isotropic shrinkage of EPS beads (Figure 6.2B). In pure ethanol, beads 
underwent rapid and uneven size reduction, evident by a wider base compared to top. The 
overall size reduction was directly correlated to operation time for all ethanol:water 
solutions. Increasing ethanol concentration was observed to increase the degree of 
shrinkage. Interestingly a 50:50 mixture had less shrinking ability compared to pure water. 
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Size reduction was greatest at early timepoints and the rate of reduction gradually slowed 
down over time (Figure 6.2C). 
 We next characterized the size and shape change of the individual EPS beads under 
optical microscopy. Increasing operation time and ethanol concentration reduced the size 
of EPS beads in an isotropic manner. The interface between the fused beads exhibited 
elongated necking. In the pure ethanol condition, uneven shrinkage of templates caused 
different size reduction of EPS beads between the top and bottom surface; EPS beads in 
the top side showed densely fused morphology whereas EPS beads in the bottom showed 
significantly elongated necks (Figure 6.2D). The dynamic shrinking of porous EPS beads 
during bead-bead fusion presents a significantly different annealing process. We further 
conducted micro-CT scans to visualize the internal packing structure and quantify the 
interstitial area. While EPS beads have regular sphericity and about 10 % of size 
distribution, their packing density was lower compared to solid beads and microbubbles. 
The characteristic interstitial area was about 26.2 % (Figure 6.2E). Quantitative analysis 
of EPS beads substantiated rapid and significant reduction of size with increasing 





Figure 6.2. Preparation of colloidal crystal templates using expanded polystyrene 
(EPS) beads.  
(A) Gross image of EPS beads in a perforated metal container (Left) and schematic of 
experimental set-up and process to fuse EPS beads using a pressure cooker (Right). (B) 
Images of free-standing fused EPS beads after a pressurized thermal process in 5 different 
ethanol solutions and 4 operating times. Zoomed-in images of side view show non-
isotropic size reduction of EPS beads processed with pure ethanol. (C) Quantitative 
analysis of overall template diameters (n=4, * P<0.05). (D) Microscopy images of fused 
EPS beads after 15 minutes of operation in varying compositions of ethanol solution. (E) 
3D reconstruction of micro-CT scanned EPS bead-templated colloidal crystal structure and 
quantitative measurement of interstitial area (n=5). (F) Quantitative analysis of shrunken 
EPS bead diameters. Due to anisotropic shrinkage of templates, top and bottom side 
templates exhibit different size reduction (n=75-100, * P<0.05). 
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6.3.2 Fabrication of ICC hydrogel scaffolds using EPS bead-based templates 
Complete infiltration of hydrogel precursor solution into the interstitial space of 
colloidal crystal templates requires centrifugation, and the templates should endure the 
gravitational force. Two critical considerations in using EPS bead-based colloidal crystal 
templates include flotation of the structure and insufficient mechanical stability. We 
addressed the flotation issue with a laser-cut acrylic structure designed to fit a standard 50 
mL centrifuge tube, consisting of thin rings that support a disk with holes which are then 
held down with long bracing pieces that become wedged once the cap is screwed on 
(Figure 6.3A). In this study, we used a hydrogel precursor solution composed of 
acrylamide monomer and bis-arylamide crosslinker activated by ammonium persulfate and 
TEMED. After overnight polymerization at room temperature, the polymerized hydrogel 
and EPS template were taken out from the tube and excess hydrogel was removed. Finally, 
hydrogel-EPS templates were soaked in chloroform for 4-6 hours during which EPS beads 
were selectively dissolved, leaving behind an ICC polyacrylamide hydrogel matrix (Figure 
6.3B). EPS templates prepared in solutions with less than 80 % ethanol were broken during 
precursor infiltration, in which the characteristic ultimate mechanical strength was 1.8 ± 
0.2 megapascals (MPa). EPS templates prepared in pure ethanol exhibited the highest 
mechanical strength (10.3 ± 1.2 MPa) but were difficult to infiltrate with precursor solution 
due to limited interstitial space (Figure 6.3C). When this mechanical correlation was 
plotted as a function of the overall template size, it turned out that more than 50 % size 
reduction was required to maintain mechanical strength necessary for centrifugation 
(Figure 6.3D). Based on these data, we determined that templates processed with 90 % 
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ethanol solution were optimal for fabrication of EPS-templated ICC polyacrylamide 
scaffolds.  
 EPS-templated ICC hydrogel scaffolds exhibited spherical pore cavities and optical 
transparency comparable to ICC hydrogel scaffolds prepared with glass beads of 
comparable sizes (Figure 6.3E). Scaffold pore size was found to be tunable based on the 
duration of EPS-templated processing. For example, pore diameters were 1.05 ± 0.2 mm, 
9.27 ± 0.18 mm and 8.23 ± 0.15 mm for ICC hydrogel scaffolds fabricated from templates 
made with 90% ethanol for 5 min, 15 min and 30 min operation, respectively (Figure 
6.3F). The EPS-templated ICC hydrogel scaffold fabrication strategy is flexible and rapid, 
enabling creation of different prototypes demonstrated by triangular, square, and hexagonal 




Figure 6.3. Preparation of EPS-templated ICC polyacrylamide hydrogel scaffolds.  
(A) Acrylic structures designed to keep EPS bead-based colloidal crystal templates 
submerged during the infiltration of precursor solution and subsequent polymerization. (B) 
Schematic of experimental procedures to obtain a hydrogel with an ICC structure. (C) 
Quantitative analysis of the ultimate strength of fused EPS beads under varying conditions 
and an indication of the optimal operating range. (D) Quantitative correlation of ultimate 
strength and diameter change highlighting the minimum mechanical strength to endure 
mechanical stress of centrifugation. (E) Camera (top) and microscope (bottom) images of 
EPS-templated ICC hydrogel scaffolds. (F) Quantitative analysis of pore diameters of ICC 
hydrogel scaffolds fabricated with three different operating periods and 90% ethanol. (n=4, 
*P<0.05). (G) Demonstration of conserved EPS template shrinking, and subsequent ICC 




6.3.3 Preparation of bioactive ICC hydrogel scaffolds via type I collagen integration 
in bulk hydrogel 
Polyacrylamide hydrogel is not conductive for cell adhesion and requires 
immobilization of collagen fibers or RGD peptides to become bioactive. However, reagents 
for the conjugate chemistry are expensive and this procedure is laborious. Instead we 
hypothesized that inclusion of collagen fibers directly in the precursor solution would 
simplify fabrication of bioactive ICC hydrogel scaffolds. To test this hypothesis, we 
fabricated ICC hydrogel scaffolds with precursor solution containing type I collagen fibers 
at a final concentration of 2 mg/mL and compared them to scaffolds prepared by attaching 
collagen fibers using Sulfo-SANPAH conjugate chemistry (Figure 6.4A). Collagen fibers 
in the hydrogel matrix were visualized via second harmonic generation in a multiphoton 
microscope. As expected, the conventional method immobilized collagen exclusively on 
the pore surface whereas collagen dispersed in the precursor solution appeared both on the 
surface and within the bulk hydrogel. Collagen fibers exhibited different morphologies; 
stretched thin fibers when surface conjugated and coiled bundles when mixed directly in 
the polymer precursor solution (Figure 6.4B). Collagen fibers are known to undergo a 
reversible conformational change depending on the surrounding pH 318. For example, at 
low pH, collagen fibers adopt an elongated morphology whereas at high pH, collagen fibers 
coil. Our results indicate that the alkaline reaction pH of acrylamide polymerization via 
addition of ammonium persulfate and TEMED could direct collagen fibers to adopt a more 
coiled morphology319.  
 We next examined whether the collagen embedded within the polyacrylamide of 
an ICC hydrogel scaffold could support stromal cell adhesion. Primary BMSCs retrieved 
from the femurs of eGFP mice were used to easily visualize stromal cells seeded on the 
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scaffold. Fluorescence images taken 3 days after seeding showed that most stromal cells 
adhered and displayed an elongated, spread morphology on scaffolds with collagen, 
whereas the stromal cells that adhered on control collagen-free hydrogel scaffolds had a 
round morphology, indicating poor surface adhesion (Figure 6.4C). Quantitative analysis 
of stromal cell morphology revealed 85 % had an elongated morphology on collagen 
scaffolds whereas only 15 % of cells adhered on collagen-free scaffolds (Figure 6.4D). 
These results indicate that direct introduction of collagen fibers in precursor solution 
promotes stromal cell adhesion comparable to conventional conjugate chemistry.  
 
Figure 6.4. Hybridization of collagen and polyacrylamide to achieve bioactive 
hydrogel scaffolds. 
(A) Schematic illustration of conventional surface modification using conjugation 
chemistry and dispersion in precursor solution for direct integration within the hydrogel 
matrix during polymerization. (B) Second harmonic generation images of collagen on 
polyacrylamide hydrogel scaffolds using multiphoton microscopy. (C) Comparison of 
fluorescent confocal images of eGFP BMSCs on the pore surface of ICC hydrogel scaffolds 
with and without bulk collagen integration. (D) Quantitative comparison of stromal cell 





6.3.4 In vitro modeling of bone marrow tissue microenvironments 
For an in vitro functional demonstration, we applied EPS-templated ICC hydrogel 
scaffolds to model the bone marrow tissue microenvironment focusing on hematopoietic 
cell activity as a function of BMSCs. BMSCs are known to secrete a variety of soluble 
factors that support and direct hematopoietic activity in the bone marrow320-322. By 
changing the availability of collagen we hypothesized that the BMSCs seeded on ICC 
hydrogel scaffolds would adopt distinctive soluble factor profiles and differentially direct 
hematopoietic colony forming activity. A critical issue in characterizing hematopoietic 
colonies in 3D scaffolds is deciphering stroma from hematopoietic cells and their 
progenitors using traditional microscopy techniques. To overcome this challenge, we 
employed cells from eGFP and DsRed reporter mice that facilitate fluorescent monitoring 
of stromal and hematopoietic cell activity while preserving the intrinsic phenotype of both 
cell types (Figure 6.5A). We first examined the secretion profile of BMSCs focusing on 
key factors involved in bone remodeling: IL-6, osteoprotegerin (OPG), and receptor 
activator of nuclear factor kappa-B ligand (RANKL). Increased RANKL and IL-6 
stimulate osteoblasts and osteoclasts to promote bone remodeling activity, whereas OPG 
secretion suppresses remodeling activity. ELISA data showed that BMSCs secreted 
significantly more IL-6 and RANKL and notably lower OPG on collagen-free ICC 
hydrogel scaffolds than collagen embedded hydrogel scaffolds (Figure 6.5B-D). These 
results indicate that BMSCs seeded on hydrogel matrix with embedded collagen suppress 
bone remodeling activity.   
We next evaluated if the different soluble environments could direct hematopoietic 
colony forming activity. After 1-week culture of eGFP BMSCs on collagen-coated and 
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control ICC hydrogel scaffolds, we introduced freshly harvested femoral bone marrow 
cells retrieved from DsRed mice. Before loading, bone marrow cells were dispersed in 
methylcellulose medium without hematopoietic cytokines. Subsequent hematopoietic 
colony development was monitored with fluorescence microscopy over a 16-day period. 
DsRed fluorescent colonies gradually emerged in and around BMSC seeded scaffolds 
(Figure 6.5E). This unconventional three-dimensional colony forming assay makes it 
difficult to distinguish specific types of hematopoietic colonies. Instead, we focused on the 
number of emerging colonies by taking advantage of the endogenous fluorescence. In 
stromal cell-free control cultures without essential hematopoietic cytokines, no 
hematopoietic colonies emerged, indicating stromal cells play a vital role in supporting the 
survival and function of hematopoietic cells ex vivo. Quantitative monitoring of colony 
number over the experimental period showed an increased number of hematopoietic 
colonies when cocultured with BMSCs seeded on scaffolds with embedded collagen, 
whereas the number of colonies stabilized after 1-week of coculture with BMSCs on 
collagen-free scaffolds (Figure 6.5F). 3D confocal imaging at the end of the study revealed 
the spatial distribution of BMSCs and hematopoietic cells, with some in physical contact 
with each other (Figure 6.5G). Collectively these results indicate that the different soluble 
milieus produced by BMSCs with and without collagen stimulation can affect 
hematopoietic colony forming activity. This also demonstrated that EPS-templated ICC 
hydrogel scaffolds are capable of identifying dynamic functional interactions between 




Figure 6.5. In vitro demonstration of functional bone marrow tissue model using EPS-
templated ICC hydrogel scaffolds.   
(A) Schematic of bone marrow tissue model with eGFP stromal cells and subsequent 
introduction of bone marrow cells from DsRed mice dispersed in methylcellulose medium 
for colony-forming assay. (B-D) Comparative ELISA of (B) IL-6, (C) osteoprotegerin 
(OPG), and (D) RANKL secretion by BMSCs seeded on collagen and collagen-free ICC 
hydrogel scaffolds. (E) Representative fluorescence microscope images of time course 
hematopoietic colony-forming activity in BMSC seeded scaffolds on collagen and 
collagen-free ICC hydrogel scaffolds. (F) Time course quantification of hematopoietic 
colony count (n=3, * P<0.05). (G) Z-projection of 3D confocal microscope images of 
stromal (green) and hematopoietic (red) cell spatial distribution in EPS-templated ICC 




6.3.5 Formation of lymphoid mimicking tissue microenvironments in vivo 
Subdermal implantation of ICC hydrogel scaffolds has been shown to direct unique 
foreign body responses leading to a richly vascularized stromal tissue with prolonged 
hematopoietic cell activity. We evaluated if EPS-templated ICC hydrogel scaffolds 
induced comparable tissue development to hydrogel scaffolds made with glass beads after 
subdermal implantation in FVB mice (Figure 6.6A). Scaffolds fabricated from glass beads 
were chosen for comparison because they are commercially available in sizes close to those 
achieved with the EPS fabrication technique. Gross observation after four weeks of 
implantation revealed EPS and glass-templated ICC hydrogel scaffolds showed similar 
tissue development and attraction of large blood vessels (Figure 6.6B). H&E staining 
confirmed complete interscaffold tissue development and a comparable pattern of spatial 
tissue microenvironments directed by the ICC geometry. In general, fibrotic tissue is 
formed within the central region of each pore whereas hematopoietic cells are localized 
near the pore surface (Figure 6.6C).  
 We further characterized the vascular network and attraction of macrophages and 
neutrophils via immunohistostaining for CD31, F4/80 and Ly6G, respectively. Tissues 
developed in EPS-templated ICC hydrogel scaffolds contained an extensive vascular 
network similar to glass-templated ICC scaffolds (Figure 6.6D). Non-degradable synthetic 
hydrogels direct macrophage response throughout the entire scaffolds (Figure 6.6E). 
Distinct from the widespread vasculature and macrophages, neutrophils were highly 
localized in 2-3 sites of each tissue section (Figure 6.6F). Overlaid CD31, F4/80, Ly6G, 
and nuclei staining substantiates the spatial distribution of vascular, stromal and immune 
cells in an ICC pore cavity (Figure 6.6G). Quantitative analysis of CD31, F4/80, and Ly6G 
Figure  SEQ Figure \* ARABIC 3 a) EPS scaffold fabrication 
setup and resulting template and acrylamide scaffold. b) Tunable 
scaffold/bead size  
Figure  SEQ Figure \* ARABIC 4 Hybrid scaffold approach and preliminary template result. Arteriole channel made 
from black EPS for clarity 
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positive areas confirmed comparable tissue development between EPS- and glass-
templated ICC hydrogel scaffolds (Figure 6.6H-I). Overall our results indicate that EPS-
templated ICC hydrogel scaffolds retain comparable ability to induce characteristic 
vascularized and hematopoietic cell attracting lymphoid tissue-mimicking 
microenvironments to glass-templated ICC hydrogel scaffolds.  
 
Figure 6.6. Comparison of tissue microenvironment formed in ICC hydrogel scaffolds 
made from glass and EPS beads after subdermal implantation.   
(A) Experimental schematic of EPS and glass-templated ICC hydrogel scaffold 
implantation for in vivo tissue microenvironment formation. (B) Gross images of glass- 
and EPS-templated ICC hydrogel scaffolds in FVB mice after 4 weeks of subdermal 
implantation. (C) Comparison of hematoxylin and eosin stained tissue microenvironments. 
(D-F) Comparison of immunohistostaining (IHS) for (D) blood vessels (CD31), (E) 
macrophages (F4/80) and (F) neutrophils (Ly6G). (G) Overlaid IHS image of blood 
vessels, macrophages, neutrophils, and nucleus (DAPI) to visualize the spatial resolution 
in the lymphoid tissue mimicking microenvironment. (H-J) Quantitative imaging analysis 




In this report, we introduced EPS bead-based ICC hydrogel scaffold fabrication. 
EPS beads are widely available at low cost. From a material aspect, EPS beads exhibit 
intermediate characteristics between solid beads and microbubbles while retaining 
mechanical integrity and flexibility. These properties facilitate the production of the 
intricate geometry of ICC scaffolds in a fast, cost-effective, and less toxic manner when 
compared to existing template materials. In addition, direct inclusion of type I collagen in 
the precursor solution has greatly simplified the manufacturing procedure for bioactive 
hydrogel scaffolds. These features represent great potential to reduce the technical and cost 
barriers in fabricating bioactive ICC hydrogel scaffolds. The presented method for EPS-
templated hydrogel scaffolds can be improved further. First, the dimension of EPS beads 
is not ideal for modeling trabecular bone cavities in hematopoietic bone marrow and other 
lymphoid tissues. This issue can be resolved by reducing the size of expandable 
polystyrene resins that are being processed into EPS. Second, the packing of EPS beads is 
suboptimal as the low density of EPS beads makes it difficult to apply centrifugation and 
agitation-assisted packing methods. This can be improved by benchmarking the previous 
methods in building colloidal crystal templates at the air-water interface323-324. Lastly, the 
coiled morphology of in situ collagen integration is also suboptimal to maximize the 
function of collagen for stromal cell adhesion. Collagen fibers undergo pH dependent 
conformational change; collagen fibers are relaxed in an acidic environment whereas they 
are coiled configuration in basic solutions325. Alkaline precursor solution likely causes the 
collagen fibers to undergo a conformational change. By adjusting the pH in the precursor 
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solution, more aligned collagen fibers and better coverage of hydrogel matrix may be 
achieved.  
 Water and ethanol were used to generate the pressurized heated vapor phase 
responsible for EPS shrinkage and fusion to form a free-standing template structure. 
Although the theoretical temperature of the chamber was lower in pure ethanol samples, 
the size reduction was the greatest. This phenomenon may be explained by the solubility 
of polystyrene in ethanol and water. Solubility parameters can be estimated from physical 
properties, as described by the Hildebrand solubility parameter and Hansen solubility 
parameter326. The Hildebrand model defines the parameter δ as the square root of the 
cohesive energy density. Cohesive energy density is the negative value of the internal 
energy commonly defined U, divided by the molar volume. The Hansen model provides 
expansion of application to polar systems via empirical observations to determine 
dispersive, polar, and hydrogen-bonding terms. Solubility parameters provide input on 
whether polymers will dissolve in solvents, effectively if solubility parameters are similar 
the two components are predicted to be miscible. The Hansen solubility parameters δ 
(MPa)1/2 for water, ethanol, and polystyrene are 47.9, 26.0, and 18.7, respectively. For 
comparison the solubility parameter for the solvent used to dissolve the template, 
chloroform is 19 (MPa)1/2. The increased, though overall poor, solubility of polystyrene in 
ethanol may provide faster collapse of the foam structure within EPS beads. The beads do 
not appear to lose their spherical geometry indicating these changes may occur on a very 
small scale. Electron microscopy may provide details on pore structure of EPS beads 
processed with different solvents. Additionally, means to calculate solubility parameters of 
mixtures are not straightforward. However, other than samples processed with a 50:50 
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mixture, this assessment provides evidence for the two extreme cases of EPS shrinkage as 
seen by use of pure vapor phase solutions. Evaluation with solvents with similar solubility 
parameter values may further substantiate these claims.  
 Besides lymphoid tissue modeling, ICC hydrogel scaffolds have been previously 
demonstrated to be advantageous in other tissue engineering applications. For example, 
ICC geometry made with cell-repulsive hydrogel matrix directed formation of multicellular 
hepatocyte and stem cell spheroids with narrow size distribution327-328. Hepatic and 
embryonic spheroids demonstrated in vivo relevant cellular processes in toxic nanoparticle 
exposure316 and differentiation into lineage cells329, respectively. ICC hydrogel scaffolds 
have demonstrated additional in vitro success modeling cartilage330, bone314 and 
neuronal331 tissues taking advantage of their unique geometry with tailored biomaterials in 
each target application. ICC hydrogel scaffolds have also demonstrated exceptional 
capability for rapid vascularization as a function of pore size298. This capability has been 
applied for cardiac tissue engineering and wound healing medical devices. The presented 
EPS-templated ICC hydrogel scaffold fabrication will leverage these abilities to broader 
academic and industrial communities.   
 ICC hydrogel scaffolds with controlled isotropic spherical pore arrays of hydrogel 
matrix has emerged as an important class of biomaterials for tissue engineering. Originally 
in the context of lymphoid tissue engineering, ICC scaffolds have many promising 
applications both in vitro and in vivo. An important next step in the advancement of ICC 
hydrogel scaffolds is improved fabrication techniques that facilitate effective scale up. 
Currently, there are no commercial ICC hydrogel scaffolds due to material cost, time, and 
safety. The presented work provides a cheaper, faster, and safer method for ICC hydrogel 
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fabrication by using EPS and directly mixing collagen fibers within the synthetic hydrogel 
matrix. ICC hydrogel scaffolds have already demonstrated many promising applications in 
lymphoid tissue engineering and beyond. We envision that the presented EPS beads-based 
scaffold fabrication will greatly facilitate broad and practical applications of ICC hydrogel 
scaffolds to the research community and enable exploration into translational opportunities 
for patients.  
6.5 Materials and Methods 
All chemicals and cell culture reagents were purchased from Thermo Fisher 
Scientific unless otherwise specified. The animal protocol was approved by the University 
of Massachusetts Amherst Institutional Animal Care and Use Committee.  
6.5.1 Pressurized thermal annealing of EPS beads 
EPS beads (Diameter = 1,626 ± 195 µm) obtained from Amazon were loaded into 
a perforated stainless-steel mesh container (Diameter = 38 mm, Height = 44 mm) to a 
height of 1 cm. The mesh container was transferred to an elevated rack in a 2.5-quart 
electric pressure cooker and the cooker was filled with 200 mL of ethanol and water 
mixture. Using the “High Pressure” setting on the cooker, an annealing time was set 
between 5-30 minutes. The lid was attached, and the pressure valve was closed to prevent 
loss of vapor. At the end of annealing, built-up pressure was released before carefully 
removing the lid and steel mesh containers. Annealed EPS templates were kept at room 
temperature prior to further processing. Template images were acquired with an inverted 






6.5.2 Micro-CT imaging and porosity characterization 
Templates fabricated using different annealing conditions and times were scanned 
using the CT imager on an IVIS SpectrumCT with a voxel size of 75 µm. Calculation of 
void fraction based on micro-CT imaging was performed in MATLAB. 
6.5.3 EPS bead-templated ICC hydrogel scaffold fabrication 
An acrylamide precursor solution was made with 30 wt% acrylamide monomer and 
1.5 wt% bis-acrylamide crosslinker dissolved in nitrogen-purged deionized (DI) water. For 
collagen experiments, nitrogen purged DI water was displaced with a 4 mg/mL rat-tail 
collagen solution to obtain a final collagen concentration of 2 mg/mL. Prior to 
polymerization of the EPS template, a 50 mL centrifuge tube was prepared with laser-cut 
acrylic inserts to keep the template fully submerged during polymerization. 10 wt/vol% 
ammonium persulfate and N,N,N’,N’-tetramethyl-ethylenediamine (TEMED) were added 
to the acrylamide precursor solution such that both were at a final concentration of 0.1 %. 
The solution was added to the EPS template-containing centrifuge tube and centrifuged at 
4,500 xg for 20 minutes at 4 °C. Tubes were carefully removed from the centrifuge and 
left at room temperature to polymerize. Once polymerized, infiltrated EPS templates were 
retrieved from the centrifuge tubes and carefully scraped on all sides with a razor blade to 
remove excess polymer. Infiltrated EPS templates were placed in chloroform and left 
overnight to dissolve EPS beads. A second wash with fresh chloroform was performed to 
remove residual EPS before thorough washing with water. Hydrogel gel scaffolds were 
sterilized by submerging in 70 % ethanol for 30 minutes. For in vitro and in vivo 
applications scaffolds fabricated with 90 % ethanol and annealing time of 30 minutes were 
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used. Initially large scaffolds were cut down (Diameter = 6 mm x Height = 2.5 mm) using 
a 6 mm biopsy punch and a razor blade. Sterile scaffolds were stored in phosphate-buffered 
saline at 4 °C.   
6.5.4 Rat tail type I collagen isolation 
Type I collagen was isolated from rat tails using serial salt precipitation and 
dissolution in acetic acid97. Briefly, tendons were extracted from rat tails using hemostats 
and a razor blade, and then dissolved in 3 % (v/v) acetic acid overnight. The resulting 
solution was passively filtered through a 500 m mesh and centrifuged for 2 hours at 
13,000 xg at 4 oC to remove debris and impurities. Next, the supernatant was collected and 
diluted 1:4 by volume in a 30 % (wt/v) NaCl solution at a rate of 350 mL/hr and then left 
still for 2 hours. To collect the collagen, the resulting solution was spun down at 8,500 xg 
for 45 min at 4 oC, and the precipitated gelatinous collagen harvested. Addition of salt 
solution and precipitation was repeated until no more collagen was extracted from the 
solution after centrifugation, upon which all collagen material was combined and 
resuspended in 0.6 % (v/v) acetic acid. The collagen solution was then dialyzed in 1 mN 
HCl, and the concentration determined using lyophilization.  
6.5.5 Glass bead-templated ICC hydrogel scaffold fabrication 
Soda lime glass beads (Diameter = 650 ± 65 µm) were sorted using an Advantech 
Sonic Sifter. Beads dispersed in DI water were gradually loaded into a glass vial (8×35mm) 
to a height of 2–2.5mm and were mechanically packed into a lattice structure in an 
ultrasonic water bath. Orderly packed glass beads were dried in a 60 °C oven and then 
thermally annealed for 4 h in a furnace between 650 and 680 °C. A hydrogel precursor 
solution composed of 30 wt% acrylamide monomer, 1.5wt% bis-acrylamide crosslinker, 
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0.2 vol% N,N,N′,N′-tetramethylethylenediamine accelerator, and 0.2 vol% 2-hydroxy-2-
methylpropiophenone photoinitiator in nitrogen-purged DI water was prepared 
immediately before use. Precursor solution (150 μl) was infiltrated into the glass bead 
template and centrifuged in a microcentrifuge at 8,500 xg for 15min and subsequently 
polymerized under a 15W ultraviolet light source for 15min. Polyacrylamide hydrogel–
glass templates were removed from the glass vials the next day to ensure complete 
polymerization. Excess hydrogel was removed by scraping the glass bead template with a 
razor blade on all surfaces. Glass beads were selectively dissolved in alternating washes of 
an acid solution containing a 1:5 dilution of hydrofluoric acid in 1.2M hydrochloric acid 
and 2.4M hydrochloric acid (caution: these chemicals are corrosive and must be used in a 
fume hood with proper protective gear). Washes were completed on a shake plate, and 
solutions were changed every 4h until the beads were removed. Scaffolds were thoroughly 
washed with DI water to remove residual acid and lyophilized. Type I collagen isolated 
from rat tails was covalently immobilized on the pore surface using Sulfo-SANPAH 
conjugate chemistry as previously described101.  
6.5.6 Mechanical testing of EPS templates 
Mechanical properties were measured using an ElectroForce 5500 (TA 
Instruments) equipped with a 50 lb-load cell. A strain rate of 0.02 mm/sec was applied with 






6.5.7 Multiphoton microscopy imaging of collagen fibers via second-harmonic 
generation 
Collagen fibers on the surface and embedded within hydrogel scaffolds were 
imaged using a Nikon A1MP multiphoton microscope equipped with a tunable Ti:Sapphire 
laser source set at an excitation wavelength of 850 nm and a 492 nm shortpass filter.   
6.5.8 Primary mouse bone marrow stromal cell isolation and culture expansion 
A breeding pair of eGFP mice (006567) were purchased from Jackson Laboratories. 
A breeding pair of DsRed (005441) was obtained from Dr. Barbara Osbourne. Femurs and 
tibias were collected from DsRed or eGFP mice. Bone marrow stromal cells (BMSCs) were 
isolated from the bone by centrifugation and cultured in alpha-Modified Eagle Medium 
supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin. Adherent 
cells were cultured for a maximum of 4 passages. 
6.5.9 ELISA of mouse IL-6, OPG, and RANKL 
EPS scaffolds with and without collagen were seeded with 500,000 adherent eGFP 
BMSCs and cultured in the wells of a 48 well plate. The culture was maintained until cells 
spread and covered the scaffold surface. 2D tissue culture plastic controls were seeded at a 
density of 50,000 cells per well and grown until confluence. Medium was changed every 
3 days for the duration of the experiment. At the end of the experiment conditioned media 
was collected 48 hours after a media change and frozen at -80 °C. ELISAs were performed 
on thawed conditioned media samples using ELISA kits acquired from R&D Systems. 
6.5.10 Methylcellulose colony-forming assay 
EPS scaffolds were seeded with 500,000 adherent eGFP stromal cells and cultured 
in wells of a 48 well plate until all surfaces were covered. Freshly isolated bone marrow 
 
 176 
cells from DsRed mice were resuspended to a concentration of 500 cells/µL in 
methylcellulose media (1.27 % alpha-Modified Eagle Medium methylcellulose, 10% fetal 
bovine serum, and 1% penicillin-streptomycin). 50,000 cells were carefully added to the 
wells containing eGFP BMSCs pre-seeded EPS-templated ICC hydrogel scaffolds and 
empty EPS scaffolds. Full well scans were acquired using an EVOS fluorescent microscope 
on day 1, 4, 8, 12 and 16. Fluorescent z-stack images were taken by confocal microscope 
(Zeiss Cell Observer) and 3D reconstructed images were generated and animated in Nikon 
Elements AR v5.2.0. FFMPEG was utilized to downsample and compress the 3D 
reconstructions.  
6.5.11 Subdermal implantation of scaffolds in mouse models 
6-week old FVB mice (001800) were obtained from Jackson Laboratory. Mice 
were anesthetized with 1.5% isoflurane before removing dorsal hair with electric clippers 
and Nair. 70% of isopropanol wipes were used to sterilize the skin. Mice received 2 mg of 
meloxicam/kg mouse weight subcutaneously prior to surgery. Four subcutaneous pockets 
were formed in mice and EPS and Glass-templated ICC hydrogel scaffolds were 
immediately place within. Wounds were closed with two 7 mm wound clips. Wound clips 
were removed after one week. Four weeks after implantation scaffolds were retrieved and 
flash frozen in Shandon Cryomatrix embedding resin. Tissue blocks were stored at -80 °C 
until use. 
6.5.12 Histological characterization 
Frozen tissue blocks were sectioned on an NX70 cryostat at a thickness of 20 µm. 
Hematoxylin and eosin, and immunohistostaining procedures were performed as 
previously described101. CD31 (550274), F4/80 (565409), and Ly6G (557445) primary 
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antibodies and anti-Rat AlexaFluor 647 (A21247) secondary antibodies were used in this 
study. Brightfield images were acquired on an EVOS FL Auto microscope and fluorescent 
images were acquired on a Zeiss Cell Observer SD.   
6.5.13 Statistics 
Unpaired Student’s t-test was performed for comparison of the mean values in all 
quantitative analysis. Statistical significance was determined if p<0.05 for a two-tailed 





















CONCLUSION AND FUTURE DIRECTIONS 
7.1 Conclusion 
 Metastasis remains a critical problem in clinics and therapeutic strategies have not 
made significant impact on patient health. The work presented here provides an enabling 
tool to better understand disseminated tumor cells (DTCs) and their progression to lethal 
metastases and potentially provide translational results to improve patient health. Inverted 
colloidal crystal (ICC) hydrogel scaffolds produce standardized and controlled in vivo 
niches for a wide variety of studies. The flexibility of ICC scaffolds and implantable niche 
models can be leveraged for further tunability. First, the physical and bulk properties of the 
scaffold can be altered by changing the pore size, the polymer material, and polymer 
properties such as crosslinking density. For example, pore size was shown to alter 
vasculature formation and control the diameter of blood vessels. Second, ex vivo cell 
seeding enables new cell populations to be directly added to the tissue niche. Here I have 
utilized human bone marrow stromal cells to generate niches that actively secrete human 
cytokines and more closely model human tissue. Third, changing the implant location 
drastically changes the local cell populations and impacts the final cellular and molecular 
niche that forms within the pores. Finally, the transplantable capabilities enable extended 
experimental duration and open the door to the development of new strategies to model 
disease. Here we transplanted to syngeneic hosts of similar age, however one exciting 
possibility is transplantation into significantly older hosts to understand how ageing affects 
the niche and metastasis. 
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 The immunomodulatory properties of ICC hydrogel scaffolds prevent fibrotic 
encapsulation, typically associated with the later stages of the foreign body response. 
Instead a highly vascularize tissue rich in bone marrow derived cells is formed. Here I 
heavily relied on these properties to create a receptive niche for circulating tumor cells. 
Additionally, I have demonstrated the ability to leverage the benefits of increased 
vascularization and altered immune response to transplant lung and liver tissue ectopically 
to the subcutaneous space. Maintenance of native tissue properties is an exciting result and 
provides evidence that xenotransplantation of mature human tissue may benefit from the 
scaffold-assisted approach. Out of patient study of fully mature human tissues in an in vivo 
setting could prove to be powerful preclinical models for drug screening and probing basic 
biological questions about human tissue.  
 The central goal of this work was to create new in vivo models that overcome the 
limitations present in traditional models of metastasis. I have shown the versatility of 
implantable models across several mouse strains: FVB, C57BL/6, and NSG. Additionally, 
the implantable niche strategy has been successful in multiple methods of tumor generation 
including intravenous, orthotopic, xenografts, and genetically engineered spontaneous 
cancer models. The work has addressed very critical problems in DTC dormancy and 
metastatic relapse. DTC dormancy models were formed using a transplantable niche 
strategy. Primary tumor burden and aggressive metastases in vital organs prevents the 
effective study of long-term dormant DTCs. Transplantation of DTC containing niches 
enabled long-term observation and identified critical niche components that are associated 
with maintenance and activation of dormancy. This was furthered by instigating the niche 
to try and force an escape from dormancy. I found that adjuvant therapy, while effective at 
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reducing burden initially did not prevent DTC growth long-term. Surgical intervention was 
also shown to play a role in increasing the growth of DTCs. These results demonstrate that 
ICC scaffolds can capture long-term DTC phenomenon and may reveal targetable factors 
that activate metastatic progression.  
 Finally, I have demonstrated a new fabrication scheme for ICC hydrogel scaffolds. 
The entirety of the in vivo metastasis studies performed in this work were performed with 
glass beads, however the manufacturing process is laborious, dangerous, and ultimately 
costly. Changing to expanded polystyrene beads provided a more scalable approach that 
may utilize existing infrastructure for large scale production of ICC hydrogel scaffolds.  
7.2 Future Directions 
 Although several milestones were achieved with the presented work, implantable 
niches to study metastasis are still relatively underutilized and the translational potential 
remains unmet. The microenvironment is finally being recognized as a key driver of DTC 
fate, and new characterization techniques enable deeper analysis into components of the 
niche. Single cell RNA sequencing has provided an unparalleled level of cellular detail but 
has not been utilized to understand niche evolution around DTCs332. Part of this challenge 
has been in capturing DTCs and their immediate niche for analysis. This process requires 
total disruption of the tissue, therefore it is not practical to capture the local niche for 
analysis. Efforts have been made to adapt single cell RNA sequencing to histological slides 
enabling spatial mapping of RNA sequencing data333. This is an exciting direction to detect 
minute differences in the DTC niche as cells undergo the transition from dormancy to a 
proliferative state and could be applied to long-term dormant DTC containing scaffold 
niches. Similar spatial analysis should be performed on the local matrix proteins. 
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Techniques such as imaging mass spectrometry provide spatial proteomic analysis and 
have been used to understand protein regulation of tumor expansion334. A final analysis to 
continue to pursue is of the local secretome. I have provided evidence of changing 
secretome after chemotherapy in this work. However, temporal monitoring would provide 
a better idea as to how the niche is evolving and provide further mechanistic understanding 
of cytokine signaling and inflammatory pathways associated with metastatic progression. 
In regard to cytokines and soluble molecules, exosomes are another exciting class of 
molecule that should be investigated in the DTC niche. Understanding exosome signaling 
during the foreign body response may enable further immune modulation.  
 The tunable nature of tissue engineered niches can reduce the gap in species-species 
differences between mice and human when using animal models. As described here a 
humanized niche was formed by pre-seeding the scaffold with human bone marrow stroma 
cells. Although not fully representative of the bone marrow, this approach may be used as 
a starting point to generate human-relevant stromal niches to study their interaction in an 
in vivo setting. For example, human lung stromal cells or human kidney stromal cells could 
be seeded onto scaffolds to identify potential differences driven by the stromal cells that 
substantiate the altered metastatic growth in typically high and low metastatic tissues, 
respectively. In addition to probing the interaction of specific cellular components, 
extracellular matrix proteins can be directly investigated using implantable scaffold niches. 
For example, fibronectin has been identified as a potential marker for the pre-metastatic 
niche development. Increased integration of fibronectin into the scaffold via surface 
coating or bulk integration within the polymer matrix may yield significantly different 
tissue formation and metastatic potential within the scaffold niches. This approach could 
 
 182 
be applied to other extracellular matrix proteins including specific collagens beyond type 
I found in rat tails, elastins, and laminins. I expect that this high level of microenvironment 
control will aid in the identification of cellular and molecular factors that drive metastatic 
relapse. In addition to changing the potential metastatic capabilities of the scaffolds, unique 
translational opportunities may arise from the formation of different tissue 
microenvironments by changing the initial cellular and molecular composition of the 
scaffolds prior to implantation.  
Deeper mechanistic understanding of the DTC niche will ultimately produce 
targetable cellular and molecular pathways that enable metastatic growth. Previous work 
has demonstrated the ability for scaffold metastasis models to act as a screening platform 
based on microarray analysis of the niche. In this dissertation work I have developed new 
methods to test syngeneic models in high throughput via transplantation of primary 
MMTV-PyMT tumor fragments. Further development as a preclinical screening model 
should be pursued and implemented based on literature and future findings. For example, 
checkpoint inhibitors are an exciting therapeutic option that have been relatively 
unexplored mechanistically within the context of metastatic relapse. This future research 
direction using biomaterial DTC niches is important in validating potential mechanisms of 
metastatic relapse and maintenance of dormancy, and screening of pre-clinical candidates.  
 Intravital imaging is a powerful technique that enables real-time observation of 
cellular events in a living organism. Extravasation and tracking of disseminated tumor cells 
into the brain microvasculature has been shown using a chronic cranial window48. This 
model also identified necessary steps that were necessary for metastasis formation 
including extravasation out of circulation and remaining in the perivascular space. Another 
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approach has been performed to examine the lung microenvironment using a vacuum 
stabilized window directly on the lung of a mouse107, 335-336. These windows have been 
critical in observing extravasation of cancer cells into the lung tissue and early immune 
cell interaction. For example, they have enabled visualization of neutrophil extracellular 
traps around pro-metastasis cancer cell lines that had extravasated into the lungs251. 
Previously our lab has utilized a dorsal-skin fold window chamber to observe tumor cells 
extravasating into the scaffold niche97. I have started to implement this technique with 
moderate success. First, scaffolds are implanted to allow for tissue development. During 
window engraftment, the skin is stretched around the scaffold such that it is sandwiched 
between the skin. Titanium supports are installed over the scaffold and held with a 
combination of screws and sutures. One side of the skin is removed, revealing the scaffold 
and a cover slip is installed (Figure 7.1a). During imaging red fluorescent dextran is 
intravenously administered to visualize blood vessels. Intravenous injection of eGFP-
MDA-MB-231 or eGFP-PC-3 tumor cells enables observation of tumor cells. Preliminary 
results reveal the ability to observe tumor cells and the local vasculature via the window 
chamber (Figure 7.1b). Plans have been made to apply an intravital window to chimeric 
eGFP mice and introduce fluorescent cancer cells to observe bone marrow cell interaction 
with DTCs. Combining this study with adjuvant chemotherapy or surgical intervention 
may provide new insight on the dynamic interactions between DTCs and the surrounding 







Although I have investigated local immune modulation, systemic changes to 
immune cell behavior have not been investigated. Previous work in biomaterial 
implantation has had success in manipulating dendritic cell homing and immune response 
120, 164, 240-242. Implantable biomaterials have also been observed to reduce metastatic tumor 
burden in vital organs by altering CTC recruitment patterns 103-104. Additionally, an 
experiment involving the implantation of human fetal tissue revealed a renewal in 
metastatic potential following either radiotherapy or injection of IL-1β 87. I hypothesize 
that implantation of ICC scaffolds has unexplored systemic immunomodulatory properties 
that could be utilized for basic biological understanding or leveraged for translational use 
in patients. The potential for this research thrust has been demonstrated by the experiments 
performed by Krall et. al. whereby dormant tumors were reawakened following 
implantation of a biomaterial by mobilization of inflammatory bone marrow cells273. 
Similar strategies may provide therapeutic benefit for disease such as chronic fibrosis by 
redirecting bone marrow cell activity. Evidence highlighting the important interactions 
between the immune system and the intestinal microbiota have become increasingly 
Figure 7.1. Intravital imaging. 
 a, Gross image of window chamber engraftment around implanted scaffold. b, Intravital 
image of DTC (green) and vessel (red). 
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prevalent. Investigation of the role biomaterial implantation has on the microbiome and 
vice versa may uncover important immunomodulatory behavior that could have therapeutic 
benefit in unforeseen diseases.    
 I hope the work presented here will convince the community that tissue 
engineering approaches and specifically implantable ICC scaffold strategies are powerful 
tools to address provocative hypotheses that are challenging to study in traditional systems. 
I believe these approaches are still early in their development and their potential has not 
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